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Abstract
The advent of massively parallel sequencing (MPS) has provided much broader opportu-
nities in the field of molecular genomics. Previously, sequencing approaches were limited
to a small number of single genes or exons. MPS has enabled assessment of hundreds
or thousands of genes associated with a particular phenotype simultaneously, providing
the clinical scientist with more information than ever before. This thesis examines the
processes and challenges of introducing whole exome sequencing (WES) technologies into
a clinical laboratory in three families, each with a distinct segregation pattern of an un-
diagnosed clinical condition. The challenges associated with the sequencing, analysis and
interpretation of sequence variants, as well as elucidating mechanism(s) of pathogenicity
of detected variants, were the focus of this thesis.
One family with five male siblings affected with intellectual disability were initially inves-
tigated for a suspected X-linked disorder. Although candidate variants were identified,
the results did not ultimately detect any clearly pathogenic variants or therefore a diag-
nosis.
In a second family, a single affected daughter presented with an undefined ageing disor-
der. We identified a novel de novo X-chromosome variant in the gene BCL-6 co-repressor
(BCOR), a G to A transition at c.3907G (p.Gly1303Ser). Although functional studies
were not performed and definitive pathogenicity was not established during the course
of this work, the BCOR variant was considered a strong candidate for this phenotype.
Skewed X-chromosome inactivation was identified in this individual which is suggestive of
an X-linked disorder, further supporting the role of BCOR dysfunction in her symptoms.
The bulk of this thesis then focused on the analysis of a third pedigree in which four
children have acute alcohol sensitivity and pronounced cardiac fibrosis, two of whom
died suddenly. Exome sequencing revealed compounding mutations in the PPA2 gene,
inherited recessively in all four children. PPA2 had not been previously associated with
human disease, however, the enzyme encoded by PPA2 localises to the mitochondria,
which implicated this enzyme in this family’s disorder. In silico algorithms supported a
damaging effect of both variants upon the protein, and early functional experiments in
yeast and zebrafish were suggestive that PPA2 was important in cardiac function.
This finding led to the identification of three additional families with PPA2 mutations
[1], in collaboration with laboratories in Germany and Austria. The phenotype of af-
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fected individuals in the European families was more severe resulting in infantile death,
whereas the NZ family experienced death in the second decade of life following ethanol
exposure. This work has established PPA2 as a new cardiac disease gene, and ended a
diagnosis odyssey for a NZ family. It has also instigated an ongoing investigation into
the mechanism of PPA2-associated disease.
Exome sequencing in these three families has highlighted both the power of MPS to
provide a diagnosis, and the challenges associated with analysing such complex data. In
particular, the work has established a pipeline for the clinical laboratory which will need
an associated laboratory for extensive follow-up functional analysis of candidate variants
where a clinically significant impact has not previously been proved.
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Genomics is a relatively new term that encompasses the study of genes, their functions and
related techniques [2]. This chapter discusses the journey of molecular diagnostics from single
gene and single mutation diseases, to the rapidly evolving world of Massively Parallel Sequencing
(MPS) and addresses the main issues that need to be considered when transferring this research
technique into a routine diagnostic tool.
1.2 History of molecular diagnostics
Genetic disease places a considerable health and financial burden on patients and affected
families, as well as the wider community. Genetic disorders have been estimated to account for
thirty percent of admissions to paediatric wards and many lead to paediatric mortality [3]. Of
those patients that survive into adulthood, many are living with severe and incurable disease.
The emphasis is often placed on prevention, of both complications related to the disease in the
individual, and recurrence within the family through genetic counselling. For both of these
cases, an accurate diagnosis is crucial [4]. Online Mendelian Inheritance in Man (OMIM), an
authoritative knowledge base of human genetics and Orphanet (a catalogue for rare disease),
predicts that there are between 6,000 and 7,000 rare monogenic disorders, however, only half
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of these currently have a described molecular aetiology [4, 5].
1.2.1 Early methodology
Molecular disease was a phrase first coined by Linus Pauling based on discoveries relating to
sickle cell disease (SCD). In 1949 Pualing et al [6] demonstrated that SCD was caused by a
defect in the haemoglobin molecule and inheritance of the disease was shown to be autosomal
recessive. In 1958 the single amino acid substitution in the beta globin chain that leads to
this abnormal haemoglobin was characterised [7]. These early experiments put SCD at the
leading edge of molecular studies in human disease. SCD falls into a class of disorders called
haemoglobinopathies, which also includes thalassemias. Haemoglobinopathy implies structrual
abnomalities in the globin protiens, whereas thalassemias usually result in underproduction
of of normal globin proteins [8]. The most clinically relevant thalassemias are the α and beta
thallassemia [8]. Mutations in the globin genes can either lead to both thalassemias characterised
by decreased production of normal globin chains, and variant haemoglobin molecules carrying
amino acid substitutions. Most mutations that give rise to haemoglobinopathies are either point
mutations or small deletions, and only rarely insertions. β-thalassemia is mostly caused by point
mutations (some located within deep intronic regions), while α-thalassemia is mostly caused
by large deletions. The deletions associated with α-thalassemia, and Hereditary Persistence of
Fetal Haemoglobin (HPFP) were first characterised using the technique of Southern blotting
[9]. The advent of recombinant DNA technology, developed in the 1970s, made it possible to
characterise DNA molecules directly and provided the basic knowledge on the primary sequence
of many genes [10]. Point mutations that cause β-thallassemia were elucidated in this way [11].
Molecular cloning techniques, and recombinant DNA technology vastly accelerated the rate
at which genes from complex organisms could be studied. Pioneered by microbiologists, this
technology arose from the use of restriction endonucleases to cleave DNA at specific DNA
sequences, and purification of specific fragments by size fractionation [12]. DNA ligase enabled
these fragments to be assembled in new combinations. Recombining DNA into vectors such as
plasmids or bacteriophage resulted in the ability to naturally replicate the DNA fragment in a
bacterial culture. Initially proposed by Peter Lobban of the Stanford University Medical School,
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the first papers describing successful recombinant DNA experiments were published in 1972 and
1973 [13, 14, 15, 16]. By 1976, prenatal diagnosis of α-thalassemia, using hybridisation of fetal
fibroblast DNA had been successfully performed [17]. Throughout the 1980s, similar diagnostic
approaches allowed prenatal testing of several other genetic disorders including cystic fibrosis
[18] and phenylketonurea [19].
Ten years after the first successful experiments, recombinant DNA technology was used to
generate human insulin, the first instance of a recombinant licensed drug [20].
Despite these rapid advances, the identification of disease causing mutations in this era was
laborious and time consuming. Routine molecular diagnosis of inherited disease was not a
feasible option in clinical laboratories until the development of the polymerase chain reaction
(PCR) technique in the late 1980’s [21, 22, 23]. This technology revolutionised molecular
diagnostics, allowing easy DNA sequence analysis of selected ’candidate’ regions of specific
genes and identification of known mutations within a single day.
1.3 DNA Sequencing
DNA sequencing was introduced in 1977, in two seminal papers by Allan Maxam and Walter
Gilbert [24], and Frederick Sanger and colleagues [25]. The Maxam-Gilbert method involved
base-specific chemical cleavage of radioactively labelled DNA fragments, and separation by gel
electrophoresis prior to visualization using autoradiography. The Sanger method incorporated
chain-terminating dideoxynucleotides in the sequencing reaction which caused base specific ter-
mination of primed DNA synthesis. The Sanger method prevailed as the more robust technique,
and became routinely adopted. Further development replaced radioactivity with fluorescent
labelled primers, then later on with fluorescent labelled dideoxynucleotide chain terminators
[26, 27]. In addition, fragment separation was converted from electrophoresis on a polyacry-
lamide gel followed by transfer onto filter paper and drying, to capillary electrophoresis (CE)
and laser detection of the nucleotide fluorescent signal. This allowed the compression of four
lanes previously required on a polyacrylamide gel into one capillary, and analysis of multiple
samples simultaneously with a capillary array. This enabled rapid commercialisation of the
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Sanger method and a leap in the sequencing production capabilities of laboratories.
1.4 Human Genome Project
The Human Genome Project (HGP) was an international, collaborative research effort, with
the key goal to detect map and identify every human gene. Initially proposed in 1985, the merit
of the project’s concept was fiercely debated [28]. The HGP was originally viewed as discovery
science, rather than hypothesis driven science, where the experiment(s) validated a pre-formed
hypothesis. One popular belief was that the non-gene-coding parts of the genome (98%) were
largely irrelevant ’spacing’ DNA, and that the project would provide limited useful data. Ad-
ditionally, the technological components for high-throughput automated DNA sequencing and
handling of the data were not available and would need to be developed. In 1998 the National
Academy of Science appointed a committee to consider the proposal.
After a year of debate and analysis, the committee unanimously endorsed the project.
The project was given a 15-year time frame, with an initial budget of $3 million to achieve six
distinct objectives:
1. To generate physical, genetic, and sequence maps of the human genome.
2. To sequence the genomes of a variety of model organisms.
3. To develop and improve the technologies for mapping and sequencing.
4. To develop computational tools for capturing, storing, analyzing, displaying, and distributing
the data.
5. To sequence expressed sequence tags (ESTs) and cDNAs to establish expression of mRNAs
in different cell types of both humans and mice.
6. To consider the ethical, legal, and social implications (ELSI) posed by genomic information.
The government-funded project was initially driven by the International Human Genome
Sequencing Consortium (IHGSC), and in 1998 a private company Celera joined the race with
a novel sequencing strategy and the promise of a draft in just three years. The competition
prompted a revision of the IHGSC time frame, and eventually resulted in the project finishing
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two years ahead of schedule. The IHGSC published the first draft of the human genome in
February 2001 [29], the same month as Celera Genomics [30]. A completed description of the
finished human genome sequence by the IHGSC was published in Nature in October 2004 [31].
This paper provided the scientific community with an assessment of the quality of sequence
that had been deposited in public databases in April of the previous year.
Up until 2001 the human genome had been sequenced on instruments running capillary elec-
trophoresis of individual fluorescent labeled Sanger sequencing reaction products. These early
instruments were limited to analysis of 500-600 base reads, from 96 reactions in approximately
10 hours. The first five years post publication of the draft genome also saw the addition of
drafts or finished sequences for several model organism genomes. These included Saccharomyces
cerevisiase [32], Escherichia coli [33],Drosophila melanogaster [34], and Caenorhabditis elegans
[35], and then, shortly after; genomes of the mouse [36], rat [37], domestic dog [38], chicken
[39], chimpanzee [40],rhesus macaquet [41], and cow [42]. These genomes provided further an-
notation of the human genome by comparative genomics; assuming highly conserved genomic
elements between species were more likely candidates for functional importance [43].
1.5 Emerging Non-Sequencing Technologies
Completion of the HGP provided a foundation for modern biomedical research and clinical
molecular diagnostics. Although advances in sequencing were perhaps most crucial to the
development of genomics, there are several other genome scale techniques that were developed,
including SNP arrays, Genome-Wide Association Studies (GWAS) and ArrayCGH (comparative
genomic hybridisation).
1.5.1 SNP arrays
SNP arrays were originally designed to genotype human DNA at thousands of polymorphic loci
across the genome simultaneously. The Affymetrix SNP array was the first to be commercially
produced, and was able to genotype 1494 SNPs on one chip. Current SNP arrays have greatly
improved on this, and contain nearly 1 milllion SNPs [44].
6 Chapter 1 – Introduction
1.5.2 Genome Wide Association Studies (GWAs)
Genome wide association studies that use SNP arrays to detect millions of variants in a single
DNA sample became a popular method for detecting association between SNPs and a disease
or trait. This technology requires comparison of a cohort of healthy controls (that do not
show the trait or disease of interest) to a cohort of affected patients. Any alleles (or group of
alleles) that are significantly more frequent in the affected group are described as associated,
and indicate that the region of DNA in which the SNP is located may influence the risk of
disease. This is based on the principle of linkage disequilibrium (the non-random association
of alleles at physically separate loci) at the population level. The first GWAS was published
in 2005 [45] which investigated alleles associated with age related macular degeneration. The
Wellcome Trust Case Control Consortium (WTCCC) study in 2007 [46] was another landmark
project, and was the first GWAS designed for complex disease that used a chip with good
coverage of the whole genome. This study included 14000 cases, covering 7 common diseases;
coronary heart disease, rheumatoid arthritis, Chrone’s disease, type 1 diabetes, type 2 diabetes,
hypertension and bipolar disorder. The number of individuals included in these studies has
increased dramatically since these early studies. An example of a more recent sample size is
200 000 individuals [47] investigating blood pressure and cardiovascular disease risk.
1.5.3 ArrayCGH
ArrayCGH (also referred to as microarray-based CGH) is a technique for detecting chromosomal
copy number variants on a genome-wide scale. The methodology is based on comparison of a
patient’s genome to that of an apparently normal reference genome, which allows the detection
of regions of imbalance as with gains or losses of copy number. This technology extended the res-
olution of the traditional cytogenetic G-banding CGH technique which could only detect larger
chromosomal abnormalities in metaphase chromosomes (in the region of >10Mb). In arrayCGH,
metaphase chromosomes are replaced by specific DNA fragments which act as probes covering
the entire non-repetitive genome. This enables identification of microdeletions/duplications at
a resolution of 10-50kb. This has applications in cancer genetics [48], and for a multitude of syn-
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dromes caused by submicroscopic aberrations such as Prader-Willi/Angelman syndrome [49],
CHARGE syndrome [50], DiGeorge syndrome [51] and Williams-Beuren syndrome [52], among
many others.
1.6 Massively Parallel Sequencing (MPS)
Although the Human Genome project was a huge accomplishment, the 13-year effort cost an
estimated $2.7 billion [29, 31]. Within five years of completion, new sequencing technologies were
able to replicate this feat for approximately $1.5 million over a five month period [53]. These new
technologies were termed ’next-generation’ sequencing (NGS) or ’massively parallel’ sequencing
(MPS) and have revolutionised genomic research, enabling experiments that were previously
not technically feasible or affordable [54]. The principle behind MPS is a paradigm shift from
that of Sanger sequencing. Instead of performing individual capillary electrophoresis reactions,
MPS employs array-based sequencing which can process millions of reactions in parallel. This
method can generate gigabases of nucleotide-sequence output in a single instrument run. The
general process of MPS is illustrated in Figure 1.1 although the specific methodology differs
between the platforms and chemistries which are now commercially available.
1.6.1 MPS sequencing approaches and platform development
Reversible dye terminators
One of the initial sequencing chemistry approaches used in massively parallel sequencing were
reversible dye terminators.
Solexa developed their system in 2007, although it was quickly acquired by Illumina, Inc [55].
The library preparation includes fragmentation of high-molecular weight DNA, enzymatic trim-
ming, and adenylation of the fragment ends and ligation of specific adapters. Bridge amplifica-
tion of the library is performed on a microfluidic conduit (a flow cell) made of flat glass with 8
channels, coated with covalently bonded adapter sequences complementing the library adapter
sequences. These fragment ends are released post amplification to allow priming with comple-
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Figure 1.1 General steps involved in MPS
A Fragmentation; Random enzymatic fragmentation of the input genomic material into short segments is
required before ligation or chemical binding of non-specific adapter DNA sequences occurs. These ligated
DNA fragments are either bound to a solid surface, or are captured by micron-scale beads. B Amplification;
Depending on the adapter ligation approach, PCR is either carried out in emulsion, or on a surface in a
bridging reaction. This step amplifies the DNA fragments in a non-specific clonal fashion, amplifying the
signal that will be detected in subsequent sequencing. C Sequencing; Techniques for base calling are platform
specific, but generally rely on either a fluorescent signal or the pH change that can be measured when a base
is incorporated into a growing chain. D Alignment; Overlapping sequencing reads are aligned and mapped
back to a reference sequence computationally.
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mentary synthetic DNA that can be extended in subsequent sequencing reactions. The use of
reversible dye terminators dictates that the addition of nucleotides is performed in a step-wise
fashion. All four uniquely fluorescent labelled nucleotides are provided in each cycle, however a
blocking group at the 3-OH position of the ribose sugar prevents additional base incorporation
after one has been added. After this cycle, unincorporated nucleotides are washed away and
the flow cell is imaged to identify clusters that are reporting a fluorescent signal. The florescent
groups are then chemically cleaved and the 3-OH blocker removed. This sequence is repeated
for up to 150 nucleotide reactions, at which point the reads are resequenced from the opposite
end of each fragment cluster [56].
Ion detection
An alternate to fluorescence was initially produced by Ion Torrent (who were later purchased
by Life Technologies, then Thermo Fisher Scientific). This technique utilises measurement of
the pH change caused by the release of hydrogen ions during nucleotide incorporation. This
removes the requirement of florescence chemistry, and instead relies on a novel silicon detector.
Library preparation for this technique involves emulsion PCR. Here, fragments of a genomic
DNA library are emulsified with small beads (with covalently linked adapter complementary
sequences on their surface), PCR reactants, and DNA polymerase molecules. The emulsion
produces hundreds of thousands of individual oil micelles, each containing one bead and allow-
ing compartmentalised PCR amplifications within one mixture. Post amplification, the beads
must be released from the emulsion, and the library enriched for beads that were successfully
amplified. Additional priming steps involve annealing a sequencing primer, and loading of the
beads into the wells of a Ion Chip. This chip is specifically designed to act as the microfluidic
conduit, and to detect the pH changes occurring in each well. In this system the nucleotides
are flowed across the chip sequentially, as there is no florescent label to provide base specificity
[56].
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Zero-mode waveguide
In 2010 Pacific Biosciences commercialised a single-molecule sequencer that uses the zero-mode
waveguide (ZMW), a nanotechnology structure small enough to allow tens of thousands to
be manufactured on a silicon wafer array [57]. The ZMW focuses light, and when bound to
DNA polymerase on a surface the instrument excitation/detection optics can be trained at the
attachment site. When fluorescent nucleotides are added to the surface, the instrument detects
the presence of each nucleotide that enters the active site in real time, as the polymerase is
copying the template. This allows read lengths of up to 10,000 nucleotides at a time, although
as yet the error rate is much higher (15%) than the amplification based approaches [56]. It
should be noted that these errors are more likely to be random, as apposed to the systematic
errors that can occur with enzymatic chemistries. Repetitive sequencing of a molecule will
reduce the effect of random errors in the consensus sequence.
Third generation sequencing
Sequencing developments beyond the MPS methods described above have been coined as the
’Third generation’ of sequencing. Currently these methods are typically in developmental stages
and are not ready for diagnostic clinical applications. Third generation sequencing currently in-
volves reading un-amplified single stranded nucleic acids as they pass through nanopores. This
technology is based on the principle first demonstrated in 1996 [58], that when a voltage is ap-
plied across an ionic system, separated by an impermeable membrane that contains a nanopore,
then ions are forced through the pore producing a current. When a charged molecule such as
DNA enters the pore, the flow of ions is resisted and this creates a change in the electrical cur-
rent that can be measured. If the 4 bases (A,T,G,C) are all of differing sizes and would resist
the ion flow uniquely, then each base would produce a electrical signature that would allow
sequencing of long strands of template. There are two major companies taking advantage of
biological nanopores: Oxford Nanopore Technologies (ONT), and Genia, and commercialisation
of their single molecule sequencing instruments is well under way. Both an MspA (Mycobac-
terium smegmatis porin A) pore [59], and an α-hemolysin pore [60] have been shown to be
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effective in DNA sequencing proof of concept papers [61].
Biological nanopores have the advantage of being easily modifiable, and able to be produced
in mass with consistent size and structure. In the case of the α-hemolysin pore, genetic mod-
ifications were required before use in sequencing. These involved the addition of a specific
mutation within the beta barrel to achieve base discrimination, and non-covalent attachment
of a cyclodextrin (CD) derivative which slowed the translational of the DNA bases through the
nanopore sufficiently to allow accurate detection [62]. In the MpsA pore, double stranded DNA
is used to block translational in place of CD. This requires extensive pre-sequencing prepara-
tion of strands in order to separate blocks of target ssDNA with dsDNA. A development on
this method is to use DNA polymerase (DNAP) phi29, which acts as a ratchet, pulling single
stranded template through the pore one base at a time [63]. This DNAP has been shown to
work in the α-hemolysin pore too, and this work has been licensed by ONT [64]. The ultimate
aim is to accelerate new and revolutionary DNA sequencing methods and technologies. ONT
are partners of READNA and their first platforms (the GridION, and the disposable version
the MinION) were commercialised to a select number of customers in late 2012. Early pub-
lications of the MinION suggested that the device had too high an error rate to be of utility
in genotyping applications [65], however more recent studies have shown an increased accuracy
with advances in sequencing chemistries [66]. The major advantage of nanopore sequencing is
evident in the length of align-able sequence reads, reaching >100kb [67] (vs 500bp reads seen
with Illumina and IonTorrent chemistries) and it is expected that sequencing accuracy and data
output will continue to improve. More recently the concept of DNA origami has been intro-
duced, as a method of producing nanopores with greater chemical and biological specificity, and
near atomic precision [68]. The other path being pursued is the use of solid state nanopores,
although biological nanopores have been more extensively studied.
Forth generation sequencing
The so called 4th generation of DNA sequencing focusses on transcript analysis of cells in par-
allel in their cellular context (in situ sequencing). This sort of development is predicted to
become important especially in tumour sequencing and is already on the distant horizon [69].
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1.6.2 WES and WGS
Whole genome sequencing (WGS) and whole exome sequencing (WES) are both unbiased and
powerful MPS approaches for detecting genetic variation [70]. WGS covers the entire sequence-
able genome, intronic and exonic. WES is amplification and sequencing of the exonic portion of
the genome, achieving greater depth at any given base pair for the same amount of genetic data.
Although only a small proportion of the genome is interrogated by this method (approximately
1%), exonic variants are significantly more likely to cause disease than those identified in the
remaining 99% of the sequence. Exome sequencing is of particular use in cases of rare, Mendelian
disease, as focusing on the coding regions often yields relevant variants at a fraction of the cost
of WGS. At the time of writing this thesis, however, the balance is shifting towards WGS
becoming more cost effective and actually providing more depth of cover than WES.
Oligocapture vs PCR Amplification
In order to examine specific regions of the genome, several ’target-enrichment’ methods have
been developed which selectively isolate regions of interest prior to sequencing. Although not
exclusive, there are two methods that are most commonly employed, PCR amplification and
oligocapture.
PCR amplification has been a key sample preparation technique for over 20 years, and has been
applied with success to generating MPS libraries. For the application of WES, amplification by
PCR of only the exonic regions quickly enriches the target. This is often performed in highly
multiplexed reactions, or emulsion PCR which allows single tube amplification of large numbers
of independent targets. One drawback of PCR target enrichment methods is the difficulties in
designing primers that will amplify 100% of the target region and a relatively high input re-
quirement of genomic material. Additionally PCR enrichment will result in variable depth and
systematic errors in the sequence. In contrast to amplification of a target region, oligocapture
target-enrichment involves hybridisation of a fragment library to specific probes that target
regions of interest. This capture can occur on a solid surface or in solution. Both methods have
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their advantages and disadvantages, and often the sample size will dictate the method [71].
The fact that oligocapture can more accurately detect large deletion and duplication events
(without PCR bias) may make this a more attractive option for diagnostic arrays. However,
an amplification panel can more readily be updated to include new regions of interest, and
currently this may be a more cost effective method.
Early application of exome sequencing
The utility of WES was first demonstrated in 2010 with the identification of genes responsible
for Freeman-Sheldon syndrome (FSS)[72], Miller syndrome [73], and Schinzel-Giedion syndrome
[74]. FSS has several characteristic features including a small pursed mouth, midface hypopla-
sia, and multiple contractures in the hands and feet. In this study, four unrelated affected
individuals underwent WES and a list of variant-containing genes was generated. When vari-
ants were compared across data sets, only one affected gene was common to all four individuals;
MYH3 [72].
This gene had been previously shown by linkage analysis to be causal for FSS, showing that
massively parallel sequencing could be used to find causal mutations for monogenic disease even
without linkage information, or any information relating to disease mechanism [75].
The first application of WES in a rare Mendelian disease of unknown cause was in Miller
syndrome[73]. Affected individuals present with multiple malformations including severe mi-
crognathia, cupped ears and missing 5th digits of the feet. This study identified DHODH as a
candidate gene in four affected individuals from three independent kindreds. Further sequenc-
ing of three unrelated affected individuals showed that compound heterozygosity of mutations
in DHODH was causative, and sequencing of parents indicated that this was a recessive disease
not typically caused by sporadic mutations.
Following on from this success, WES was employed to determine the basis of Schinzel-Giedion
syndrome, a distinctive disorder causing abnormal facial features, congenital malformations and
severe mental retardation. It is usually fatal by 10 years of age. Exome sequencing of four un-
related affected individuals identified de novo heterozygous mutations in SETBP1 as causative
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in all four cases. Sanger sequencing of SETBP1 in additional patients with clinically diagnosed
Schinzel-Giedion syndrome showed mutations in eight of the nine individuals investigated and
confirmed the autosomal dominant mode of inheritance [74].
Autosomal recessive disorders are largely over-represented in early literature on massively par-
allel sequencing, with over 115 novel disease genes identified [76]. This is largely due to the
relative simplicity of identifying rare, compound heterozygous mutations (in the absence of
consanguinity) in only one affected sibpair [76].
1.7 MPS Data analysis
1.7.1 General steps and available software
As MPS rapidly generates a flood of heterogeneous data, management and analysis of the
data has become crucial in avoiding the bottleneck in clinical utility. In order to efficiently
perform the multiple analysis steps required, there are a large range of commercial and free-
ware programs, databases, and tools available.
For each different application of MPS one pipeline (or set of analysis steps) may be more
suitable than another, and for very specific applications there may be particular workflows that
are required. Choosing a pipeline or workflow to facilitate analysis of a particular application
involves a comprehensive understanding of the stages of analysis and what choices are available.
Quality assessment
The first analysis step once data has been generated, is to evaluate the quality of the raw reads,
and trim or remove reads that do not meet the required standard. This step typically addresses
issues such as base calling errors, INDELs, adapter/primer contamination and poor quality
sequencing at the ends of fragments [77].
There are multiple tools that can perform all or some stages of quality assessment, and many of
these are inbuilt to the MPS platform being run. Comparison of these tools is outside the scope
of this thesis, but the existance of so many methods suggests that all have their limitations or
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particular strengths. Of the platform-independent tools, NGSQC Toolkit [78], PRINSEQ[79],
FastQC (http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc) and Galaxy [80] are some of
the most commonly employed. NGSQC Toolkit and PRINSEQ are able to handle FASTQ and
SFF input files, trim and filter, and produce a summary QC report. FastQC is compatible
with all major MPS platforms and quickly produces summary tables and graphs to asses data
quality. Galaxy is an integrated web-based tool that can create a FASTQ summary, as well as
perform trimming and filtering tasks. SolexaQA47 and htSeqTools [81, 82] are two additional
tools that include quality assessment, processing and visualisation functionality, htSeq Tools in
particular is well suited to the high throughput requirements of ChIP-Seq or RNA-Seq studies
while SolexaQA is designed for Illumina data.
Read alignment
Reads that pass a QC requirement are usually aligned to an existing reference genome. Both the
University of California at Santa Cruz (UCSC) and the Genome Reference Consortium (GRC)
are reliable sources for the human reference genome assembly. Both host multiple versions of
the genome, UCSC currently provides hg18 and hg19, while GRC currently provides GRCh36
and GRCh37. The hg prefixed and GRCh prefixed references are identical at the nucleotide
level but differ in nomenclature. The implementation of MPS required the rapid development
of programs capable of aligning millions of short reads to a reference. The more commonly used
tools to achieve this include BWA; [83], Bowtie/Bowtie2; [84], Novalign (http://novocraft.com),
SOAP2 [85], MAQ [86], SSAHA [87] and YOABS [88]. Initial alignment programs were designed
to deal with the short reads generated by early MPS runs. More recent software can deal with
longer reads and gaps and largely follow the seed-and-extend method. This involves searching
for one or more so-called seeds before extension to cover the whole query sequence [89].
Variant identification
One of the most critical steps in the clinical implementation of MPS is the variant identification
stage. Tools for variant calling can be grouped into four applications: somatic, germline, copy
number variant (CNV) and structural variant (SV) detection. Some key tools for germline
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mutation calling include GATK [90], CRISP [91], SAMtools [92] and SNVer [93]. GATK can be
used as both a germline and somatic mutation caller. It is a software library that hosts several
tools for working with MPS data including depth of coverage analysers, a local re-aligner, and
SNP/INDEL caller. CRISP was developed to detect both rare and common variants from
pooled MPS data. It is not intended for analysis of single samples, however. SAMtools is a
collation of multiple tools that contains a subset of commands called BCFtools. These have the
ability to call SNPs and short INDELs from a single alignment file, as well as identify somatic
mutations. SNVer is primarily a statistical tool for the identification of SNPs and INDELs in
both individual and pooled MPS data. These tools all differ slightly in which file formats they
can manage, and which applications they are most useful for. Often, several callers may be
combined in one analysis to ensure best coverage of potentially pathogenic mutations.
Annotation
The sheer size of the output files generated by MPS requires rapid and accurate automated
variant annotation to filter and prioritise variants based on their functional impact and potential
pathogenicity. The variants that can be annotated include SNPs, INDELs, and more recently
CNVs, depending on the software and the application. The easiest way to provide annotation
data is to link variants to entries in public variant databases such as dbSNP. There are various
tools available for variant annotation, both web-based and off line. Some of the more common
tools currently in use include ANNOVAR [94], SeattleSeq (http://snp.gs.washington.edu
/SeattleSeqAnnotation138/), ExAC [95] and AnnTools (http://anntools.sourceforge.net/).
Visualisation
Visualisation of sequence properties is an important feature in any analysis pipeline. There
are several browsers that enable loading of sequence data, and can display multiple tracks
with user-specified information. Browsers enable visualisation of not only the aligned reads
and annotated variants, but also quality information such as coverage and read depth. The
browsers available generally fit into two categories; a web-based application, or stand-alone
tool. The Ensembl Genome Browser [96] is a popular example of a web-based application
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that hosts multiple reference genomes, as well as local annotation sets and external resources.
The University of California at Santa Cruz (UCSC) Genome browser [97] is also a web-based
application that offers phenotype and disease annotations among its other uses. The UCSC
database is comprehensive, containing nearly 1800 annotation tracts for the human genome
GRCh37/hg19.
Stand-alone tools include Artemis [98], Intergrative Genomics Viewer (IGV) [99] and Sequence
Annotation and Visualisation and Analysis tool (Savant) [100]. Artemis utilizes BamView [101]
to display aligned reads. It allows filtering of variants based selected properties and the export
of calculated properties such as SNP density and read counts [77] . IGV is a versatile tool,
allowing import and the handling of >30 file formats. Reference genomes as well as data tracks
and annotation from local or remote data sources can be viewed easily. The Savant tool allows
loading of local as well as remote data sources and supports simple file formatting such as VCF
zipping and indexing.
Prioritisation/Filtering
The process of identifying pathogenic mutations amongst the large number (typically 20,000)
of variants generated by WES, can involve multiple approaches.
In general, for monogenic Mendelian disease the causative variant(s) will be rare in the popula-
tion, likely to be located in a coding region, highly penetrant, of large effect and will segregate
with disease. Initial filtering therefore would usually highlight missense and nonsense substi-
tutions, as well as coding indels and splice site acceptor and donor sites. This list would then
be further refined to those variants that are rare or novel. An additional method of filtering
is based on the effect of a variant on protein structure and function, and how well this protein
is conserved between species [75]. Several tools are available that assign pathogenicity scores
based on one or more of these parameters. Sorting Intolerant From Tolerant (SIFT) [102],
Polymorphism Phenotyping (PolyPhen) [103], PhyloP [104], and Genomic Evolutionary Rate
Profiling (GERP) [105] are some examples. In many cases, potential causal variants will be
identified, but further functional studies will often be required to show pathogenicity. All pri-
oritisation approaches risk removing the pathogenic variant, which is reflected in the high rates
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of false-negative predictions (30% in one study of trios [106]) currently reported, and therefore
the use of multiple prioritisation tools with phenotypic, pedigree and external (neutral and
pathogenic) variant database information may be the most accurate approach. Removal of
non-coding pathogenic variants will be a large contributor to false negative results.
1.8 Challenges
The current estimated number of heterozygous variants that will be found in any one sequenced
genome, classified by the Human Gene Mutation Database as causing an inherited disorder is
50-100 [107]. This is in addition to any novel or uncharacterised variants that may be found in
disease causing genes. This presents a challenge for not only correctly identifying the cause of
disease, but also for counselling a individual to make them aware of the potential consequences
of identifying a genetic variant that may be involved in future and/or unrelated disease. This
has raised a number of ethical issues, such as the obligation of researchers to actively look for
pathogenic variants or how individuals should receive their genome data back. In addition to
known pathogenic variants, there will be the chance of finding variants of uncertain significance
(VUS). As more human variation is discovered, there is a significant lag in accurate in silico
prediction tools and functional studies to characterise these variants as benign, pathogenic
or otherwise. Clear guidelines for distinguishing pathogenic sequence variants from the many
benign changes in the human genome are urgently needed, particularly to reduce an acceleration
of false-positive reports which would ”impede the translation of genomic research findings into
the clinical diagnostic setting and hinder biological understanding of disease” [107]. The hugely
increased amount of data now readily produced increases both the computing and analysis
burden. Where previously a handful of genes were examined one by one, now thousands of
genes are condensed into lists of variants (or variations from the reference sequence) which
need to be filtered and prioritised. In the early stages of MPS these genomic changes may also
need to be validated by a secondary method, usually Sanger sequencing, which can increase
the workload for an individual patient considerably. The terabytes of data being produced
puts an increased demand on resources for storage and handling, requiring more expensive in-
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house storage systems, or pushing data into the cloud which then causes issue regarding patient
privacy.
On one hand there are many groups addressing these challenges to responsibly deal with genomic
data, including the EuroGentest Validation Group [108], the CDC-convened Next-Generation
Sequencing Standardization of Clinical Testing work group (Nex-StoCT) [109], the College of
American Pathologist (CAP) [110] and many others [111, 109, 112, 113]. On the other hand
there is the advent of direct-to-consumer(DTC) genetic testing [114]. The companies 23&Me
and XX are perhaps the best known of these DTC options, with Time magazine selecting the
23&Me genetic test kit as retail invention of the year in 2008. Illumina also offers DTC genome
sequencing, but this service does involve extensive involvement of a medical professional around
ordering and returning results. Despite the public popularity of this kind of personalised DNA
sequencing and interpretation, there are several concerns surrounding this new paradigm. The
tests offered have not necessarily undergone clinical evaluation, and as they can be requested
directly by the patient, the results are also interpreted by the requester without professional
health-care advice. In addition, the measurable health value of the tests on offer has not been
clearly established [115]. A Lacet Oncology editorial went to far as to call DTC tests for cancer
and other conditions ”flawed and unethical” [116]. Large scale studies have begun to examine
how consumers of DTC testing understand and use their genetic risk information, but the
potential harms and benefits are not yet well understood.
1.9 Implementation
This thesis has largely explored exome sequencing as a proof-of-principle step in utilising the
emerging genomic technology of massively parallel sequencing (MPS). However, the analysis of
isolated case studies presented in this thesis has several differences to utilising this technology
in a routine diagnostic service. In order to implement MPS testing in our clinical diagnostic
laboratory, several issues identified in these case studies need to be considered, along with
additional factors pertaining to delivering a robust clinical service which are discussed in this
chapter. This is not a comprehensive summary of all the issues, requirements, and planning
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that is necessary, but it highlights key factors which need to be considered by the laboratory
before and during the implementation process. Although general guidelines are available for
clinical laboratories using MPS testing, this is a rapidly changing field and the protocols and
processes constantly evolve. Therefore laboratories are required to develop their own protocols
and policies around MPS testing which requires extensive consideration and planning.
1.10 Sequencing approaches
Although sequencing of the entire human genome may represent the most comprehensive test of
human Mendelian disease, at the time of writing, a clinical laboratory whole genome sequencing
test was not available. Sequencing of the coding regions (whole exome sequencing: WES),
or disease-targeted gene panels are the main approaches used as cheaper and more practical
alternatives [117]. Whole genome sequencing is beyond the scale that our clinical laboratory
will likely offer in the near future and is not further discussed in depth here.
1.10.1 Disease-targeted gene panels
Disease-targeted gene panels are a logical extension of the current service of the clinical lab-
oratory, where a physician orders specific genetic testing for a particular phenotype, and the
laboratory reports a result. Disease-targeted panels contain an array of genes relevant to one
or more particular clinical phenotype, which would quickly provide a result in patients that
share that phenotype without the need for multiple genes being investigated in a sequential
manner, and the time and money that involves [118]. These panels can be disease specific,
or broader and designed to cover multiple overlapping phenotypes. A clinical application of
gene panels would be those relating to specific disorders such as hereditary deafness, neonatal
diabetes mellitus and Charcot-Marie-Tooth, where mutations in any number of candidate genes
can be causal. Diagnosis would traditionally require sequentially screening these genes in their
entirety by PCR and Sanger sequencing, a laborious and expensive process [119].
The key advantage of gene panels over exome sequencing is that targeted sequencing avoids
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many of the challenges described for WES, such as time, cost, reporting variants or genes of un-
certain significance (VUS/GUS) or uncovering incidental findings (IF) not related to the disease
phenotype being investigated [70]. Compared to exome sequencing, a limited gene set provides
greater read depth in a given run, which increases analytical sensitivity and specificity, signifi-
cantly increasing the confidence in variant calls. This is particularly useful in cases of mosaicism
or low level heterogeneity in mitochondrial or oncology applications. One of the new challenges
for laboratories developing disease-targeted gene panels is to define an appropriate list of genes
that should be included for a given phenotype. This is largely due to the variability of clinical
presentation and the constantly evolving understanding of which genes are disease-associated.
If a laboratory chooses to offer disease-targeted gene panels, these should only include genes
with sufficient evidence for a causative role in disease. In addition, any gene panel developed
for a phenotype will also need to be updated with newly discovered genes with a relevance to
the phenotype in question [118].
1.10.2 Exome sequencing
Although the exome makes up 1-2% of the genome, it contains>80% of the recognised pathogenic
mutations. Obviously this figure represents the ascertainment bias caused by the focus on se-
quencing coding portions of the genome. This larger-scale sequencing moves away from the
physician-ordered single gene test model and towards a hypothesis-free approach, requiring
more collaboration between the laboratory and health-care provider to enable appropriate data
interpretation. The current estimate for target coverage of the exome by MPS is 90-95% as
certain regions are too complex for enrichment by currently available methodology. This leads
to reduced analytical sensitivity (but also increased risk of incidental findings), while analytical
specificity is also reduced as depth of read coverage is reduced compared to disease-targeted
gene panels. One method that clinical laboratories may chose to adopt is to perform an ex-
ome sequence, but proceed only with the analysis and interpretation of know disease-associated
genes, effectively creating a disease-specific analysis panel while retaining a single sample analy-
sis work flow. Only if this does not provide a result would the remaining exome data be analysed.
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Exome sequencing in the research setting has been instrumental in disease-associated gene
discovery. This is now changing as more clinical labs generate exome data and are in a position
to identify new causative genes, however often further functional studies are required to prove
the association. The ability to perform these studies, or for an association research facility to
perform them, is a new challenge that clinical laboratories are facing, as more VUS’s and GUS’s
are identified. It may be argued that clinical laboratories are in a unique position to identify
new variants that should be investigated further, particularly in cases of rare disease. Detailed
clinical and phenotypic information is critical in these cases, not only for analysis and interpre-
tation, but for longer term evaluation of variant significance. Tracking patient phenotypes and
correlating them with identified genotypes can be a powerful method of evaluation that clinical
laboratories could contribute to significantly. The need for periodic review and reanalysis of
existing data in clinical cases is a challenge that the laboratory already faces, but the scale of
this may increase with exome sequencing becoming routine practice.
1.11 Platforms
Concurrent to this PhD, our clinical laboratory was evaluating bench top NGS platforms that
would be suitable to install and validate clinical testing on. At the time of starting the evalu-
ation, two producers of sequencing platforms were considered, Illumina and IonTorrent, while
multiple third parties were also considered for sample preparation, work flow automation and
data analysis. While instrument specifications are easily obtained, it is difficult to maintain a
current assessment of factors such as data output and run times across different platforms as
each technology was being constantly improved upon and any review is rapidly outdated. The
following data should, therefore, be considered as current only at the time of writing, although
it will generally remain useful for comparison purposes.
1.11.1 Illumina
At the time of evaluation, llumina marketed four sequencing platforms; MiSeq, NextSeq, HiSeq
and HiSeq X. These platforms differ largely in output and are designed for small and large-scale
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genomics. The MiSeq is the smallest platform with a maximum output of 15Gb of data and
long paired-end reads of 300bp. A single run can take between 5 and 65 hours depending on the
application. The NextSeq increases this maximum output to 120Gb but the paired end reads
are shorter at approximately 150bp. The run time can be between 15 and 30 hours. These two
instruments would be sufficient for routine diagnostic work and could handle exome sequencing
or small genomes. The HiSeq was developed for large-scale genomics with a greatly increased
maximum output of 1000Gb, with a paired-end read length of 150bp. Run times varied from
7 hours to 6 days for larger applications. The HiSeq X offers the greatest power for projects
such as human genome sequencing. It is only sold in lots of 10, which together comprise the
HiSeqX Ten platform which was the first system to achieve the $1000 human genome goal. The
maximum output of this instrument was 1800Gb with 150bp paired-end reads, meaning the
HiSeqX Ten is capable of producing 1.6-1.8Tb of data in a single run which takes less than
three days.
1.11.2 IonTorrent
IonTorrent, was acquired by Life Technologies in 2010, which subsequently become part of
ThermoFisher Scientific. Whilst still using a sequencing-by-synthesis approach similar to other
systems, the IonTorrent technology measures H+ ion release during base incorporation rather
than fluorescent signals. This has enabled the technology to improve rapidly as it is not re-
lying on any optics. The fast run time and inexpensive reagents are also a positive feature
of IonTorrent. The first instrument produced, the Ion Personal Genome Machine (IonPGM),
was marketed as an affordable, flexible and fast sequencing system. The IonPGM can generate
200bp or 400bp reads and is compatible with three sequencing chips, the Ion314, 316 and 318
chip which greatly increases the scalability of this platform. These chips span an output range
from 30Mb to 2Gb, meaning small projects can be run more economically than with other
platforms in a rapid run time of 2.3 to 7.3 hours.
The IonProton was launched in sept 2012 and extended IonTorrent technology into exome
and whole genome sequencing due to its larger, high density chips, allowing much larger data
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outputs. This instrument is compatible with the PI chip which allows an output of up to 10Gb
and 200bp reads. Sequencing run times typically take between 2 and 4 hours. The Ion S5 is
designed for a lower weekly throughput of gene panels, microbes, exomes and transcriptomes.
It is compatible with three chips, the Ion 520, 530 and 540 chip, which all support 200bp or
400bp reads. The output of this instrument ranges from 0.6-15Gb depending on chip type and
read length, though all runs can be completed in under 4 hours. The Ion S5 XL is identical in
output, reads and run time to the Ion S5, but the advantage lies in the greatly reduced analysis
time compared to the Ion S5.
1.11.3 Automation of template preparation
As much sample handling automation as possible is required in a diagnostic setting where large
numbers of samples are processed and there is no acceptable level of mix-up. A key factor in
implementing MPS involves the exploration of the various options regarding automation.
IonChef
The IonChef is an system which automates the template preparation and chip loading for the
IonTorrent sequencing instruments, IonPGM and IonProton. The IonChef integrates several
steps which were previously handled manually including amplification mix preparation, emul-
sification and amplification, enrichment, washing, sequencing prep and chip loading. The total
hands on time for the IonChef is 15 minutes while the total run time will vary with chip type
and read length. The IonChef is flexible in its applications so it can be used in conjunction
with any IonPGM or IonProton template preparation chemistries and chips.
NeoPrep
Starting with DNA or RNA, the NeoPrep System performs all Illumina library preparation
steps, including PCR amplification, quantification, and normalization. It is able to prepare
16 libraries per run, with an estimated 30 minutes hands on time. Currently the neoprep is
only marketed as compatible with two library preparation methods, the TruSeq Nano DNA
Chapter 1 – Introduction 25
protocol for whole-genome sequencing applications, and the TruSeq Stranded mRNA protocol
for transcriptome interrogation.
1.11.4 Third party - library prep, automation and analysis
Standard enrichment kits are currently available for most key applications, including cancer,
inherited disease, cardiomyopathy and autism (Table 1.1). Illumina and Life Technologies both
offer products which are suitable for clinical applications, in particular the TruSight panels
(Illumina) and IonAmpliSeq panels (Life Technologies). In addition to standard panels, some
vendors provide custom panel design which allow a laboratory to enrich their chosen library
targets.
Illumina and Life Technologies both offer custom design of their standard panels, but there
are several additional custom library preparation methods provided by third parties (Table
1.2). These include Raindance (RainDance Technologies), HaloPlex and SureSelect (Agilent
Techonologies), AccessArray (Fluidigm Corporation), GeneRead DNAseq (QIAGEN) and Seq-
Cap (Roche NimbleGen) [120].
1.12 Test development
Independent of which library preparation method/target capture/NGS platform/or analytical
pipeline a clinical laboratory chooses, appropriate validation of the technology must be per-
formed during development of any clinical test. Typically each component of the sequencing
pipeline will undergo cycles of rigorous performance optimisation, then the entire pipeline as-
sessed until assay conditions and analysis settings are optimised. Part of this process is including
all sample types that will be evaluated during clinical testing; whole blood, urine, saliva, FFPE.
In July 2013 the American College of Medical Genetics and Genomics (ACMG) produced a doc-
ument entitled ACMG clinical laboratory standards for next-generation sequencing [121]. This
document was a guide, and it was not a requirement to follow these recommendations, although
it is an excellent educational resource to guide clinical laboratories developing or validating
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Table 1.1 Commercial gene panels
Table 1.2 Custom gene panels
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MPS testing.
Successful test development should include optimisation of factors such as the general assay
conditions, read coverage, analysis settings, sample pooling and batching, costings and TAT
estimates. Several of these factors impact conversely on each other (ie sample pooling and read
coverage), and therefore a balance should be reached which reflects the clinical appropriate-
ness of the testing performed. As data analysis is significantly more complex than previous
single-gene sequencing assays, the performance of the sequencing pipeline should be analysed
by running samples containing a range of known variants (SNVs, small indels). Recently the
Genetic Testing Reference Material Coordination Program of the CDC and and the Coriell
Institute for Medical Research announced the availability of transformed cell line samples for
use in NGS development, validation and QC. There are DNA samples available through the Co-
rial Cell Repositories for diseases including cystic fibrosis (CF), 5-10-methylenetetrahydrofolate
reductase deficiency (MTHFR), HFE-associated hereditary hemochromatosis, Huntington dis-
eases (HD), fragile X syndrome, alpha thalassemia and connexin 26-associated deafness. These
synthetic variants may be used to optimise settings and thresholds, and compare various tools
within the test pipeline. Each laboratory needs to be aware of any challenges in sequencing
variants for a given disease target [122], and confirmation or gap-filling Sanger sequencing may
need to be performed alongside the NGS testing in routine practise as part of the NGS testing
process.
1.13 Validation
Following development and optimisation of pipeline conditions, validation of the entire test
should be performed in an end-to-end manner. Assay performance should be assessed for
analytical sensitivity (false negative rate), specificity (false positive rate), repeatability and
reproducibility. Generally the first test developed by the laboratory will undergo very extensive
validation, while subsequent tests that modify the pipeline slightly may only require validation of
these changes. Although each test will require their own particular validation focus, in general,
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every test needs to pass minimum metrics that define a high-quality run. These metrics will
need to be defined by the laboratory and should cover such factors as: minimum read coverage,
average coverage across genome, percentage of target area covered to list a few. In addition, the
accuracy of sequencing across challenging regions such as homopolymer stretches, or regions
of high homology should be assessed. For disease-targeted panels, validation should include
assessment of all common mutations that should be detected in clinical samples. CDC-Corial
Cell Repository samples, previously-tested patient samples, or other synthetic controls which are
well-characterised reference samples may be used to extend the spectrum of variants available
to validate. Exome sequencing validation relies more on the metrics of a high quality run, in
addition to analysis of samples that have been previously analysed using an alternative platform.
Validation samples that are being run through the entire pipeline should be blinded to ensure
quality of the validation process.
1.14 Quality Control and Proficiency Testing
Each laboratory should develop quality control measures which can be applied to every MPS run.
Typically these measures act to identify sample-prep failures or sequencing run failures so the
next processing step is not initiated prior to samples passing these checks. In addition, sample
identity must be accurately tracked throughout the testing process which is particularly critical
when barcoded samples may be pooled. Proficiency testing should be carried out periodically,
and the laboratory should investigate suitable schemes to enrol in based on what testing is
being offered, as well as internationally accredited auditing processes, although generally there
is no external quality assessment or reference method for MPS.
1.15 Technical considerations
Many file types exist for exporting raw variants and annotation data though the more commonly
used are bam files for alignments and fastq files for sequence reads. A standard file format that
has emerged is the variant call format (vcf). The Centres for Disease Control and Prevention
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is currently leading an effort to develop a consensus gVCF file format. This format is designed
to store sequencing information for both variant and non-variant positions which is required for
human clinical applications and involves a set of conventions applied to the standard variant
call format as documented by the 1000 genomes project. Many of the issues with file type
compatibility and conversion were present in the early days of MPS, and most platforms and
software now handle the standard file types with ease.
The biggest challenge that MPS presents to the clinical laboratory infrastructure is that of
data storage. In addition to the huge amount of data being produced on instrument, there are
also large databases to be accessed and updated. The two issues the laboratory will face are
the immediate storage of data and transmission of data to and from databases or other users.
An on-site server allows for the storage of much greater data volumes, and is a near essential
component for a diagnostic lab considering MPS technology on a larger-scale. There appears
to be a movement within the bioinformatic community towards cloud computing. Described
in 2010 by Stein et al [123] as a general term for computation-as-a-service; cloud computing
allows users to pay for the usage of hardware and storage for as long as they require for their
purposes. Each laboratory will need to consider their own data storage needs, and data security
requirements to decide on an appropriate solution to this emerging issue.
1.16 Data analysis
One of the biggest challenges in MPS is the hugely increased amount of data produced per
sample which needs to be accurately analysed. The ACMG has published a specific set of
guidelines entitled Standards and guidelines for the interpretation of sequence variants: a joint
consensus recommendation of the American College of Medical Genetics and Genomics and the
Association for Molecular Pathology [124], which provide guidance for the clinical laboratory
on the various approaches to variant classification.
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1.16.1 Incidental Findings
As with all genetic testing, appropriate informed consent is important to ensure the patient
is aware of the potential harms that may occur as a consequence of the testing process. Any
comprehensive test, including arrayCGH and microarray, may result in findings unrelated to the
disease status of the patient, but which may have other health implications now or in the future.
These findings, commonly referred to as incidental findings (IF), are significantly increased with
MPS methods and have been a source of concern since the early implementation of MPS. No
specific guidelines exist for appropriate consenting, and each institution offering MPS testing
are currently devising their own policies, particularly concerning the level of detail provided
in reports. The ACMG does provide recommendations for reporting incidental findings. They
state that a laboratory should provide the following information about incidental findings: (i)
Whether the laboratory will systematically search for and report on the ACMG recommended
variants (detailed in the ACMG Recommendations for reporting of Incidental Findings in Clin-
ical Exome and Genome Sequencing [125]; (ii) whether IFs are routinely confirmed to ensure
analytical accuracy, or whether confirmation is recommended through additional follow-up test-
ing; (iii) a clear definition of the criteria used to decide which types of IF will be reported and
how these can be requested or declined. A previous version of the ACMG guidelines recom-
mended that there be an opt-out process for patients who did not wish to receive IF results,
however this has been amended to a decision which is made in the consenting process, so the
ordering provider and patient are clear on what data will be disclosed prior to the testing being
performed.
1.16.2 Finding of uncertain significance
Similar challenges apply to identified variants which may be related to the disease phenotype in
a patient, but for which little or no classification is available. This is not a situation unique to
genetics, as all medical tests can highlight abnormalities that were incidental to the the main
line of enquiry. In terms of MPS these are termed variants of uncertain significance (VUS),
and often occur in genes of uncertain significance (GUS) which have never been associated
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with any patient phenotype previously, or have only been associated with a phenotype not
observed in the patient in question. Although VUS are more common in exome or genome
sequencing, some laboratories have also acknowledged the issue in larger gene panels which
cover multiple phenotypes. A response to this is to allow physicians the choice of requesting that
only the relevant subset of genes will be analysed. VUS’s that are discovered as IF’s in genes
unrelated to the diagnostic evaluation should not be returned because they have no clinical
implications and are more likely to cause confusion than harm. VUS may be considered as
candidates for disease causality, but must be reported as of uncertain significance until additional
evidence is obtained that support an association to disease. Multiple cases with deleterious
variants in the same gene would provide evidence for association and allow the variant to be re-
classified according to the specific recommendations of the ACMG guidelines (Pathogenic/Likely
pathogenic/Benign/Likely Benign). This raises interesting questions about the responsibility of
the laboratory to review historical VUS cases in light of new evidence for disease association,
this is particularly pertinent for exome and genome sequencing. Should the laboratory undergo
periodic review of VUS in exome and genome cases where a cause of disease was not found,
or should a clinical report include advice to the requesting professional that they request re-
analysis of the data at a future date? Additionally, is there any responsibility on the laboratory
to contribute to research aimed at providing evidence on potential pathogenicity of VUS, either
by aligning with a research laboratory or curating an internal database of phenotype/genotype
data? As shown in the case presented in Chapter 5, advances in knowledge on VUS’s can be
a long and slow process. It is recommended that the laboratory carefully develop a policy and
process for returning information and ensuring that it conforms to accepted medical and ethical
obligations.
1.16.3 Computational predictive programs
Computational predictive programs (in silico analysis) can be used to aid the interpretation of
sequence variants. There are many tools available, but generally the algorithms used determine
the effect of the variants at the nucleotide and amino acid level, and the impacts that then
may have on protein function. An important factor to consider when using computational
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predictive programs is that these tools are between 65 and 80% accurate [126] even when used
to predict clinically proven disease-causing variants. Generally these tools have a low specificity,
resulting in over-classifying missense changes as deleterious [127]. Due to this inaccuracy, it is
not recommended that these predictions be used as the single source of evidence when classifying
a VUS.
1.17 Reporting
There are several guidelines on the essential elements of a clinical laboratory report [110, 121],
which all emphasise the importance of succinct, informative reports which are nevertheless
easy to understand. Reports should include structured results, an interpretation of the results,
methodology, references and disclaimers.
Results
The results section of a clinical report should clearly state the variants identified that pass
all validation and QC metrics, as well as the ACMG classification that these fall into. In the
instance of larger gene panels, or exome and genome sequencing, this list may be extensive and
may be more clearly presented in table form. Nomenclature of variants should be in accordance
with the standards of the Human Genome Variation Society (HGVS) [128]. Laboratories should
report the version of nomenclature used in their test methods. Sequence references should be
provided to ensure unambiguous identification of the variant. Genome sequence ”g.”, coding
sequence ”c.” and protein sequence ”p.” should be used to assist in functional interpretations.
For mitochondrial variants ”m.” should be used. If historical nomenclature for a variant differs
from the current nomenclature, an additional notation should draw attention to this. The
reference sequence used for each test should be derived from either the National Centre for
Biotechnology Information (NCBI) RefSeq database (http://www.ncbi/nlm.nigh.gov/RefSeq)
or the of the Locus Reference Genomic database (http://www.lrg-sequence.org). If using the
NCBI reference, the version number must be recorded.
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Interpretation
The interpretation of the result provides evidence supporting the variant classification that
has been made, and identifying the impact of these variants on the patients phenotype. The
interpretation should also include recommendations for any supplementary testing which could
further support the variant classification.
Methodology
This section should detail the test method; Disease-specific panel/Exome for example, and what
types of variants are expected to be detected. It is important for laboratories to be aware of
refractory regions in any commercial enrichment protocol used in exomes/gene panels (genomes
don’t need enrichment), and report the method used and the capture or enrichment efficiency
expected based on their validation studies.
1.18 Thesis direction
DNA sequencing is a core technology that over the last 40 years has contributed greatly to
biology as a whole, and in particular the characterization of the genome, although historically
it did not drive diagnosis so much as have a confirmatory role. The recent advent of massively
parallel sequencing (MPS) technologies has revolutionised the role of DNA sequencing in both
biological research and human diagnostic genetics settings. Indeed, the new technology has
enabled sequencing techniques to be used in a much more diverse range of disciplines, including
for previously unconsidered applications [129].
This thesis considers the developing state of genomic technologies and explores how these can
be applied within the sphere of clinical diagnostic molecular genetics. In particular it focuses
on the role of exome sequencing in rare disease, as this approach encompasses many of the
processes and issues discussed in this introductory chapter and is an approach currently being
successfully applied by many clinical laboratories to provide a genetic diagnosis in complex
cases.
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The number of rare diseases described to date lies between 5000 and 8000 [5]. Although the
definition of ’rare’ varies between countries, the EU definition of a rare disease affects less than 5
individuals in 10,000 [130], collectively affecting an estimated 29 million people [131]. In the US,
rare disease affects up to 25% of paediatric inpatient admissions [132], though unfortunately,
only 46% of patients referred to a medical geneticist will receive a genetic diagnosis [133]. A
genetic diagnosis can affect both patient treatment and management, as well as further or future
reproductive choices where prenatal, or pre-implantation (PGD) screening may be possible.
Thus a diagnosis can benefit the affected individual and the wider family even where there is
no known treatment.
This body of work will focus on investigations in three families, where one or more individuals
have a clearly inherited disease or syndrome, but traditional diagnostic techniques have failed
to identify a genetic cause. The following chapters will test whether we can implement WES
in a clinical setting for complex cases, and highlight difficulties associated with this technique,
with the ultimate aim being the introduction of MPS into the NZ diagnostic setting. Given the
requirement for strict auditing of analysis and reporting, and the drive for maximal automation
of diagnostic processes, this thesis focusses on commercial solutions for data handling. Supplier
analysis solutions have been preferred over third party commercial software to ensure that
validation of a pipeline or process would not need to be repeated if a third party supplier
stop supporting a software. Additionally, given that the work encompassed in this thesis was
performed in a clinical diagnostic setting, this impacted on the selection on case individuals and
the resources to follow up on functional validation of candidate variants. The specific aims of
this thesis are outlined in Table 1.3.
Table 1.3
Thesis Aims and Objectives
1 Explore the benefits and challenges of NGS technology in complex diagnostic cases.
2 Analyse exome sequencing data in multiple case studies with the aim of identifying
candidate gene variants.




2.1 Suppliers and nomenclature
2.1.1 Equipment, reagents and consumables
The source details of each item is given in full in the first instance in the chapter, after which
the item is referred to by name only.
2.1.2 Nomenclature
The nomenclature for DNA and protein mutations used in this thesis aligns to the recommen-
dations of the Human Genome Variation Society (www.hgvs.org/mutnomen/) unless otherwise
stated.
2.2 Clinical Samples
Patient samples were obtained from referring physicians who obtained the requisite consent for
diagnostic testing. Several sample types were collected, including peripheral blood collected by
venipuncture into 10ml EDTA tubes, formalin-fixed parafen-embedded (FFPE), post-mortem
tissue and blood spot cards.
35
36 Chapter 2 – Materials and Methods
2.3 General Methods
2.3.1 DNA extraction
Genomic DNA extraction (Manual method)
Genomic DNA (gDNA) was extracted from peripheral blood collected into 5ml EDTA vacutainer
tubes using an adapted guanidine thiocyanate/isopropanol method. EDTA blood was mixed
1:4 to lysis buffer (0.32M sucrose, 10mM HEPES (pH7.5), 5mM MgCl2, 1% (v/v) Triton X-100,
0.1% (w/v) sodium azide) and mixed with gentle inversion to lyse red blood cells. Leukocytes
were then pelleted by centrifugation at 3000 x g for 10 min and the supernatant decanted and
discarded. The nuclear pellet was resuspended in 5mL of denatuation solution (4M guanidine
thiocyanate, 25mM sodium acetate, 0.84% (v/v) beta-mercaptoethanol) by vigorous vortexing
and the tube placed on a roller and mixed overnight. An equal volume of isopropanol was added
and the tube mixed by gentle partial inversion to precipitate the gDNA. The filamentous DNA
precipitate was collected by centrifugation, spooled out and washed twice in 70% (v/v) ethanol
before being pelleted by a pulse centrifugation and the excess ethanol carefully removed. The
precipitated DNA was resuspended in 0.2-0.5mL of 0.1 x Tris EDTA buffer (1mM Tris-HCL
(pH8.0), 0.1mM EDTA) at 4◦C for ∼24 hours before being placed on a rotating wheel at room
temperature for a further 48 hours to ensure complete resuspension.
Genomic DNA extraction (Spin column method)
Genomic DNA (gDNA) was extracted from peripheral blood collected into 5ml EDTA vacutainer
tubes using the Machery-Nagel NucleoSpin Blood-L (Machery-Nagel, Duren, Germany) method.
2mL of whole blood was added to 150µL proteinase K and 2ml of Buffer BQ1 and vortexed
thoroughly.
Blood was incubated at 56◦C for 30 min (vortexing every 10 min) before being cooled to room
temperature. 2mL of 100% (v/v) ethanol was added and mixed immediately by inversion.
The lysate was pipetted into a Nucleospin filter tube (3mL at a time) and centrifuged for 3
min at 5000 rpm. The flowthrough was discarded and 2mL of Buffer BQ2 added to the tube.
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This was centrifuged for 2 mins at 5000 rpm and a further 2mL of Buffer BQ2 added. Tubes
were centrifuged for 10 min at 5000 rpm and the column placed into a fresh collection tbe. A
volume of 200µL of preheated (70◦C) buffer BE was added directly to the silica membrane and
incubated at room temperature for 2 min. A final centrifugation at 5000 rpm colleted the eluted
DNA into the sample collection tube.
DNA extraction from non-blood samples
Genomic DNA (gDNA) from bucal cells, fresh tissue, FFPE tissue and cultured cells was ex-
tracted as above using the Machery-Nagel method with the variations detailed in the kit in-
structions for non-blood samples.
DNA extraction from Guthrie card
Genomic DNA (gDNA) was extracted from Guthrie card blood spots using an in-house extrac-
tion method. For each patient, a 3mm punch from a dry Guthrie spot was placed into a 600µL
96-well plate. 60µL of 50mM NaOH was added to the well containing the punch and the plate
incubated at 100◦C for 15 mins. Following incubation, the plate was removed from heat and
15µL of 1M HEPES (pH7.5) was added to the sample. The plate was centrifuged at 14000rpm
for 30s to pellet the blood spot and particulates. The resulting supernatant is the DNA stock
solution used directly in subsequent PCR reactions. No quantification is performed on this
DNA as it is a crude extraction and concentration is typically <5ng.µL−1. This was sufficient
for standard PCR reactions.
2.3.2 DNA quantification
Aliquots of 2µL gDNA were analysed by the ND-1000 UV-visible spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). DNA concentration was measured by absorbance at
260nm using the conversion coefficient; 1AU260=50ng.µL
−1
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2.3.3 Standard Polymerase Chain Reaction
Standard polymerase chain reaction (PCR) amplification was performed with FastStart Taq
DNA polymerase (Roche) using the buffer and reagents provided. Oligonucleotide primers were
designed manually and ordered from IDT (Intergrated DNA Technologies Inc., Coralville, IA,
USA) Standard reactions contained 200µM of each deoxribonucleotide triphosphate (dNTP), 1x
reaction buffer, 0.5U of FastStart Taq DNA polymerase, 0.25µM of each oligonucleotide primer
(forward and reverse), 20ng gDNA and sterile water to a final volume of 10µL. Reactions were
prepared in 0.2mL thin wall polypropylene tubes (Axygen Scientific Inc., Union City, CA, USA)
and thermal cycling was performed on an iCycler (Bio-Rad Laboratories Inc., Hercules, CA,
USA) or a SimpliAmp (Applied Biosystems Corp., Foster city, CA, USA) instrument. Thermo-




72◦C 1 min 29x
4◦C Hold
for each primer pair.
Oligonucleotide primers were designed to be approximately twently nucleotides in length, with
approximately 50% guanine/cytosine composition (G/C%). Negative (no DNA) amplifications
were run in parallel, and where possible, positive controls were included.
2.3.4 Agarose gel electrophoresis
Small (6.0 x 8.5cm) gels were cast from low electroendosmosis (LE) agarose (Roche Diagnostics
GmBH, Mannheim, Germany) prepared at 0.7% or 2% (w/v) in Tris-borate EDTA buffer (TBE;
90mM Tris-borate, 2mM EDTA) with CyberSafe interchelating dye. Combs were inserted at
the anodal end and the gel set by cooling to RT. Once set, gels were immersed in 0.5x TBE
and the comb removed. For assesing DNA quality, 2-5µg of whole gDNA was digested, then
mixed with 5µL of a 5 x loading buffer (40% (w/v) sucrose, 0.25% (w/v) bromophenol blue
(BPB), 0.25% (w/v) xylene cyanol (XC)) and loaded onto a 0.7% gel with a 12Kb DNA ladder.
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When assessing PCR reactions, 2µL of PCR product was mixed with 2µL of 5x loading buffer
buffer (40% (w/v) sucrose, 0.25% (w/v) bromophenol blue (BPB), 0.25% (w/v) xylene cyanol
(XC)) and loaded onto a 2% gel. 2.5µL of either HindIII digested PhiX DNA [10ng.µL−1] or
100bp DNA ladder [50ng.µL−1] (Both from Roche Applied Sciences) were loaded to provide
size standards. Samples were electrophoresed at 1-2 V.(cm2)−1 until the BPB dye front had
sufficiently migrated toward the cathodal end of the gel. Visualisation and capture of digital
images were performed with a Gel Doc 2000 molecular imager and Quantity One v.4.6.5 software
(Bio-Rad Laboratories Inc.).
2.3.5 CGH Array
Array CGH to determine copy number variants was performed using Nimblegen CGX12 arrays
Roche NimbleGen, Mdison, WI, USA), containing 135,000 oligos across the genome. Analysis
of array data was performed using Genoglyphix v3.0-0 software (PerkinElmer, Waltham, MA,
USA).
2.3.6 Automated DNA sequencing methods (Sanger)
Sequencing reactions
PCR products were initially diluted 1:4 in sterile water prior to inclusion in a sequencing
reaction. Sequencing reactions were prepared with 500pmol of oligonucleotide primer, 20ng of
purified PCR product, 0.5µL BigDye Terminator v.3.1 enzyme (Applied Biosystems) and and
2µL of 5x sequencing buffer (Applied Biosystems). Reactions were prepared in 0.2mL thin
wall polypropylene tubes (Axygen Scientific Inc., Union City, CA, USA) and thermal cycling
was performed on an iCycler (Bio-Rad Laboratories Inc., Hercules, CA, USA) or a SimpliAmp
(details needed) instrument. Thermocycling parameters were as folows:
2.3.7 Sequencing reaction purification
Sequencing reactions were firstly diluted 1:4 in sterile water and then purified by resin filtra-
tion. 800µL of a Sephadex G-50 fine DNA grade resin (GE Healthcare, Chalfont St. Giles, UK)




60◦C 2 min 25x
10◦C Hold
(hydrated in sterile water) was pipetted into the wells of a Unifilter 800 96-well microtitre plate.
Excess sterile water was removed by centrifugation at 750 x g for 5 min and the Unifilter plate
placed on a semi-skirted 96-well PCR plate (Scientific Specialties Inc., Lodi, CA, USA) contain-
ing 20µL of sterile water in appropriate wells. 10µL of sequencing reactions were transferred
onto the sephadex column and centrifuged at 750 x g for 5 min.
2.3.8 Sequencing analysis
Sequencing was perfomed on a 3130XL Genetic Analyser (Applied Biosystems) using POP-7
polymer (Applied Biosystems) using a 50cm, 16-capillary array. The data was collected using
Data Collection software v.3.0 as per the manufacturers instructions (Applied Biosystems). Se-
quence data was analysed using Sequencing Analsyis software v.5.2 and Geneious Pro software
v.5.6.4 (Biomatters Limited).
2.4 Methods used in Chapter 3
Analysis of an intellectual disability pedigree
2.4.1 Ion Proton sequencing methods
Library preparation
Exome library preparation was performed using the Ion Ampliseq Exome RDY Library Prepa-
ration kit (Catalog # 4489840). For each sample a master mix was prepared containing 14µL
5 x Ion AmpliseqTM HiFi Mix, 50-100ng gDNA, and sterile water to make up to 70µL total
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volume. A volume of 5µL was dispensed into 12 wells of an Ion AmpliSeq Exome RDY plate
which contains the dry primers, before the plate was sealed and run on the following thermocy-
cler program. The 12 PCR reactions for each sample were combined into a central well in the
99◦C 2 mins
99◦C 15s
60◦C 16 mins 10x
72◦C 30s
plate. 6µL of FuPa Reagent was added to this well to partially digest primer sequences. The






Ligation of barcode adapters
In preparation for running pooled exome libraries on one P1 chip, Ion P1 Adapters and Ion
XpressTM barcodes were added. For each sample a mix was prepared with 1.5µL Ion P1
Adapter, 1.5µL Ion XpressTM Barcode X (unique for each mix) and 3µL nuclease-free water.
6µL of this mix was pipetted into the plate well containing digested amplicons. 12µL of Switch
Solution and 6µL of DNA Ligase is added to bring the total reaction volume to 80µL. The
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Purification of library
80µL (1 x sample volume) of Agencourt AMPure XP Reagent (thawed slowly to room tem-
perature and vortexed before use) was added to each library and the bead suspension mixed
thoroughly by pipetting up and down 5 times. The bead/DNA mix was incubated for 5 min
at room temperature and then for 2 min in a magnetic rack until the solution cleared. The
supernatant was carefully removed and discarded. 150µL of freshly prepared 70% ethanol was
added to wash the beads, then removed and discarded. This wash was repeated a second time.
The beads were air dried in the magnet at room temperature for 5 min.
Quantification of library by qPCR
The plate was removed from the magnet and 50µL of Low TE was added to the pellet to
disperse the beads. The plate was sealed, vortexed, and spun down to remove droplets before
being placed back in the magnet for>2 min. A 100-fold dilution of the supernatant was prepared
for quantitation with the Ion Library Quantitation kit. Three 10-fold serial dillutions of the E.
coli DH10B Ion Control Library (∼68pM) were prepared at 6.8pM, 0.68pM and 0.068pM. For
each sample, standard and negative control the reaction mixture prepared contained 20µL of
2 x TaqMan MasterMix and 2µL of 20 x Ion TaqMan Assay. 11µL of this mix was aliquoted
into a 96 well PCR plate. 9µL of the diluted (1:100) library or control dilution was added to
appropriate wells (in duplicate reactions). The final reaction volume for each duplicate was
20µL. The qPCR instrument was programmed with the concentration of the control library
standards. ROXTM Reference Dye was the passive reference dye used, and FAMTM dye/MGB
was the TaqMan probe reporter/quencher option selected. The qPCR parameters are as follows.





that the resulting sample contained equal pM of library. The final concentration aimed for was
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100pM, although this was lowered to 50pM for some samples.
Template preperation Ion ChefTM system
Pooled libraries were loaded onto the Ion P1 chip using the Ion ChefTM system with the Ion
P1TM 200 Kit (Catalog number 4488377). The protocol for this stage is detailed in the Life
Technologies user guide (publication number MAN0010078).
2.4.2 Ion ProtonTM Sequencing
Sequencing of exome libraries was performed on the Ion ProtonTM instrument as per the
protocol detailed in the Life Technologies user guide (publication number MAN0010078).
2.4.3 Variant Analysis
Variant annotation and filtering was performed in IonReporterTM v.4.2 (Thermo Scientific).
Variant Analysis - Proband only
Analysis was initially performed on exome data from the proband only. The filtering parameters
employed in IonTorrent are described in Table 2.1
Variant Analysis - Multiple siblings
Analysis was subsequently extended to three siblings (proband included) and widened to include
autosomes. The filtering parameters employed in IonTorrent are described in Table 2.2
2.4.4 Resequencing
DACH2
Resequencing to confirm the DACH2 mutation detected in exome data was performed under
standard conditions (see 2.3.3). Sequences of oligonuclotide primers used are detailed in Ap-
pendix A.2.
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Table 2.1 Proband-only X chromosome variant filtering
























Table 2.2 Sibling variant filtering







Common to all three siblings
Variants:66 Genes:58
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KMT2C
Resequencing of the KMT2C mutations detected in exome data was performed under standard
conditions (see 2.3.3). Sequences of oligonuclotide primers used are detailed in Appendix A.2.
Due to suspected non-specific amplification of KMT2C, PrimerBlast tool was used to identify
a BAGE gene family member on chromosome 21 which was an unintended target of the orginal
primer pairs. Redesign of new allele specific primers was performed using the Web-based Allele
Specific Primer (WASP) tool described by Wangkumhang P et al [134]. Sequences of oligonu-
clotide primers used are detailed in Appendix A.3.
2.5 Methods used in Chapter 4
Trio analysis - a sporadic case of premature aging
IonTorrent sequencing method previously described in 2.4.1.
2.5.1 Variant Analysis
Variant annotation and filtering was performed in IonReporterTM v.4.2 (Thermo Scientific).
Recessive inheritance
An initial filtering approach was used to identify compounding or homozygous mutations that
would suggest a recessive disease inheritance mode. The filtering parameters employed in Ion-
Torrent are described in Table 2.3
De novo inheritance
An second approach aimed to identify new mutations present only in the proband that would
suggest a de novo inheritance mode. The filtering parameters employed in IonTorrent are
described in Table 2.4
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Table 2.3 Recessive analysis filtering pipeline












Genetic Category Type in









Resequencing to confirm the BCOR mutation detected in exome data was performed under stan-
dard conditions (see 2.3.3). A nested allele-specific PCR approach was employed to investigate
parental mosaicism, using allele specifc primers in a second round of standard amplification.
Sequences of oligonuclotide primers used are detailed in Appendix A.3.
2.5.3 Allele specific amplification of BCOR
In order to try and detect parental mosaicism of the BCOR mutation identified in the affected
child, an allele-specific PCR assay was designed with primers targeted specifically to the wild-
type (wt) or mutant allele. Design of the specific oligonuclotide primers was performed using
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Table 2.4 De novo filtering pipeline












Genetic Category Type in
HasDeNovoNonRefAllele
Variants:3 Genes:3
the Web-based Allele Specific Primer (WASP) tool [134]. Sequences of oligonuclotide primers
used are detailed in Appendix A.3.
2.5.4 X-inactivation analysis
Digestion and PCR
As part of investigations into X-linked gene mutations, an X-inactivation assay was adapted to
determine if non-random X-chromosome inactivation could be observed in extracted DNA from
various tissues. The final protocol was a modification of the protocol described in Current Pro-
tocols in Human Genetics (Nonrandom X Chromosome Inactivation Detection : Supplement
80). The assay is based on a methylation-sensitive restriction digestion with HpaII which will
only cleave unmethylated DNA, which in this situation equates to the active X chromosome.
The inactive X chromosome will be methylated and therefore not a target of HpaII. A PCR of
the highly polymorphic CAG repeat in the coding region of the human androgen receptor gene(
AR) is performed on the predigested samples and the methylation status of the X chromosomes
can be determined by comparison of the digested/undigested sample on fragment analysis.
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Two seperate restriction predigestion reactions were prepared for each patient DNA sample, one
with HpaII and one without. In addition to the patient samples, a previously determined highly
skewed sample, a healthy female sample, and a no-template sample were included as controls.
The two reaction mixtures were prepared with 1µL 10x Cutsmart buffer, 2µL100ng/µL DNA.
The enzyme-included digestion reaction included 1µL10 U/µL of HpaII. Both reaction mixtures
were made up to 10U/µL with sterile water. The no-template sample was prepared with 2U/µL
sterile water in place of DNA. The reactions were mixed gently and incubated at 37◦C for >60
mins - not exceeding 16 hours. After incubation the samples were incubated at 80◦C for 20
mins to deactivate the HpaII.
One PCR mixture was prepared and amplification performed on the both the digested and undi-
gested samples. The PCR mixture contained 2.5µL 10x AmpliTaq Gold PCR buffer (without
magnesium), 1µL25 mM MgCl2, 5µL dNTP mix (0.25mM each), 1.5µL DMSO, 0.5µLAmpliTaq
Gold Polymerase (5U/µL), 10 µM primer mix (primers detailed in Appendix A.3) and 10µL
sterile water to a total volume of 22.5µL/reaction. 2.5µL of pre-digested/undigested template







The products of this reaction were diluted 1:5 in sterile water and 1µL of diluted template was
combined with 0.2µL LIZ 500 size standard (Thermo Fisher Scientific, Waltham, MA, USA)
and 12µL of Hi-Di formamide (Thermo Fisher Scientific, Waltham, MA, USA) per reaction in
preparation for fragment analysis. Each sample was prepared in duplicate and denatured for 2
mins at 95◦C. Capillary electrophoreses was performed on the ABI 31300XL per manufacturer
instructions. Raw data was processed with the GeneMapper software to determine the peak
area for each amplified allele. The calculation of the relative X-inactivation ratio for each sam-
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ple was performed as per the original protocol.
2.6 Methods used in Chapter 5
A case of sudden cardiac death
2.6.1 MiSeq sequencing methods
Library preparation
Library preparation was performed with the Illumina TruSeq DNA LT sample Prep Kit, using
the protocol detailed in the TruSeq DNA Sample Preparation Guide (Part # 15026486 Rev.C).
Exome enrichment
Exome capture (enrichment) was performed with the Illumina TruSeq Exome Enrichment Kit,
using the protocol detailed in the TruSeq Enrichment Guide (Part # 15013230 Rev. J).
2.6.2 Sequencing protocol
Exome sequencing was performed on the Illumina HiSeq 2000 (paired-end 100 base pair reads)
using the protocol detailed in the HiSeq 2000 System User Guide (Part # 15011190 Rev. M).
2.6.3 Variant annotation
Initial data analysis was performed with the Illumina HiSeq analysis software enrichment
pipeline v.0.9 using default parameters. The pipeline includes Burrows-Wheeler Aligner v.0.6.1-
r104-tpx, and Genome Analysis Toolkit (GATK) v1.6-22-g3ec78bd.
2.6.4 Variant filtering
Variant calls were further annotated and filtered with ANNOVAR and ENCODE Gencode v.12
(GRCh37). Variants were sequentially filtered against the 1000 Genomes (Apr 2012 release)
50 Chapter 2 – Materials and Methods
and dbSNP137 databases, whereby variants with a minor allele frequency >0.01 were removed.
Synonymous variants were excluded from analysis. Annotated variants were initially filtered
on segregation with the phenotype. Only variants shared by the two affected individuals were
retained. Two independant lines of further filtering were then performed on this subset:
Candidate gene analysis
A list of known cardiomyopathy genes was then interrogated in this subset, and any genes
represented in the affected individuals (as containing shared variants) were marked for further
investigation.
Exome wide analysis
A filtering system based on a recessive inheritance pattern pulled out any genes in which there
were two or more shared variants in the two affected individuals. These genes were then system-
atically reviewed for variant phasing in the unaffected parents, and potential association with
phenotype. Variants in genes of interest that passed this filter were marked for confirmation
and further analysis by Sanger sequencing in additional family members.
2.6.5 Resequencing
Resequencing to confirm PPA2 mutations detected in exome data was performed under standard
conditions (see 2.3.3). Sequences of oligonuclotide primers used are detailed in Appendix A.4.
2.6.6 Structural modelling
Structural modelling of human PPA2 in order to determine positioning of mutant residues was
based on the high homology between human and yeast ppa2. Basic space fill models of ppa2
were visualised in Cn3D.
Modelling of PPA2 and MT- COX IIII was performed using Swiss-Pdb viewer (Spdbv)/ Deep-
View for OSX v.4.1.0 (www.expase.org/spdbv/). Reference pdb files were sourced from the
RCSB Protein Data Base (www.rcsb.org/pdb/home/home.do). PPA2 base model ID: PDB=1M38 B/
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MMDB=21720 (Saccharomyces cerevisiae), MT-COXIII base model ID: PDB=2OCC C/MMDB=53955
(Bovine).
2.7 Methods used in Chapter 6
Wider investigations of PPA2
2.7.1 Structural modelling
Software used to produce structural models is previously described in 2.6.6.
2.7.2 Oxidative stress sensitivity of PPA2 knockout yeast
All yeast methods were performed in conjunction with Thomas Hoefken (Brunel University,
Uxbridge, London UK), and relied on his expertise and laboratory setup. Oxidative stress
sensitivity of ppa2 knockout yeast was assessed by comparative growth to WT yeast on media
containing diamide, which specifically oxidises intracellular thiols. Plates were prepared con-
taining diamide at a concentration of 0mM, 1mM, 1,25mM and 1.5mM. A volume of 4µL of
ppa2 knockout and WT yeast cell dilutions (at an OD600 of 0.1, serially diluted to 1:10, 1:100
and 1:1000) were spotted onto plates at each diamide concentration and incubated at 37◦C for
2-3 days to allow sufficient growth for comparison of WT and ppa2 knockout strains in each
condition. Plates were photographed using a Geldoc system under white light.
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2.8 Methods used in Chapter 7
Zebrafish modellling of PPA2 dysfunction and
mitochondrial disease
2.8.1 Zebrafish husbandry
Zebrafish used in this reseach were contained in the the Otago Zebrafish Facility (Department
of Pathology, Dunedin School of Medicine, Dunedin, New Zealand). Fish procedures and hus-
bandry protocols are detailed in the Otago Zebrafish Facility Standard Operating Procedures.
Zebrafish tanks were connected in a self-siphoning ZebTec system (Techniplast, Italy). Optimal
water conditions: pH 7.0-8.0, temperature 24-30◦C, and conductivity of 150-600µS. These qual-
ity parameters were continually monitered by the zebrafish facitiy manager/technician and any
values that fell outside of ideal ranges were corrected promptly. Zebrafish were fed twice daily
with dry food (Zebrafish Management Limited, Hampshire, UK) and once daily with Artemia
(Brine Shrimp Direct, Ogden, UT, USA) that had been cultured for 48 hours. Juvenile fish (up
until six weeks of age) were additionally fed rotifers.
Zebrafish strain details
Two strains of transgenic reportor zebrafish were used in these experiments; Tg(bactin:GFP)(Heart
reporter), and Tg(sox10:GFP)(Neural crest reporter).
Zebrafish breeding
In order to obtain embryos for these experiments, adult zebrafish were set up in breeding
containers in male/female pairs the afternoon prior to egg collection as described by Westerfield1
in more detail. The two fish were kept seperated by a plastic insert until the following morning
where the insert was removed and the fish allowed to breed. The inner container of the breeding
system has slots in the bottom, that allows eggs to fall through into the lower compartment
to avoid consumption by the adults. To collect the eggs from this lower compartment after
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breeding, the adult zebrafish were removed into a fresh container, and the water containing the
eggs poured through a fine sieve. The eggs were then rinsed from the sieve into a petri dish
containing 1x E3 and either incubated at 28◦C, or used immediately for microinjection.
2.8.2 Preparation of ppa2 RNA for microinjection
To generate synthetic ppa2 mRNA, the pExpress-1-ppa2 construct (Appendix B.1) was digested
with NotI and capped mRNA was synthesized in vitro by using the SP6 mMESSAGEmMA-
CHINE Kit (Ambion) as described by Moore et al[135].
2.8.3 Preparation of PPA2 RNA for microinjection
Plasmids containing wildtype or mutant human PPA2 genes were synthesised and cloned using
GeneArt (Life Technologies) into a pCS2+ vector. Construct, vector and cloning details are
provided in Appendices B.2 and B.3.
2.8.4 Morpholino preparation
Two independent missense mopholino oligonucleotides (MOs) (GeneTools LLC, OR, USA) were
used to transiently knock down ppa2 protein function in developing zebrafish embryos. These
∼20bp nucleic acid analogues act by binding to complementary sequences of mRNA, blocking
the access of other molecules. The two MOs used in these experiments targeted the ppa2 5UTR
region (including the initiation codon) to block translation, and the ppa2 exon 5-6 splice junction
to modify pre-mRNA splicing. An additional morpholino was ordered as a negative control;
PPA2 Splice 5mispair. This has a 5-base mismatch when compared to ppa2 Splice MO should
not cause any ppa2 knockdown. Morpholino sequences are shown in Appendix B.1. The MOs
arrived as lyophilised specimens that were reconstitued with Danieau buffer to give stocks of
2mM. These stocks were subsequently diluted in Danieau buffer to give working concentrations
as required.
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2.8.5 Microinjection of mopholino and/or RNA
Morpholinos and/or RNA were delivered into embryos that were positioned in channels of a 1.2%
agarose mold (made with 1 x E3 media instead of TAE/TBE) in a petri dish. Microinjection
was performed using a YOU-1 manipulator set (Narishige Co. Ltd, Tokyo, Japan). Injection
needles were made using 1.0mm x 0.58mm borosilicate glass capillaries (Harvard Apparatus;
Edenbridge, Kent TN86HE) pulled by a horizontal micropipette puller (Sutter Instrument Co,
Novato, CA, USA). Approximately 1ng of the appropriate working concentration of MO, RNA,
or MO + RNA was injected into either the yolk (MO), or the single cell (RNA and MO+RNA)
of embryos at the 1-2 cell stage. Following microinjection, embryos were transferred from the
agarose mold back into a petri dish containing 1 x E3 media and incubated at 28◦C until the
embryos had developed to the desired stage for analysis and imaging.
2.8.6 Dechorionation of embryos
Up until 48 h.p.f the zebrafish embryo is contained within an outer chorion. This may be
removed manually prior to experiments on the embryo by the use of ultra fine-tipped forceps.
Under magnification, one pair of foceps was used to stabilise an embryo while the other pair
was used to pierce and split the outer chorion, freeing the developing embryo.
2.8.7 Characterisation of phenotype
Measurement of shortening faction (%)
Still images were captured from video clips of zebrafish hearts at maximum ventircular sytole
(VS) and maximum ventricular diastole (VD). The width of the ventrical was measured in pixels
using ImageJ software and the shortening faction calculated using the formula: (max VS/max
VD)*100 = Shortening faction.
Heartrate measurement
Heartrate measurements were estimated from >10 second video clips of beating embryo hearts.
Rate was calculated using the formula: (Number of beats counted/duration (secs))*60 = Beats
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per minute.
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Chapter 3
Analysis of an intellectual disability
pedigree
3.1 Introduction
In any case of intellectual disability (ID) which appears to only affect male individuals in a
family, the possibility of an X-linked genetic cause is often the first consideration for inheri-
tance. Female carriers in the family will normally be unaffected due to dosage compensation
of their second normal X chromosome. The pedigree investigated in this chapter present just
such a family - five affected males, and one unaffected female sibling (Figure 3.1). It was
considered likely that the five males would all share a mutation on the X-chromosome which
would account for their phenotype. As the focus of any variant analysis in this pedigree would
initially be restricted to the sex chromosome, exome analysis of the proband only (rather than
multiple affected family members) was undertaken. The price of sequencing and analysing one
individual is significantly lower than multiple family members, however, the analysis loses the
power gained from being able to reduce a candidate variant list to only variants shared by af-
fected individuals. As this thesis explores the implementation of exome analysis (among other
technologies) in a diagnostic setting, cost and time considerations are critical. This case study
compares the approach of investigating one individual against the more common multi-family
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Figure 3.1 Pedigree with multiple affected individuals with ID
Moderate intellectual disability affects five males of this Caucasian family (II.1-II.5), who have estimated
Wechsler Adult Intelligence Scale (WAIS) IQ scores below 50. Their female sibling (II.6) has normal intellect,
and has two unaffected daughters.
member analysis.
3.1.1 Case history
A 57 year old man (patient II.2 in Figure 3.1) with intellectual disability and behavioural prob-
lems which had worsened with age was referred to a geneticist. Investigation into the family
history revealed that he was one of 5 brothers who all suffered from impaired intellect. Inter-
estingly, there is one unaffected female sibling, leading the geneticist to consider a potential
X-linked genetic cause.
Patient II.2 had been previously assessed at age 42 by a psychologist and was given a men-
tal age of 3 years 11 months. He was unable to speak clearly at times and could not read
or write. He did have reasonable skills in eating, toileting, and washing, and could use the
local public transport system. In addition to intellectual disability, patient II.2 was unreliable
in social interactions; displaying both verbal and physical aggression at times. A chromosome
microarray (arrayCGH) and Fragile X genetic testing were requested, both of which returned
’normal’ results.
Based on the family history recorded by the geneticist, patient II.1 had a slightly higher
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functional level with a Wechsler Adult Intelligence Scale (WAIS) IQ score of 50. He had poor
articulation and could not read or write, but did have some understanding of numbers and
counting. He was very cooperative and social and worked well with little supervision, although
requiring residential care. Patient II.3 died aged 58. Patient II.4 lives in residential care but
no further information is available. Patient II.5 had been assessed to have a mental age of
4 years and 3 months. He was reported to be cooperative and attentive, but overly familiar
with strangers and had some behavioural problems. The assessment made by the geneticist (A.
Kidd, personal communication, 2012) was that patient II.2 and his brothers most likely have a
non-syndromal X-linked intellectual disability.
3.1.2 Proband exome analysis
WES was initially only performed on a sample from patient II.2. A total of 71177 variants in
15508 genes were identified. The decision to attempt analysis on a single individual in this family
was based on the assumption that this was likely an X-linked disorder. The analysis could then
be restricted considerably by excluded any variants not located on the X chromosome, reducing
the number of variants to 759. Splice variants in IonTorrent data sequencing were excluded
from analysis as they produced a large number of false positive calls which required exclusion
later. Details of analysis parameters are available in the Methods chapter (Table 2.1). Three
genes were identified as harbouring potentially pathogenic mutations; DACH2, MAGEE1, and
TBC1D25 (Table 3.1).
Table 3.1 Candidate variant details







ChrX:86067863 C G SNV DACH2 c.1245G>C (p.Glu415Asp)
ChrX:75649405 C G SNV MAGEE1 c.1082G>C (p.Gly361Ala)
ChrX:48417710 T C SNV TBC1D25 c.729C>T (p.Gly243Gly)
The variant in MAGEE1 was determined to be a sequence error caused by poor quality at
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the end of reads when the sequence read pileup was visualised in IGV, and was discarded. The
variant in TBC1D25 was confirmed in IGV, however it was actually a synonymous variant.
Although this does not exclude a pathogenic effect, our ability to follow up on synonymous
variants is currently limited and since TBC1D25 has not been previously associated with in-
tellectual disability, it was not considered a strong candidate. The DACH2 variant was not
immediately excluded in IGV visualisation or by reference sequence comparison and although
there is no literature definitively implicating DACH2 as a gene involved in intellectual disability
(it is more commonly described in premature ovarian failure [136, 137], there is one reference
[138] to a 325kb duplication spanning nearly the whole gene in an affected individual. DACH2
was therefore a candidate gene further considered for investigation based on this analysis.
3.1.3 DACH2 Analysis
DACH2 was a promising candidate gene, as a c.1245G>C (p.Glu415Asp) variant within this
gene had passed filtering parameters designed to identify damaging mutations. In silico evalua-
tions of pathogenicity also supported this variant as potentially pathogenic/damaging and thus
a candidate for disease in this individual (Table 3.2).
Table 3.2 In silico pathogenicity predictions for DACH2:p.Glu415Asp
SIFT PolyPhen-2 MutationTaster PROVEAN PhyloP Grantham MAF
0.07 0.412 0.979 - 0.412 45 0.001
Sanger sequencing was performed to confirm the presence of p.Glu415Asp in the proband, as
well as genotype the two additional brothers for which DNA was available. Interestingly, this
showed that the segregation of the variant is not consistent with the presentation of ID. Al-
though the proband (II.2) and a second sibling (II.4) were confirmed to be hemizygous for the
p.Glu415Asp variant, the third sibling (II.1) was hemizygous for the wildtype allele (Figure 3.2).
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An X-linked disorder require that all affected males have inherited the same maternal X chro-
mosome with the paternal Y chromosome. The differing genotypes of the DACH2 variant in
these siblings has two implications for X chromosome inheritance. Either DACH2 is located in
a region of the X-chromosome which has been affected by recombination, or the siblings have
not inherited the same maternal X allele (Figure 3.3). Both of these scenarios exclude DACH2
as the pathogenic cause of ID in this family, and if alternate X allele inheritance has occured
then this also excludes any X-linked genetic cause and a wider analysis of autosomes should
be undertaken assuming an alternative inheritance pattern. It should be noted that sample
mix-up was not excluded in the non-concordant brother as a second sample was not able to be
obtained.
Figure 3.2 Amplification and segregation of DACH2:p.Glu415Asp
A The region of DACH2 encompassing the residue Glu415 was amplified in individuals II.1, II.2 and II.4. The
amplification products were visualised on a 2% agarose gel against a molecular weight standard produced
from a HaeIII digest of the φX 174 bacteriophage. B Sanger sequencing of these products showed that the
p.Glu415Asp variant does not segregate with disease in this pedigree.
3.2 Multi-sample exome analysis
Following the results generated by the single proband approach described above in the previous
section, it was decided that additional exome analysis on two additional brothers (for whom
DNA was available) would be a valuable extension of the analysis thereby providing enough
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Figure 3.3 Mechanism of recombination of the X chromosome
Recombination occurs between homologous chromosomes prior to gamete formation. The red bar represents
a pathogenic mutation on one maternal allele, while the blue bar represents another SNP (in this case
DACH2 :p.Glu415Asp) that is analysed. The fact that individual II.1 does not share the p.Glu415Asp variant
as individuals II.2 and II.4 indicates that either recombination has occurred between this and the causative
loci, or that the siblings have inherited alternate X alleles and the cause of ID in this pedigree is not X-linked.
This diagram also illustrates how siblings II.2 and II.4 may not have inherited the same X allele despite sharing
the DACH2 mutation.
power to examine variants in the autosomal chromosomes. For this analysis a combination of
in-house scripts and the Ionreporter software was employed to identify candidate variants in
parallel.
Based on the broader autosomal mechanism of disease now proposed, the autosome analy-
sis was initially targeted to a panel of known ID genes (Appendix C.1). A perl script was
written by Zoe Ward to identify variants in genes on these panels from the exome data. This
was initially run on only the proband, resulting in 123 variants (SNVs and indels) which was
narrowed down to three genes where compound heterozygosity of variants may be occurring;
MAPT (Microtubule-associated protein tau), SLX4 (SLX4 structure-specific endonuclease sub-
unit) and KMT2D (Lysine (K)-Specific Methyltransferase 2D).
A second script was used to identify variants shared by all three brothers. This list contained
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6564 variants that were interrogated against the ID panel, though this produced no instances
of predicted compound heterozygosity of likely pathogenic variants. The same script was also
used to identify variants in known autism-associated genes (Appendix C.2), included due to
the phenotype overlap and produced 4 candidate genes; NCKAP5 (NCK-associated protein 5),
KMT2C (Lysine (K)-Specific Methyltransferase 2C), HYDIN (HYDIN, axonemal central pair
apparatus protein) and MYH4 (myosin, heavy chain 4, skeletal muscle).
Parallel analysis in the IonReporter software had also produced a list of 66 variants, which
included 5 candidate genes (containing two or more variants shared between all three broth-
ers) under loose filtering conditions; HYDIN, KMT2C, KRT6A (keratin 6A, type II), ZNF717
(zinc finger protein 717) and FRG2C (FSHD region gene 2 family, member C). Due to its re-
occurrence under different filtering conditions KMT2C was identified as the strongest candidate
gene for further investigation in this family, specifically the variants c.871C>T (P.Leu291Phe)
and c.2512G>A (p.Gly838Ser). Other less highly ranked variants were catalogued for potential
follow up analysis, beyond the scope of this thesis.
The possibility of sample mix-up that had been highlighted in the X-chromosome analysis
of DACH2 was deemed unlikely after analysis of these additional exomes, as Y chromosome
variants between the three brothers were 100% concordant.
3.2.1 KMT2C Analysis
The presence of two KMT2C variants identified by both the IonReporter based analysis, and
the comparison to ’candidate’ gene panels, meant that this was considered a promising candi-
date for further analysis. In silico predictions of pathogenicity for both variants were variable,
but several methods suggested that the amino acid change would be pathogenic (Table 3.3).
Sanger sequencing was performed to confirm that both the p.Leu291Phe and p.Gly838Ser vari-
ants detected in WES data in the three brothers (II1,II.2 and II.4), and additionally in the forth
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Figure 3.4 Sibling exome variant filtering - Autism and ID panel script written for this thesis
A script was written to mimic the IonReporter function to display and filter variants that were common to
multiple individual analyses. The list of 6564 variants shared between individuals II.1, II.2 and II.4 was then
interrogated based on the pre-defined ID and Autism panels (See Appendix D) and filtered to exclude genes
that contained less than two variants. No variants were identified in genes listed on the ID panel, but four
Autism panel genes harboured shared variants in all siblings; NCKAP5, KMT2C, HYDIN and MYH4.
Figure 3.5 Sibling exome variant filtering - IonReporter
Filtering for possible causal recessive variants within these siblings was performed using the Venn diagram
function within IonReporter that allows identification of overlapping variants between analyses on seperate
individuals, in this case II.1, II.2 and II.4. When the filter chain described in the Methods (Table 2.2) was
run on these samples, the overlapping number of variants was 66. Between 103-193 additional variants were
only identified in one sibling. A further 176 variants were shared by 2/3 of the siblings.
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Table 3.3 In silico prediction of pathogenicity for KMT2C
Pathogenicity prediction scores from six in silico software and minor allele frequency (MAF) as defined by the
ExAC (http://exac.broadinstitute.org/).
KMT2C SIFT PolyPhen-2 MutationTaster PROVEAN PhyloP Grantham MAF
p.Gly838Ser 0.0 1 1 - 2.66 56 1.65E−5
p.Leu291Phe 0.05 1 1 - 2.43 22 -
Damaging (Pink); Moderate (Orange); Neutral (Green)
surviving brother (II.5) where DNA was acquired after exome analysis was performed. Initial
sequencing results for both variants did not support the exome sequencing results. The vari-
ant p.Leu291Phe appeared homozygous rather than heterozygous (Figure 3.6), and the variant
p.Gly838Ser appeared absent entirely (Figure 3.7) in all four brothers.
To examine whether these results may have been generated by non-specific PCR amplifica-
tion or other causes of allele amplification failure that we have previously investigated ([139],
the PrimerBLAST tool was used to identify unintended targets that may be amplified with
the primers used across the p.Gly838Ser variant. Along with the expected result for KMT2C,
there was an additional complementary region identified within chromosome 21 (Figure 3.8).
Alignment of the nucleotide sequence between the expected KMT2C region (NG 033948.1)
and the chromosome 21 region ( NC 000021.9 (10473535-10499510) from the GRCH38 p2 pri-
mary assembly) indicated strong conservation. The original primers used to sequence these two
KMT2C variants did not differentiate between the intended chr 7 target and the homologous
region on chr 21. Allele specific primers were designed to cover regions of difference between the
two sequences (Figures 3.9) and specifically amplify KMT2C. KMT2C -specific resequencing of
both variants identified in the exome analysis confirmed that neither variant was present in
these brothers, but were instead an artifact of the chromosome 21 BAGE gene family reads
mis-aligning to KMT2C during the mapping process (Figure 3.11).
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Figure 3.6 Sequencing of KMT2C; p.Leu291Phe
A IGV visualisation of exome sequencing read pileup from individual II.2 indicating heterozygousity for a C>T
nucleotide change resulting in p.Leu291Phe. B Sanger sequencing electropherogram of the same individual
indicating homozygosity of the T allele. Note the reverse orientation of display between the IGV output and
the electropherogram.
Figure 3.7 Sequencing of KMT2C ; p.Gly838Ser
A IGV visualisation of exome sequencing read pileup from individual II.2 indicating heterozygosity for a T>C
nucleotide change resulting in p.Gly838Ser. B Sanger sequencing electropherogram of the same individual
indicating no nucleotide change. Heterozygosity at a second allele in the electropherogram is also non-
concordant with the IGV visualisation, prompting investigation. Note the reverse orientation of display between
the IGV output and the electropherogram.
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Figure 3.8 Chromosome 21 homologous region (BAGE)
A PrimerBLAST was used to identify potential unintended amplification targets which might explain the
abberant sequencing results (see Figures 3.6 and 3.7), a region on chromosome 21 was identified with
a histone-lysine N-methyltransferase feature which is also a possible target of the primers used to amplify
chromosome 7 KMT2C variants. B The chromosome 21 region aligning with KMT2C showed hits for B
melanoma antigen (BAGE) gene family members with 99%-100% identity. This corresponds with the known
history of BAGE genes, that they arose from a duplication of KMT2C.
3.3 Discussion
This chapter was intended to investigate the power of exome analysis in one affected individ-
ual, when the causal mutation was likely to be X- linked, rather than a trio or multi-sibling
analysis. However, after initial analysis indicated that the underlying genetic cause could not
be identified on the X- chromosome the project was extended to further family members and
an analysis of all chromosomes (WES).
Originally, analysis of the proband’s exome identified one candidate X-chromosome gene, DACH2,
harbouring a missense mutation p.Glu415Asp. Multiple in silico predictions for this variant sup-
ported a pathogenic effect, as did the rare MAF score. However, further investigation of this
variant by Sanger sequencing in two additional affected brothers did not support DACH2 as
the causative gene, as only two of the three siblings that were sequenced, shared the variant.
No DNA was available on the two additional brothers. This also indicated the possibility that
not all of the 5 brothers had inherited the same maternal X-chromosome, and that an X-linked
disease may not be the inheritance pattern after all.
Two further brothers underwent exome sequencing, and the analysis of the three siblings was
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Figure 3.11 KMT2C- specific Sanger sequence
A Specific sequencing for KMT2C residue 838 B Specific sequencing for KMT2C reside 291
performed independently by two methods. The first involved using the ThermoFisher Scientific
software IonReporter, and the second used in-house Perl scripts to mimic the analysis processes
that IonReporter was carrying out automatically, but with a focus on specific gene lists relating
to autism and ID. The scope of these analyses was extended from the X-chromosome to all
chromosomes. Both analysis approaches identified the gene KMT2C as a candidate gene for
further investigation. This gene contained two variants (p.Leu291Phe and p.Gly838Ser) shared
by all three brothers analysed, raising the possibility of a recessive model of inheritance if the
variants were compound heterozygous. Both variants were predicted by various in silico models
to be probably pathogenic, and further investigation and confirmation with Sanger sequencing
was performed on all three siblings.
Interestingly, the Sanger sequencing did not correlate with the exome sequencing data, and
neither mutation could be confirmed as heterozygous. The earlier variant (p.Leu291Phe) ap-
peared to be homozygous for the mutant allele in all three brothers and an unrelated healthy
control, while the second variant (p.Gly838Ser) was not present in any individual when Sanger
sequencing was undertaken. This discrepancy indicated an issue with the specificity of the PCR,
and it was noted that the primers used to amplify KMT2C were also targeting a homologous
region on chromosome 21. This region relates to a member of the B melanoma antigen (BAGE)
gene family which originally arose from a duplication of KMT2C [140, 141], explaining the
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90-100% identity seen between these sequences.
KMT2C -specific primers were designed to ensure that no amplification of BAGE was occurring.
KMT2C -specific resequencing of both variants confirmed that neither variant was truly present
in these brothers, but were instead an artefact of the chromosome 21 BAGE gene family reads
mis-aligning to KMT2C during the mapping process of the exome data processing.
No other significant candidate gene mutations were identified in this family which would account
for the ID phenotype in all 5 brothers, although identifying candidates largely relied on prior
knowledge of ID-associated genes. This approach is not a good way to identify novel genes,
and would have missed a diagnosis such as the one presented further on this thesis (Chapter
5). Another limitation of this analysis is the difficulty of investigating mutations present on
the Y-chromosome. Approximately 78 protein coding genes have been identified on the Y-
chromosome, and the function of many is still unknown [142]. There are however, several genes
that are expressed mainly in the brain such as PCDH11Y and NLGN4Y which are involved
in formation of dendrites and axons in the CNS [143]. Some Y-chromosome rearrangement,
duplication and deletion events have been associated with ID [144, 145], but specific genes are
rarely implicated. Exome coverage of this chromosome is hampered by the highly repetitive
nature of the male specific region (MSY) of the Y-chromosome, and the X-homologous regions
at the telomeric tips.
If this family is harbouring a molecular defect in the Y-chromosome, then the exome anal-
ysis performed here will likely not be able to detect this event.
Another explanation for not detecting a causative variant, is that it occurs outside the cod-
ing regions sequenced in the current analysis. MPS has recently been successfully employed
to identify a non-coding regulatory mutation which is associated with moderate X-linked ID
in a Northern European family [146]. In this case, the causative variant had been mapped to
Xq28-qter, and a custom capture array was designed to target all coding regions and putative
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functional non-coding regions in the linkage interval identifying a mutation in the intergenic
region between HCFC1 and TMEM187 which was not visible on exome sequencing. Due to the
massively increased data produced by whole genome sequencing (WGS), this was not consid-
ered a feasible or appropriate use of resources in the case of this family and due to the absence
of parental samples or more distant relatives, a linkage approach by other methods would be
more difficult. The five patients are in their 5th or 6th decade, and a diagnosis is unlikely
to significantly affect their management. The unaffected parents are deceased, and therefore
there is no clinical imperative to identify a causative mutation for pre natal screening purposes.
There would be a considerable benefit for the unaffected sister in this family, given that she has
produced two healthy female offspring who may go on to have children at-risk of ID but there is
little interest from these family members in the analysis performed here, and DNA would likely
not be obtained.
In the context of a diagnostic laboratory, this case would currently fall beyond the scope of
feasibility, as neither the time or resources would be available to investigate this case to the
extent it might otherwise deserve. Until WGS is a practical alternative that can be routinely
performed, cases like this may remain undiagnosed unless new approaches or candidate genes
become available to change the prediction weightings and modify our analysis to produce new
findings which may have been discarded by the algorithms used for this analysis.
Chapter 4
Trio analysis - a sporadic case of
premature ageing
4.1 Introduction
Exome analysis of parent-child trios is a technique which has previously identified casual mu-
tations in neurodevelopmental cases such as autism spectrum disorder (ASD) and intellectual
disability (ID) [147, 133, 148]. Reported success rates for a diagnostic result are significantly
improved among families undergoing trio sequencing as opposed to a single individual analysis,
37% compared to 21% respectively according to one US clinical laboratory [133]. For patients
with sporadic disease a diagnosis can be particularly challenging and trio sequencing provides
more information on inheritance patterns of variants than singleton sequencing. This chapter
investigates whether trio sequencing of an affected proband and her unaffected parents could de-
tect an underlying mutation causative of a premature ageing phenotype and provide a unifying
diagnosis.
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Figure 4.1 Pedigree and morphology
A The proband is the third child born to healthy non-consanguineous Chinese parents. The proband suffers
from a syndrome that includes global developmental delay and macrocytosis among other symptoms. She
has two unaffected brothers. B Unusual facies, nails, and skin abnormalities of the proband.
4.2 Case history
An 8 year old girl (individual II.3 in Figure 4.1) presented with an ageing syndrome including pri-
mary adrenal failure, microcephaly with global developmental delay, hyperactivity, behavioural
problems, short stature, dyserythropoietic macrocytosis (Hb 118g/L), recurrent otitis media
and several skin conditions including reticulate pigmentation, keratotic papular skin lesions
and atopic eczema. Notable facial features included short palpebral fissures, a smooth filtrum
and a flattened nasal bridge. The description of an ’aging disorder’ related to her brittle nails,
evidence of greying hair, and general skin appearance. Her parents are both of Chinese ancestry
and were not known to be related. She has two brothers, neither of whom are affected.
Cytogenetic analysis using G-banding showed a normal female karyotype 46XX, and an ar-
rayCGH analysis was also normal. Fanconi’s anemia (FA) was considered but excluded as no
excessive chromosome breakage was observed in peripheral blood cells cultured with mitoycin C
(a specific feature of FA). A diagnosis of dyskeratosis congenita was considered, but determined
to be unlikely as there was no evidence of the characteristic shortening of telomeres seen in
this disorder. Exome analysis was considered an appropriate step to take in this case where
a unifying diagnosis could potentially improve the treatment and management of the patient,
and have implications for other family members.
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4.3 Exome analysis
Exome sequencing of the family trio was performed on an Ion Proton instrument. Analysis of the
variants was performed in the cloud-based software IonReporter (https://ionreporter.thermofisher
.com/ir/), utilising the inbuilt Trio exome analysis pipeline which distinguishes the proband
from the mother and father, allowing identification of compounding recessive or rare de novo
mutations predicted to have deleterious impact.
4.3.1 Recessive analysis
To investigate a possible recessive inheritance pattern of disease, an analysis was performed
to identify genes in which compounding mutations are present in the proband. Details of
analysis parameters are available in the Methods chapter (Table 2.3). This analysis identified
only one candidate gene, MIR4273 (microRNA 4273). Two trans-phase MIR4273 variants
were present in the proband while both parents were heterozygotes (Table 4.1). Unfortunately,
assigning function to this microRNA through the available literature was not possible (beyond
an association with risk of colorectal cancer [149]), and no further analysis was performed on
this variant.











Chr3:75786802 G/A G/A G/G G SNV MIR4273
Chr3:75787996 C/T C/T C/C C SNV MIR4273
4.3.2 De novo analysis
A second approach to the analysis was to identify possible pathogenic variants occurring in a
de novo manner in the proband (therefore not observed in either parent). Details of analysis
parameters for this approach are available in the Methods chapter (Table 2.4). This identified
candidate variants in three distinct genes considered to be relevant to the observed phenotype;
ZNF595 (Zinc Finger Protein 595), PRIM2 (Primase, DNA, Polypeptide 2), and BCOR (BCL6
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corepressor) (Table 4.2).
ZNF595 encodes a protein belonging to the Cys2His2 zinc finger protein family, whose mem-











Chr4:59350 A/G A/A A/A A ZNF595 N/A
Chr6:57398226 A/G T/G T/G T PRIM2 N/A
ChrX:39922265 C/T C/C C/C C BCOR c.3907G>A (p.Gly1303Ser)
bers function as transcription factors that can regulate a broad variety of developmental and
cellular processes [150]. PRIM2 encodes the 58 kilodalton subunit of DNA primase, an enzyme
that plays a key role in the replication of DNA. The subunit functions as a DNA-directed RNA
polymerase to synthesize small RNA primers that are used to create Okazaki fragments on the
lagging strand of DNA [151]. The protein encoded by BCOR was identified as an interacting
corepressor of BCL6, a POZ/zinc finger transcription repressor that is required for germinal
centre formation and may influence apoptosis [152]. Diseases associated with BCOR include
oculofaciocardiodental syndrome (OFCD), myelodysplastic disorders, and Lenz microphthalmia
syndrome (LM) [153]. Visualisation of the read pileup across these six candidate variants in
IGV showed that all but the heterozygous Gly1303Ser variant in BCOR were false positive calls
by the software. This was attributed to either poor coverage of the variant site, highly repetitive
regions, or the variant being inherited but not called in the carrier parent due to either of the
two prior reasons.
False positive variants in ZNF595 and PRIM2 were excluded at this point. The BCOR variant,
c.3907G>A (p.Gly1303Ser), was confirmed as present in the proband but neither parent in IGV
(Figure 4.2).
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Figure 4.2 BCOR; p.Gly1303Ser - IGV visualisation
This variant was confirmed to be heterozygous in the proband when the exome read pileup was visualised in
IGV. There was no evidence of the variant in either parent.
4.4 Investigation of BCOR, BCL6 co-repressor
4.4.1 Sanger confirmation
Sanger sequencing was employed to confirm the presence of the BCOR variant in the proband,
and also the de novo classification by examining the parents for absence of the variant in
the germ-line. This approach confirmed that the proband was heterozygous for c.3907G>A
(p.Gly1303Ser) in DNA extracted from both blood and buccal cell, while both parents were
homozygous for the wild type G nucleotide (Figure 4.3).
4.4.2 Allele-specific Sanger sequencing
Because Sanger sequencing is not sensitive enough to reliably distinguish somatic from germline
mutations, apparent de novo mutations may in fact have arisen during gametogenesis in one of
the parents, or very early in the proband’s embryonic development. In order to investigate the
possibility of parental mosaicism, a nested allele-specific PCR assay was designed to preferen-
tially amplify either the wild type or mutant allele. Initial attempts to amplify proband BCOR
using these highly specific primers failed, and optimisation of annealing temperature did not
resolve the issue. Since non-allele-specific amplification of the region had been achieved using a
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Figure 4.3 BCOR (Gly1303Ser) confirmation
A Agarose gel showing PCR products amplified from the parents of the proband, and blood and buccal DNA
from the proband prior to sequencing of the products. B Sanger sequencing electropherogram of the amplified
products. The variant c.3907G>A (p.Gly1303Ser) is present in both blood and buccal DNA in the proband
(II.3) but neither parent (I.1 and I.2). No evidence of mosaicism in the proband is evident based on the two
tissues analysed.
previous primer set (BCOR F1 and BCOR R1) (Figure 4.3), a combination of BCOR R1 and
the allele specific forward primers (WASP MUT and WASP WT) were employed with proband
DNA as the template, although this also resulted in failed amplification (data not shown).
A nested approach was utilised, using a dilution of the amplicon produced with BCOR F1
and BCOR R1 (PCR product 1) as the template material for a second amplification with the
allele-specific primers. This nested PCR was performed over a temperature gradient of 55◦C to
65◦C (Figure 4.4). Amplification of the WT-specific product remains clear in all three family
members even at 65◦C. Importantly, background amplification in the two parents drops out at
the higher annealing temperature, while no change is observed in the proband. An annealing
temperature of 65◦C was used in all subsequent PCR to ensure reduction of any non-specific
amplification.
A further nested PCR was performed using two dilutions of this product; 10−4 (Figure 4.5A)
and 10−6 (Figure 4.5B) to assess sensitivity of the PCR to detect mutant product. At both
dilutions, there is clear amplification of WT-specific bands in all individuals, and clear amplifi-
cation of mutation-specific product in the proband with no evidence of mutant product in the
unaffected samples (Figure 4.5).
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Table 4.3 In silico prediction of pathogenicity for BCOR; p.Gly1303Ser
SIFT PolyPhen-2 MutationTaster PROVEAN PhyloP Grantham MAF
0 0.804 0.89 0.481 0.43 56 5.24E−5
Damaging (Pink); Moderate (Orange); Neutral (Green)
As a final measure to exclude the presence of any mutant amplification in either parental blood,
the nested PCR using PCR product 1 template dilution 10−6 was repeated in an extended
50-cycle protocol. The number of PCR cycles in this protocol should amplify even very small
amounts of mutant allele present in the diluted template. No amplification of mutant product
was observed in either parent or normal control, although some non-specific amplification was
observed at a lower molecular weight indicating possible primer dimerisation or off taget effects
due to a high number of cycles. The proband displayed a strong mutant product at 118bp. A
strong wildtype product was observed in all four samples, and absent in the negative control
with no evidence of non-specific amplification or primer dimerisation (Figure 4.6). This does
not definitively rule out parental gonadal mosaicism as this method has limited sensitivity,
particularly when using DNA extracted from peripheral blood.
4.4.3 Frequency and mutation effect
In silico tools were used to predict the pathogencity of the BCOR variant c.3907G>A (p.Gly1303Ser).
SIFT and MutationTaster both predicted the variant to be damaging to the protein’s function,
with scores of 0 and 0.89 respectively. PROVEAN predicted it was a neutral change, while the
PolyPhen, PhyloP and Grantham scores predict moderate damage. At the time of investigation,
the ExAC Browser MAF for this variant was 0.00005236 (1 allele in 190970)(Table 4.3). All of
these points of evidence indicate that further investigation into this variant was warranted.
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Figure 4.5 BCOR nested PCR-template dilutions
Lane 1 - Proband (II.3), lane 2 - Mother (I.1), lane 3 - Father (I.2), lane 4 - Normal control, lane 5 - Negative
control. A Nested PCR (65◦ annealing/31 cycles) using PCR product 1 diluted 10−4 as template material,
shows clear amplification of WT-specific bands and a MUT-specific band in the proband. The two parents
and the unrelated normal control show no amplification or significant background at this dilution/annealing
temperature. C The specificity of the nested PCR was further examined by using PCR product 1 diluted
10−6 as the template material. Even at this dilution, there is clear amplification of WT-specific bands in
all individuals, and clear amplification of MUT-specific product in the proband with no evidence of mutant
product in the unaffected samples.
Figure 4.6 BCOR allele specific PCR optimi-
sation
Lane 1 - Proband (II.3), lane 2 - Mother (I.1), lane
3 - Father (I.2), lane 4 - Normal control, lane 5
- Negative control. Nested PCR (65◦ annealing/
50 cycles) using PCR product 1 diluted 10−6 as
the template material. Extended cycling of these
products shows clear amplification of WT-specific
bands in all individuals, but only the proband shows
any amplification of MUT-specific product. Note
that gel has been cropped at point indicated with
white line.
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Figure 4.7 BCOR associations
Interactions of BCOR generated by STRING (Known and predicted Protein-Protein Interactions v.9.1:
http://string91.embl.de) evidence view. Interacting proteins of BCOR include the BCL6 complex proteins
RING1, PCGF1, KDM2B, RYBP, BCL6 and HDACs as well as MLLT3 (Myeloid/Lymphoid Or Mixed-Lineage
Leukemia Translocated To, 3).
4.4.4 BCOR functional role
BCOR encodes an interacting corepressor of the BCL6 complex (Figure 4.7). The complex
also includes the proteins ring finger1B (RING1B), polycomb group ring finger1 (PGCF1) and
KDM2B, a lysine-specific demethylase. RING1B catalyses the monoubiquitylation of H2AK119,
while the binding of PCGF1 and KDM2B stimulates the E3 ligase activity of RING1B. KDM2B
recruits the BCL6 complex to non-methylated CpG islands, where it functions to remove histone
H3K36me2 and induce repressive histone H2A monoubiquitylation, enhancing BCL6-mediated
transcriptional repression [154] (Figure 4.8).
The disruption or dysregulation of proper transcription control is recognised as a major
cause of cancers and developmental disorders [155, 156]. BCOR appears to be ubiquitously
expressed in all tissues, based on supporting evidence from literature [152] and experimental
data collection from the EMBL-EBI Expression Atlas (a subset of data shown in Figure 4.9).
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Figure 4.8 The BCL6 complex
The BCL6 complex acts as a unique repressive, transcriptional machinery at CpG islands within transcription
start sites. Nonmethylated CpG islands are used to recruit KDM2B which then recruits the BCL6 complex
resulting in H3K36me2 depletion and repression of histone H2A monoubiquitylation in these regions.
4.4.5 BCOR disease association
BCOR mutations have been associated with human disease, although not previously with
the phenotype presenting in individual II.3. Oculofaciocardiodental syndrome (OFCD) is a
rare X-linked dominant condition with male lethality, characterized by microphthalmia, con-
genital cataracts, facial dysmorphic features, congenital heart defects, and dental anomalies
[157]. Ng et al were first to identify and report frameshift, deletion and nonsense mutations in
BCOR in seven OFCD syndrome pedigrees. They also reported one missense BCOR mutation
(p.Phe85Leu) in two male patients with Lenz microphthalmia (LM) syndrome (characterized
by abnormal development of the eyes and several other parts of the body) [158, 159]. These
findings support the role of BCOR as a key transcriptional regulator during early embryogene-
sis [160], as well as regulating adult mesenchymal stem cell (MSC) functions via an epigenetic
mechanism [161].
To date, OFCD and LM are solely caused by mutations in BCOR (although BCOR muta-
tion are not considered the major molecular cause of LM). All BCOR mutations implicated in
OFCD so far are null alleles that introduce premature stop codons and transcripts are presumed
to be degraded by nonsense mediated decay. These mutations are shown along with the de novo
variant found in this study in Figure 4.10. A study by Hilton et al indicated that OFCD is
a spectrum disorder, and at the mild end may have relatively insignificant non-ocular features
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Figure 4.9 BCOR expression in tissues
Visual extract of from the EMBL-EBI Expression Atlas (http://www.ebi.ac.uk/) showing a summary of the
expression data cataloged from twelve experimental sources, providing evidence for ubiquitous expression of
BCOR in human tissues (ID: ENSG00000183337).
[159]. Truncated BCOR protein is not detected in OFCD patients, likely due to nonsense-
mediated mRNA decay of the transcript [158]. OFCD is therefore considered a condition of
haploinsufficiency rather than a dominant negative effect of mutant BCOR in sensitive cells
[162, 163, 164].
Chimeric fusion transcripts of BCOR have been found in a broad range of cancers, includ-
ing a fusion transcript with the retinoic acid receptor alpha (RARA) in acute promyelocytic
leukemia (APL). Somatic mutations in BCOR have been detected in acute myeloid leukemia
(AML) patients with normal karyotypes (CN-AML), myelodysplastic syndrome (MDS) and
chronic myelomonocytic leukemia (CMML) patients [154]. Somatic BCOR mutations have
been associated with poor prognosis in MDS and CN-AML patients [165, 166]. Additionally,
somatic BCOR mutations have been identified in 3.3% of patients with medulloblastoma [167]
and 9.5% of patients with retinoblastoma [168]. These findings imply that BCOR is a tumour
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suppressor gene, and that the BCOR complex signalling may be an important theraputic tar-
get in BCOR complex-dysregulated cancers, as well as showing that the BCOR complex is
necessary for proper cell differentiation and proliferation [154].
4.5 X-inactivation
During early human female development, one X chromosome is inactivated in each cell to com-
pensate for the difference in X chromosome gene dosage between males and females. This
is typically a random process resulting in approximately half of the cells expressing the ma-
ternal or paternal X allele. Non-random X-inactivation has been observed in some females,
including symptomatic carriers of an X-linked recessive disease and asymptomatic carriers of
an X-linked dominant disorder [169]. In female patients with OFCD, investigation of peripheral
blood lymphocytes show a strong bias towards inactivation of the mutant BCOR allele-carrying
X chromosome. This was seen in six individuals with OFCD in whom X-inactivation studies
were informative, all showing skewing of 90-100% towards the non-mutant BCOR allele, indi-
cating that BCOR is essential for normal hematopoiesis [158]. The varying degree of skewed
X-inactivation which can occur between tissue types, and even between OFCD patients would
explain some of the heterogeneity of phenotype seen in OFCD.
To investigate X-inactivation patterns in this pedigree, the highly polymorphic trinucleotide
repeat within the first exon of the human androgen receptor gene (AR) and the methylation-
sensitive restriction enzyme HpaII were used to distinguish between the maternal and paternal X
alleles and simultaneously determine their methylation. The X-inactivation assay was performed
on samples from the proband’s mother (peripheral blood DNA), the proband (peripheral blood
DNA and buccal cell DNA) as well as a known non-random X-inactivation control to investigate
potential skewed inactivation in this pedigree (Figure 4.11). In a healthy female individual with
random X-inactivation the ratio of each allele ranges from 50:50 to 70:30. Moderate skewing
is usually defined as a ratio above 80:20, while extreme skewing is a ratio above 90:10 [169].
In this analysis the peripheral blood DNA sample of the proband showed moderate skewing
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just below the cutoff for extreme skewing (13:87), while her buccal DNA showed random X-
inactivation (42:58) similar to that of the healthy, age matched female control (41:59). The
proband’s mother showed moderate skewing with a ratio of 19:81. The frequency of moderate
skewing increases with age [170], and although the proband and her mother both show similar
levels of skewing, this is likely to be more significant in the proband who is only in her second
decade of life.
Differentiation between the maternal and paternal BCOR allele in the proband revealed that
the paternal allele was preferentially inactivated (maternal allele is reduced after digestion with
HpaII which targets the active allele) . Since the BCOR variant appears to be de novo in the
proband, the parental allele cannot be determined. Therefore, we can only predict that skewed
inactivation of the paternal X chromosome is due to presence of the BCOR variant. This is
consistent with evidence that a father confers significantly more de novo mutations to their
children than do mothers [171].
4.6 FA exclusion
The finding of skewed X-inactivation, preferentially inactivating the paternal X chromosome,
prompted further consideration of a previous diagnostic assay performed on this individual to
exclude Fanconi’s anemia (FA). FA is the most common type of inherited bone-marrow failure
syndrome with an incidence of 1 per 350,000 births [172]. FA results from mutations in a num-
ber of genes involved in DNA repair mechanisms. These mutations increase the cell’s sensitivity
to cross-linking agents (such a mitomycin C), and diagnosis is often made on observing chro-
mosome breakage after treatment with one of these agents [173, 174]. The clinical features of
FA are varied, including growth retardation, malformations of the kidneys, heart and skeleton,
microcephaly, hypogonadism, cutaneous abnormalities (hyper/hypopigmentation, cafe-au-lait
spots) and unusual facies. Life threatening symptoms are bone marrow failure (BMF) and a
predisposition to cancer. There are currently 17 genes known to cause FA. The majority of these
genes are responsible for DNA repair at stalled replication forks generated either spontaneously
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Figure 4.11 X-inactivation assay for non-random skewing
Analysis of the relative inactivation ratio of the X alleles in this pedigree based on the amplification of the
highly polymorphic (CAG)n repeat within the 5’ end of the coding region of the human androgen receptor
gene (AR), revealed moderate/significant skewing (13:87) in peripheral blood DNA from the proband, while
DNA from a buccal sample appeared to have random X-inactivation (42:58). Sizing of the alleles between the
maternal sample and the proband indicates that inactivation of the paternal allele is occurring in the proband’s
peripheral blood sample. The proband’s mother also displays moderate skewing with an allele ratio of 19:81.
Near complete skewing (8:92) is visible in the positive control sample, previously determined to have skewed
X-inactivation. A healthy female individual was included as a normal control, and random X-inactivation is
visible as an allele ratio of 41:59. X allele ratios are reported as averages of four replicates.
or by DNA interstrand cross-links and other DNA damage [172].
A positive result for FA has been previously reported in one female with OFCD [175] and
the authors of this report raised the question of BCOR mutations potentially being implicated
in FA, particularly as a possible causes of AML development often seen in these patients [176].
When FA analysis was initially performed in this patient, prior to exome sequencing, peripheral
blood cells were cultured in the presence of mitomycin C which induces chromosome breakage
in individuals with FA. The issue arising from the discovery of skewed X-inactivation is that the
percentage of cells expressing a mutant allele may be too low for detection. In individual II.3,
peripheral blood cells may be expressing only approximately 10% mutant BCOR and 90% nor-
mal BCOR. Any chromosome breakage analysis performed on these cells will be biased towards
the breakage observed in cells expressing a normal allele (assuming BCOR variant inactivation),
resulting in a possible false negative result.
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Figure 4.12 X-inactivation assay of skin biopsy
DNA was extracted from both the hyperpigmented and normal pigmentation biopsy. X-inactivation analysis
was performed on both samples pre and post cell culture. No evidence of skewing was observed either pre or
post culture with allele ratios <60:40. X allele ratios are reported as averages of all replicates.
In order to exclude FA as a diagnosis for this individual it was decided that the mitomycin
C assay should be repeated on cultured cells which were not affected by skewed X-inactivation.
A sample of the proband’s buccal cells showed random X-inactivation when analysed, but a
sample of buccal cells is inappropriate for culture due to the non-sterile environment of the
mouth. Instead, two skin biopsies were performed by a dermatologist to obtain fibroblasts for
culture. One biopsy was collected from skin with normal pigmentation, and the second from a
hyperpigmented area in case X-inactivation was associated with the pigmentation phenotype.
X-inactivation analysis was performed on DNA extracted from the biopsy samples immediately
post collection, and then following culturing to firstly determine if skewed X-inactivation was
present in either sample and secondly to ensure that no significant skewing was introduced
during the culture process. No skewing was observed in either skin biopsy pre or post cul-
turing (Figure 4.12). Both cell cultures were then sent to Cincinnati Children’s Hospital who
could perform a diagnostic Mitomycin C assay. Neither sample showed significant levels of
chromosome breakage and were reported negative for FA.
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4.7 Discussion
A mutation in BCOR (p.Gly1303Ser) was identified in a female patient with a syndrome charac-
terised by premature ageing, behavioural problems, developmental delay and dyserythropoietic
macrocytosis among several other symptoms. Although not entirely novel, the BCOR mutation
is only documented once in a person of South Asian descent in the ExAC database and has
not been functionally characterised. The proband has two brothers who are healthy aside from
some slight learning difficulties. Prior to exome sequencing, both dyskeratosis congenita and
Fanconi’s anemia (FA) had been considered possible diagnoses, although they were subsequently
excluded (or considered unlikely) following gold standard diagnostic testing.
Analysis of the parents indicated that this mutation is a de novo occurrence in the proband. In
silico prediction scores of pathogenicity varied but largely supported a deleterious effect of the
Gly1303Ser change. SIFT and MutationTaster gave scores of 0 and 0.89 respectively, indicating
the mutation is likely to be damaging or disease causing. PolyPhen-2 scored the variant at
0.804 which equates to a possibly damaging prediction. The mutation frequency as assessed
by ExAC was extremely rare, seen in only 1/190970 alleles, and the wildtype Gly amino acid
at position 1303 is strongly conserved between species (PhyloP, 4.7; PhastCons, 1). Structural
modelling of the variant was limited as there is no 3D structure of the whole gene as yet.
In the past, the field of Mendelian medical genetics has largely been restricted to inherited
variation by family-based linkage studies. The more recent advances of microarrays and MPS
technologies have allowed the study of de novo mutations, which were largely missed in previ-
ous investigative models. It is only now emerging, the extent to which de novo mutations play
a role in both common and rare forms of neurodevelopmental disease [177]. On average, an
individual’s genome contains 74 germ line de novo SNVs [178], which although rare, have not
been subjected to stringent evolutionary selection [179, 180] and are therefore strong candidates
for sporadic disease [177]. In addition to SNVs, de novo indels and CNVs are present, although
these occur at a lower frequency. The rate of indel occurrence equates to approximately three
Chapter 4 – Trio analysis - a sporadic case of premature ageing 91
novel changes per genome per generation [181], and the frequency of CNVs even lower, occur-
ring only once in every 50 individual genomes [182].
For an apparent de novo mutation that occurs in an affected child, it is often important for
the parents future reproductive choices to ascertain whether the mutation occurred exclusively
in the proband in either a germline or mosaic form, or whether it has been transmitted via
parental mosaicism. De novo mutations can occur at any stage of gametogenesis and at further
stages of development. If the affected proband is mosaic, then it is likely that the mutation
arose postzygotically and the chances of recurrence in another sibling is negligible. If, however,
a parent was an unaffected somatic mosaic carrier of the mutation the recurrence rate in a
future child may be up to 50%, requiring very different counselling situations [183, 184]. In
this pedigree, an allele specific PCR assay was designed to try and exclude the possibility that
either parent is a significant somatic mosaic for the BCOR mutation. However, no detection of
the mutation in peripheral blood does not exclude the possibility that one parent is a gonadal
mosaic. Analysis of this scenario would require ovarian or sperm samples, which were consid-
ered too invasive to procure. The basis for investigating peripheral blood in the parents was
considered a good compromise based on a recent study which found that apparent high quality
de novo mutations in a proband actually arose from low level parental somatic mosaicism (in
4/50 trios) [185], or gonadal mosaicism which is detectable in the parental peripheral blood by
sequencing [186]. It is important to note that deep sequencing across the BCOR mutation was
not performed in either parent, and therefore the question of pre or post zygotic inheritance is
not fully resolved in this pedigree.
Although there is a reasonable association between the de novo BCOR mutation identified
in this proband, and the phenotype displayed, the process of establishing pathogenicity and
causality of an uncharacterised variant in this context is achieved by building evidence from
multiple sources. The avenues of information that can be used in establishing pathogenicity
are summarised in Figure 4.13. Gene function is an important aspect to be considered, and
consideration of the effect of the mutated gene in the context of the phenotypic characteristics.
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The former relies on known information available, while the latter may be assessed by in silico
approaches although with the current low level of genomic data available, in silico models are
problematic for de novo missense mutations in particular. Evidence for the pathogenicity of a
mutation may be built from factors such as the gene in question known to cause the specific
disease, or in a related pathway. Or less strongly, mRNA expression patterns in disease affected
tissues and inferred functional attributes. Data from model organisms and protein-protein in-
teraction studies can further support this evidence [177]. An integrated approach of all lines
of evidence, and the phenotype of the patient currently remains the most accurate predication
tool for variant pathogenicity.
Figure 4.13 Establishing de novo mutation causality
One of the biggest challenges in interpreting exome data is understanding which mutations may be causal
in the phenotype at hand. In the case of de novo mutations this can be a difficult task as irrelevant de
novo variants are likely to outnumber disease causing mutations. There are several factors to consider when
assigning disease causality to a de novo mutation. Mutation effect and Gene function should be considered
in terms of the phenotype. Nonsense mutations in a relevant gene for example is more likely to be causal of
disease than a synonymous SNV in an gene not expressed in affected tissues. Frequency of the mutation
can also be an indication of pathogenicity, as common SNVs are unlikely to cause disease. Most compellingly
would be Clinical evidence which would include multiple unrelated affected individuals with the same de
novo mutation, or segregation of the mutation within a large pedigree. Figure adapted from Veltman et al
2012 [177].
BCOR is an important corepressor, potentiating transcriptional repression of the proto-oncoprotein
BCL-6 and suppressing the transcriptional activity of AF9, a common mixed-lineage leukemia
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fusion partner. BCOR mutations have been implicated in Lenz microphthalmia (LM), oculo-
faciocardiodental syndrome (OFCD) and myelodysplastic disorders, and recent studies suggest
that BCOR uses a unique combination of epigenetic modifications to direct gene silencing [187].
Characterisation of protein expression in mice shows that Bcor displays widespread but specific
expression during embryonic development. Strong expression of Bcor was observed in the de-
veloping eye, tooth primordial, limb buds, branchial arches, and multiple nervous system tissue
which correlates with the tissues most commonly affected in OFCD and LM patients [160, 188].
Hilton et al [189] additionally confirmed a role of BCOR in vertebrate laterality determination
(defective in some cases of OFCD causing dextrocardia and intestinal malrotation) and ocular
development, modeling OFCD in Xenopus tropicalis.
BCL-6 is a subclass of zinc finger proteins with a N terminus POZ/BTB domain and C termi-
nus zinc fingers. BCL-6 interacts with several corepressors via these domains, with the POZ
domain interacting with NCOR, SMRT and BCOR in a mutually exclusive fashion, suggesting
that the functions of BCL-6 may be segregated among the corepressors. The BCOR complex
and the mono-ubiquitylated form of histone H2A are shown to localise to several BCL-6 targets,
including p53 (TP53) and Cyclin D2 (CCND2) in lymphoma cells, suggesting that the BCOR
complex is regulating these genes through H2A monoubiquitylation activity [187]. Cyclin D2
is one of three cyclins that act as critical governors of the mammalian cell-cycle clock during
the G1 phase. Cylin D2-deficient female mice are sterile as ovarian granulosa cells cannot pro-
liferate normally in response to follicle stimulating hormone (FSH), and deficient male mice
display hypoplastic testes [190]. TP53 is crucial in multicellular organisms where it functions as
a tumour suppressor. In human cancer, TP53 is the most frequently mutated gene, functionally
involved in gene transcription, DNA synthesis and repair, genomic plasticity and programmed
cell death. Additionally, tumours with TP53 mutations are often more aggressive and gene
expression has been implicated as an independent prognostic factor in carcinomas [191].
BCL-6 plays a critical role in specific immunological processes, acting as a transcriptional
switch that controls germinal centre formation. BCL-6 deficient mice do not form germinal
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centres, have defects in T-cell-dependent antibody response and go on to develop inflamma-
tory disease. Growth retardation, and prominent myocarditis and pulmonary vasculitis were
observed in BCL-6 deficient mice who often died prior to 5 weeks of age [192]. Further investiga-
tion of BCL-6 null mice showed systemic inflammatory disease involving multiple organs, most
commonly the myocardium, spleen, gut, liver and skin. Prominent eosinophilic infiltrates and
an increase in IgG1 and IgE-bearing B cells were observed in these mice, consistent with a T
helper 2 (Th2)-mediated inflammatory response [193]. Th2 cells are involved in mediating the
activation and maintenance of the antibody-mediated immune response by producing cytokines
which have a variety of effects on numerous cell types. Among these effects is the stimulation
and recruitment of specialised subsets of immune cells in response to allergens or infection.
Additionally Th2 cells stimulate the maturation of B cells into IgE-producing plasma cells. A
summary of the symptoms and features observed in the proband of the affected family in this
case study is provided in Section 4.2. Of interest in relation to the immunological involvement
of BCOR are the numerous symptoms that may have an inflammatory basis such as otitis me-
dia, atopic eczema, reticulate pigmentation, general ageing appearance of skin, nails and hair,
and even her primary adrenal failure. Although the p.Gly1303Ser mutation in BCOR found in
the proband does not lie within the region of the gene that encodes the BCL-6 binding region,
without a structural model it is uncertain whether there may still be a deleterious effect of the
mutation on BCL-6 binding when the protein folds. It is therefore possible that this mutation
in BCOR could modulate the BCL-6 immune response of various cell types. In the context of
BCOR mutations and LM it is interesting to note that affected individuals have no immunoreg-
ulatory deficits, as the BCOR mutation involved in LM (p.Pro85Leu) interacts normally with
BCL-6, indicating that BCOR mutations can affect development through non-BCL-6 pathways
[158].
BCOR mutations have also been implicated in a range of cancers including acute promyelocytic
leukemia (APL), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML).
Mutations include both chimeric fusion transcripts and somatic variants [154]. In patients
with myelodysplastic disorders, somatic BCOR mutations arise secondary to mutation in genes
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involved in splicing or epigenetic regulation [165]. Somatic mutations are scattered through
the BCOR coding sequence, however there is a tendency to accumulate at the c-terminal end
which contains the the critical binding domains for other subunits of the BCOR complex. The
p.Gly1303Ser mutation in BCOR lies linearly distant to the c terminal PCGF1 binding site,
which begins at residue 1634. However, as previously noted, there is no structural model for
BCOR at present that might provide more information on the spatial separation and effect
of the residue at 1303 on binding activity at the C terminal. The proband in this case study
has had ongoing unexplained dyserythropoietic macrocytosis and lowered haemoglobin levels.
Considering the implications of cancer development with somatic BCOR mutations it would be
indicated that the proband was seen by a haematologist for monitoring.
One avenue of investigation that arose from investigations into BCOR and a possible mech-
anism for the ageing disorder seen in this proband was the DNA repair defect syndrome Fan-
coni’s anemia (FA). Although high sensitivity to cross-linking agents (chromosome fragility)
is the hallmark of FA, somatic mosaicism (present in 15-25% of patients) can influence the
detection of this leading to false negative test results. If reversion of a haematopoietic precur-
sor cell occurs, then the increased proliferative advantage means that these reverted cells can
expand and chromosome fragility will be reduced. Retrospective analysis of the investigations
undertaken on the proband (II.3) in this study highlighted that chromosome fragility of cultured
peripheral blood lymphocytes in response to exposure to mitomycin C was examined at an early
age, though the result of that test did not support a diagnosis of Fanconi’s anemia. The finding
of skewed X-inactivation in blood (but not buccal cells or fibroblasts) of the proband raised the
possibility that the X chromosome harbouring the mutant BCOR allele was being preferentially
inactivated and therefore any investigations of chromosome fragility would be dependant on the
level of inactivation of the mutant allele. Non-random X-inactivation more commonly occurs in
female carriers of an X-chromosome mutation, where the mutant allele is being selected against
in rapidly dividing tissues or in tissues where function of the affected gene is critical. This
scenario would appear to mimic the case of reversion of a haematopoietic precursor cell leading
to a normal chromosome fragility result in a patient who does in fact have an FA-causing muta-
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tion. In extreme skewing (>90:10) less than 10% of the cells in a peripheral blood lymphocyte
culture will be expressing the mutant BCOR allele, and this ratio may be further influenced by
the selective pressure on cultured cells. In this instance, the proband showed moderate skewing
(88:12) that would result in <15% of cultured cells expressing the BCOR mutant (based on
the assumption that the mutant BCOR allele is preferentially inactivated). The X-inactivation
analysis also identified moderate skewing in the proband’s mother. This was at a lower ratio
(81:19), closer to the normal range seen in unaffected females (50:50-80:20), and is unlikely to
be significant given that she is >50years. There is evidence for a significant increase in normal
females displaying skewing in a >60 years age group compared to 28-32 years [194].
Repeated mitomycin C testing of cultured skin fibroblasts was performed on the proband after
it was ascertained that these cells showed a random X-inactivation pattern. This testing also
returned a negative result for FA. however, it should be noted that in a previous case of two
sisters with OFCD, a positive mitomycin C test was returned for one sibling but not the other,
leading to speculation that there may be confounding issues around the mitomycin C assay in
the presence of BCOR mutations [175]. There is currently at least one example of a BCOR
mutation identified in exome data of an FA patient [195] which may support this theory and
warrant further investigation of an association between BCOR mutations and FA patients.
As previously mentioned in Section 4.4.5, BCOR mutations that are causative of OFCD are
truncating mutations that are expected to produce transcripts which are degraded through
nonsense-mediated mRNA decay. Hence, the mechanism of pathogenicity in OFCD is con-
sidered haploinsufficiency rather than a dominant negative effect. However the sensitivity of
cells to BCOR haploinsufficiency must be considerable given that patients experience skewed
X-inactivation in multiple cell types, and therefore mutant BCOR may only be active in <10%
of cells in the first place. This does not correspond to a 50% loss of wildtype BCOR, but rather
a 10% loss (or less). In some tissue types of course, the X-inactivation ratio is not skewed and
50% haploinsufficiency will be experienced, but these are presumably tissues in which BCOR
function is less critical. The missense mutation seen in this case study does not truncate the
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transcript, and therefore should not be targeted by nonsense-mediated mRNA decay. It is rea-
sonable to assume that mutant protein would be produced and expressed in cells, and could
possibly be altering the normal function of BCOR, in contrast to the haploinsufficiency effect
seen in OFCD. As the proband in this case study shows moderate-extreme skewing in at least
one tissue type analysed, the ratio of mutant BCOR that could potentially be expressed ranges
from <10% to 50%. This could lead to differing effects depending on the skewing present a given
tissue or cell type. It would be interesting to quantify expression of mutant BCOR in differing
tissues, particularly those with apparent random X-inactivation to determine if expression is
truly 50% or there is some bias against correct processing of the mutant RNA. Unfortunately,
acquiring such tissues would be highly invasive and was not considered necessary for the project.
Difficulties in pursuing this BCOR variant further in the setting of this affected individual
include lack of structural information, and a clear understanding of how components of the
BCOR complex associate. Without understanding the importance of the affected sequence re-
gion (and how this may impair complex association by structurally preventing association or
altering a recognition sequence) it is difficult to explain how a mutation in BCOR could lead to
the phenotype observed. Further work is needed to properly explore the context of this variant
in this individual, however, such work is outside the scope of this PhD thesis.
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Chapter 5
A case of sudden cardiac death
5.1 Family Christchurch
This chapter focuses on an undiagnosed family with an inherited cardiac phenotype. This
chapter discusses the analysis of the exome sequencing data, while subsequent chapters will
explore the research avenues that have arisen from the findings in this chapter.
5.1.1 Case history
A Caucasian family of two parents and four children were identified as harbouring a possible
genetic abnormality following the death of two teenage male children (II.1 and II.3 in Figure 5.1)
with presumed sudden arrhythmia (Figure 5.1). On autopsy, marked mid-myocardial fibrosis
was documented. Subsequent clinical review of the surviving children (II.2 and II.4 in Figure
5.1) detected dilated cardiomyopathy with mid-myocardial fibrosis. All four children in this
family had previously shown an unexplained, exquisite sensitivity to alcohol ingestion resulting
in pain and discomfort. Analysis of the parents showed no cardiac abnormalities and they were
considered unaffected. No other patients with this set of features have been identified to date
and it is believed the family may characterise a novel syndrome with predisposition to sudden
arrhythmic cardiac death.
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Figure 5.1 Family Christchurch pedigree showing cardiac condition
All four children are affected with the familial cardiac condition as diagnosed by cardiac MRI (CMR). Individuals
II.1 and II.3 died suddenly at ages 15 and 20 years respectively. Both parents are unaffected on cardiac MRI
(CMR).
Individual II.1 collapsed and died aged 15, after drinking a small amount of beer (150mL,
or 6g of ethanol). He was previously well, and had no prior cardiac symptoms, but like all his
siblings had been exquisitely sensitive to alcohol. This manifested as dull pain in the chest,
a feeling of heaviness throughout the limbs, and pallor, following the consumption of small
amounts of alcohol (typically dessert such as trifle or medicine such as children’s cough syrup).
At post mortem examination the only macroscopic abnormality observed was slight dilation
of the heart, with both ventricles being enlarged and small pale area on the epicardium of the
left ventricle. Microscopic examination of cardiac tissue revealed evidence of focal inflammation
with neutrophils, lymphocytes and eosinophils. The coronary arteries were normal. A diagnosis
of myocarditis and sudden arrhythmic cardiac death was made.
Individual II.2 exhibited the same sensitivity to alcohol. He was clinically assessed because
of his family history after the death of sibling II.1. Physical examination was normal as was
an echocardiogram, exercise test and Holter monitor. However a MRI scan showed marked
mid-myocardial fibrosis (Figure 5.2). He subsequently received an implanted defibrillator for
primary prophylaxis of sudden arrhythmic cardiac death. No events of device triggering have
occurred to date.
Patient II.3 died aged 20 years after drinking a small amount of alcohol (anecdotally, two
spirit drinks). He was previously well, and had no prior cardiac symptoms, but had also been
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Figure 5.2 Cardiac MRI
Siblings II.2 and II.4 show prominent
midmyocardial fibrosis on CMR.
A Sibling II.2 shows moderate cardiac
fibrosis.
B Sibling II.4 shows severe cardiac fi-
brosis.
Fibrosis marked by arrows. Image
credit: Ian Crozier.
Figure 5.3 Heart section
A Sibling II.3, post-mortem transverse
section through left ventricle showing
a virtually circumferential lamina of
scarring in midmyocardium with focal
subendocardial involvement.
B / C Low and high power microscopy
of the posterior free wall of the left
ventricle showing prominent midmy-
ocardial loose fibrosis. Image credit:
Ian Crozier.
exquisitely sensitive to alcohol. At post mortem examination the only abnormalities observed
were in the heart. The heart weighed 395g (normal 300g). The left ventricle was dilated with a
virtually circumferential lamina of scarring in the mid-myocardium and with focal subendocar-
dial involvement. Microscopic examination revealed very widespread, mostly mature, scarring
of mid-myocardium in all sectors (Figure 5.3). No ischaemic changes were observed and there
was no microscopic evidence to suggest acute hypersensitivity or interstitial acute myocarditis.
The coronary arteries were normal.
Patient II.4 remains well with no cardiac symptoms, but exhibited the family sensitivity to
alcohol. She was clinically assessed because of her family history after the death of her sibling;
individual II.1. Physical examination was normal, as was echocardiogram, exercise test and
Holter monitor. However a MRI showed marked mid-myocardial fibrosis (Figure 5.2). She sub-
sequently also received an implanted defibrillator for primary prophylaxis of sudden arrhythmic
cardiac death. No events of device triggering have occurred to date. At the time the defibrilla-
tor was implanted a skeletal muscle biopsy was obtained which showed no obvious abnormality
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under histopathology examination, although a muscular dystrophy or metabolic disorder could
not be excluded. Stains for fat and glycogen were within normal limits. A panel of enzyme
antibody stains (including myophosphorylase, NADH, COX, SDH, MADA, aldolase and PFK)
was normal. Immuno-histochemical studies of skeletal muscle showed changes suggestive of a
mild chronic myopathy. However immunostaining for dystrophin, dysferlin, emerin and laminin
showed no obvious abnormality. Urine organic/amino acid, and blood spot acylcarnitine pro-
filing showed no abnormalities. Whole blood carnitine was within normal limits at 23µmol/L
(normal range 11-58).
5.1.2 Array CGH
In order to detect significant copy number variants within the family, which wouldn’t be de-
tected by DNA sequencing approaches, arrayCGH was performed using Nimblegen 135k oligo
microrrays in the four living individuals. No clinically significant CNVs were detected in any
of the four family members (data not shown), nor were there any variants of unknown clinical
significance. We detected common CNVs which segregated within the family. Although not
exhaustive, this analysis discounted larger CNV’s (>50kb) underlying the inheritance of this
pedigree’s cardiac condition.
5.1.3 Targeted genetic analysis
Previous molecular investigation in II.4 included targeted sequencing of all 12 exons of the
lamin A/C gene (LMNA) and also all coding regions of the lamin-associated protein 2 gene
(LAP2). These exons, together with flanking intronic sequences were analysed and no muta-
tions were detected. Mitochondrial genome sequencing was undertaken on whole blood, buccal
cells and a skeletal muscle biopsy from II.4 and on whole blood from II.3. No known patho-
logical mitochondrial sequence variants were detected. However both siblings were found to be
homoplasmic for a novel sequence variant (m.9751T>C) in the Cytochrome C oxidase subunit
III (MT-CO3) gene, which results in the substitution of a phenylalanine for a serine at residue
182 of the COXIII protein (p.COXIII:Phe182Ser) (Data not shown). Other mutations in MT-
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CO3 are known to be causative of mitochondrial disorders such as Leigh syndrome, Leber’s
optic atrophy and cytochrom-c oxidase deficiency. However sequence analysis of the MT-CO3
gene from a whole blood sample from the mother showed she was also homoplasmic for the
m.9751T>C sequence variant, indicating the substitution is unlikely to be solely responsible for
the phenotype seen in her children.
Due to the lack of adequate explanation for the alcohol sensitivity and sudden cardiac death in
this family, further analysis was undertaken. Instead of sequentially sequencing less convincing
candidate genes in an attempt to uncover a basis for the condition, the implementation of exome
sequencing allowed us to investigate the entire coding region of the genome, avoiding the bias
of selecting genes to be analysed.
5.1.4 DNA preparation
DNA from all six family members had been previously extracted for mitochondrial sequence
studies, and stored at 4◦C for >5 years. DNA from I.1, I.2, II.2 and II.4 was in usable condition,
however, samples from II.1 and II.3 were considered fully degraded and not suitable for further
analysis (data not shown).
5.1.5 Exome analysis
Library preparation and exome sequencing was performed by New Zealand Genomics Lim-
ited (NZGL). The Illumina software enrichment pipeline v.0.9 generated between 64,691 -
71,555 annotated variants for each individual exome, this data was returned in variant call
files (VCF). Further filtering of the VCF’s in ANNOVAR was performed to exclude variants
with a MAF>0.01. This reduced the number of variants to 3,350 - 6,581 variants which were
available in VARLIST files. After manual filtering within excel to exclude variants not shared
by the two affected siblings, the number of variants on which to focus further attention on was
reduced to 724.
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Cardiomyopathy-associated gene analysis
A comparison of these 724 variants to a list of 41 cardiomyopathy-associated genes (See Table
5.1) yielded three variants in the large gene TTN that were common to both affected siblings.
These three variants were paternally inherited, and polymorphic. No other genes from the
candidate list had variants present in both affected siblings. Titin is the largest known protein
with up to 364 exons , and missense variants of no pathogenic consequence are very common,
with an average of 23 present in any individual in the EVS database [196]. No variants from
this panel were progressed for further analysis, and a wider analysis of the exome data was
considered.
Table 5.1 Cardiomyopathy-associated gene list
ABCC9 ILK PDLIM3 TPM1
ACTC1 LAMP2 PLN TTN
ANKRD1 LAP2 RBM20 TTR
ATCN2 LDB3/ZASP SCN5A TXNRD2
BAG3 LMNA SGCD VCL
CRYAB MYBPC3 TAZ PSEN2
CSRP3 MYH6 TCAP PSEN1





As both parents of these affected siblings are unaffected, a recessive model of inheritance was
explored. Fifty genes were identified as containing two or more variants in both living affected
siblings. Of these, 47 were excluded from further exploration due to lack of evidence supporting
relevance to this family’s phenotype (Figure 5.4). Three genes remained as potential candidates
for a cardiac-type disorder; TTN (Titin ), KCNJ12 (Potassium Voltage-Gated Channel Sub-
family J Member 12) and PPA2 (Inorganic Pyrophosphatase 2). KCNJ12 encodes a protein
which functions as an inwardly rectifying channel contributing to the cardiac inward rectifier
current. TTN has previously been associated with familial hypertrophic cardiomyopathy, and
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Figure 5.4 Variant filtration
Schematic of variant filtration, showing the scale of variants detected by whole exome sequencing (WES).
as such was included on the candidate gene list in the approach above (see Section 5.1.5).
PPA2 produces an enzyme involved in the mitochondrial oxidation-phosphorylation pathway
(OXPHOS) which has multiple components implicated in cardiac myopathy [197]. Analysis of
all these genes was performed in both unaffected parents. The three TTN variants were previ-
ously excluded by the candidate gene approach as being paternally inherited and polymorphic
while the two KCNJ12 variants were excluded based on non-segregation with the phenotype.
The remaining candidate gene, PPA2, had not been associated with human disease previously;
however the localisation of the product to the mitochondrial OXPHOS pathway was of interest.
The two variants identified in PPA2 ; c.514G>A (p.Glu172Lys) and c.683C>T (p.Pro228Leu)
segregated with the phenotype, and importantly, both parents were found to each have one of
the two variants suggesting a compound heterozygous mode of inheritance if proved pathogenic
(Figure 5.5). Therefore, PPA2 was the sole remaining candidate following filtering. The fact
that PPA2 is a mitochondrial-associated gene meant that the additional COXIII variant iden-
tified in all four children (see 5.1.3), was not excluded as a factor that could be contributing to
the familial condition.
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Figure 5.5 PPA2 variants - IGV visualisation
Variants c.514G>A (p.Glu172Lys) (left) and c.683C>T (p.Pro228Leu) (right) can be seen in both affected
surviving children (II.4 and II.2). Variant p.Glu172Lys is present in the the father (I.1) but not mother (I.2).
Conversely, p.Pro228Leu is present in the mother (I.2) but not father (I.1) confirming children are compound
heterozygous for these variants.
5.1.6 Sanger sequencing
Although initial analysis was performed on historical DNA (including FFPE autopsy samples),
new EDTA blood samples were collected from the living patients for DNA extraction and
confirmatory Sanger sequencing. DNA from stored Guthrie spots was used in the case of
patients II.1 and II.3. Sanger sequencing of the region surrounding p.Glu172 and p.Pro228
confirmed that all four children were compound heterozygotes for both mutations, located in
exons 6 and 8 of PPA2 (Figure 5.6). Supporting this, both parents were confirmed to be carriers
of one mutation (Glu172Lys = paternal; Pro228Leu = maternal).
5.2 PPA2 variant investigations
5.2.1 In silico predictions of PPA2 variants
The PPA2 variants; c.514G>A (p.Glu172Lys) and c.683C>T (p.Pro228Leu) were assessed in
silico for predicted functional effects and evolutionary conservation of the affected residue.
These predictions strongly indicated that both variants involve highly evolutionarily conserved
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residues, and are predicted to cause severe functional effects (Tables 5.2). Glu172Lys is ac-
tually present in the database dbSNP (rs146013446), however, given the segregation data and
damaging in silico predictions it was not excluded based on this.
Table 5.2 In silico predictions for PPA2 variants
SIFT PolyPhen-2 MutationTaster Grantham MAF
p.Glu172Lys 0 1 1 56 4.9E−4
p.Pro228Leu 0 0.996 1 98 2.5E−4
Damaging (Pink); Moderate (Orange); Neutral (Green)
5.2.2 Modelling
The high degree of homology between the human and yeast pyrophosphatase proteins allowed
predictive modelling based on the known yeast structure of PPA1 [198] in the absence of a PPA2
model. This allowed visualisation of the predicted change in hydrogen bonding and structural
characteristics of the variant residues compared to wildtype at the two points of interest. A
substitution of glutamine to lysine at residue 172 is predicted to disrupt at least 3 hydrogen
bonds between interacting protein chains (Figure 5.7). A substitution of Proline to Leucine at
residue 228 is also predicted to disrupt the secondary structure of PPA2 based on the exceptional
conformational rigidity that proline confers. This residue forms the turn between two helixes,
and may be essential for the correct position and orientation of these structures. Proline’s
struction mean that in evolutionary terms it forms an important element of the tertiary protein
structure, allowing twists and turns of the amino acid sequence to facilitate distinct domain
formation and transitions from α to β sheets (Figure 5.8).
5.3 In silico prediction of mitochondrial variant
Previous in silico analysis of the COXIII variant m.9751T>C (p.Phe182Ser), indicated that
the phenylalanine residue is not highly conserved among vertebrates. There is, however, some
structural conservation (Figure 5.9). Phenylalanine, tyrosine and less commonly isoleucine are
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Figure 5.6 Variant resequencing and modelling.
A Variant re-sequencing and exon position of PPA2 variants p.Glu172Lys and p.Pro288Leu. Electropherogram
shown is an example of one affected family member who is compound heterozygous for the two PPA2 variants.
B Saccharomyces cerevisiae space fill model indicating the position of the homologous Glu172 residue in
yellow. C Saccharomyces cerevisiae space fill model indicating the position of the homologous Pro228 residue
in yellow.
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Figure 5.7 Yeast structural model (PPA1) showing predicted position of human PPA2 variant at
172
Position within dimer molecule of residue 172 highlighted in red (Glu123 label refers to equivalent residue
in Saccharomyces structure). Putative active site residues are highlighted in yellow (Left). A substitution
of Glutamine to Lysine at residue 172 is predicted to disrupt at least 3 hydrogen bonds between interacting
protein chains, and convert the charge on the residue from negative to positive (Right)
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Figure 5.8 Yeast structural model (PPA1) showing predicted position of human PPA2 variant at
228.
A substitution of Proline to Leucine at residue 228 is predicted to disrupt the secondary structure of PPA2
based on the exceptional conformational rigidity that proline confers (Left). Position within dimer molecule of
residue 172 highlighted in red (Pro179 label refers to equivalent residue in Saccharomyces structure). Putative
active site residues are highlighted in yellow (Right).
Chapter 5 – A case of sudden cardiac death 111
Figure 5.9 COXIII structural conservation
Structural conservation between the amino acids present at COXIII residue 182. Phenylalanine is the wildtype
human residue, whilst tyrosine and infrequently isoleucine are present in different species. These three amino
acids all contain a hydrophobic side chain, and are physiochemically quite distinct from the Serine residue
seen at position 182 in the maternal line of this family.
the only three amino acids present across an extensive range of sequence entries. These amino
acids all contain a hydrophobic side chain and are grouped similarly under several measures
of amino acid diversity. Given the structural conservation observed this residue may be more
damaging than previously suggested by in silico algorithms.
5.4 Discussion
Mitochondrial sequencing and whole exome sequencing (WES) have been used to extensively
investigate the genetic basis of this familial condition, identifying three variants that are con-
sidered strong candidates for pathogenicity. Two of the variants in the nuclear encoded (but
mitochondrial associated) gene PPA2 (p.Glu172Lys and p.Pro228Leu) were identified segregat-
ing in a compound heterozygous configuration in two symptomatic individuals in a family with
a history of dilated cardiomyopathy and sudden cardiac death. Sanger sequencing confirmed
the presence of both variants in all four affected children, and that both parents were carriers of
one variant. In silico analyses supported the hypothesis that these variants would be damaging,
despite p.Glu172Lys being included in the dbSNP database as a polymorphism (rs146013446).
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As previously detailed, in addition to the PPA2 variants, the affected individuals (and their
mother) are homoplasmic for a novel sequence variant (m.9751T>C) in the Cytochrome C ox-
idase subunit III (MT-CO3) gene, which results in the substitution of a phenylalanine to a
serine at residue 182 of the COXIII protein (p.COXIII:Phe182Ser). This variant was classified
as of unknown significance when it was first identified, and early in silico prections indicated
it may be benign. When analysing this variant in the context of PPA2 variants also being
present, the low PolyPhen-2 score was attributed to an apparent lack of conservation of residue
Phe182 within MT-CO3. In a comparison of this residue across multiple species, phenylalanine,
tyrosine and isoleucine are all represented but not serine, notably. So, although there is weak
sequence conservation, there is, strong structural conservation. Phenylalanine, tyrosine and
isoleucine all share chemical features that are distinct from the serine residue which is present
in this family. Bearing this in mind this variant may have more functional importance than
the in silico measures initially predicted, with the distinct possibility that it may genetically
interact with the PPA2 variants.
Modelling of the PPA2 variants based on the highly homologous yeast pyrophosphatase struc-
ture indicated the potential importance of their position within the molecule. Glu172 lies
directly behind the magnesium binding catalytic cleft. Previous studies in yeast have shown
that altering residues around Glu172 can completely abolish PPA2 function [199]. In particular
residues 164 and 169 are necessary for the binding of magnesium [199]. In contrast Pro228 is
not located within the active site of the molecule, but lies on the interface of the two PPA2
molecules interacting to form a dimer. As a proline residue confers exceptional conformational
rigidity and peptide chain turning ability, it would be predicted that a Pro228Leu mutation
could disrupt this interface structure. It is interesting to note that given the dimeric nature
of PPA2 molecules, and the presence of two independent mutations, there are three different
dimer products that can potentially form a compound heterozygote (Figure 5.10). The dif-
ference between a carrier and a compound heterozygote is the overall complement of wildtype
PPA2 dimers, dimers with one mutant molecule, and dimers with two mutant molecules (either
the same mutation or different). In a carrier, 1/3 of dimers would be wildtype (two wildtype
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Figure 5.10 Dimer combinations
Combinations of dimer molecules that can occur in PPA2 mutation carriers, and compound heterozygotes.
molecules). In a compound heterozygote 0/3 of dimers would be wildtype. It would be interest-
ing to compare the functionality of these dimer products and determine approximate percentage
of PPA2 function in a carrier vs a compound heterozygote setting.
The Exome Aggregation Consortium (Exome Aggregation Consortium (ExAC), Cambridge,
MA (URL: http://exac.broadinstitute.org [Sept 2016]) browser is currently one of the most
comprehensive summaries of exome data; consisting of over 120000 high-quality allele calls
from 60706 unrelated individuals sequenced as part of various disease-specific and population
genetic studies. Cases of severe paediatirc disease have been removed, so this data set should
serve as a useful reference set of allele frequencies for severe disease studies.
The allele frequency of the p.Pro228Leu variants in ExAC is <0.0002 (30/120268 alleles).The
allele frequency of the p.Glu172Lys variants in ExAC is <0.0004 (59/120800 alleles) Interest-
ingly, of all 147 missense and loss of function (LOF) PPA2 variants included in the ExAC
database, only four missense mutations have been observed in a homozygous state, and one of
those has been observed only once. This is usually a reflection of strict conservation required
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for correct function of the protein. Variants that either do not occur at all or are not present in
the population in a homozygous state reflect strict functional control at the coding region of the
genome. No occurrence of homozygosity was observed for either p.Glu172Lys or p.Pro228Leu.
The occurrence of the Glu172 Lys variant in dbSNP is important, as many filtering strate-
gies exclude all variants present in this database as a way of minimising polymorphisms in
the variants to be investigated. Applying such a filtering strategy in this case would not have
brought PPA2 to attention. As quoted by Sherry et al ”There is no requirement or assump-
tion about minimum allele frequencies or functional neutrality for the polymorphisms in the
database. Thus, the scope of dbSNP includes disease-causing clinical mutations as well as neu-
tral polymorphisms” [200]. Therefore the use of presence of dbSNP as exclusion criteria should
be avoided. The possible involvement of alcohol in relation to the SCD events occurring in
this family is a unique factor that warrants further investigation. There are known reactions to
alcohol metabolism defects, such as the ADH and ALDH mutations which contribute to the
”flushing reaction” seen frequently in Asian populations [201], though no variants of this type
were observed in affected members of this family. The effects apparently induced by alcohol in-
gestion in these individuals were described as a generalised but severe aching in their torso and
limbs, accompanied by pallor. Both SCD events occurred in the hours after alcohol ingestion
possibly suggesting alcohol is triggering SCD in this family, although it is not clear how this
relates to the mutations in MT-CO3 and PPA2 observed.
Mitochondria perform a range of tasks such as the Krebs cycle, pyruvate oxidation, amino
acid, fatty acid and steroid metabolism, and generation of ATP via the respiratory chain. The
respiratory chain is also know as the electron transport chain/oxidative phosphorylation sys-
tem (OXPHOS) (See Figure 5.11). The system is comprised of five protein complexes in the
inner mitochondrial membrane, and involves two small electron carriers; ubiquinone (coenzyme
Q10) and cytochrome c (Figure 5.11). There is extensive evidence that mutations that impair
OXPHOS function, reducing energy supply to the heart and consequently resulting in cardiomy-
opathy [202]. Complexes I to IV are enzyme complexes, while complex V is the ATP synthesis
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unit. Energy generated by electron transport across the four enzyme complexes drives the ATP
production in complex V [203, 204, 205].
The subunits of all these complexes are encoded in both nuclear DNA and mtDNA. Defects
within each complex have their own array of clinical effects which are well described [206, 207].
Complex IV comprises 13 subunits, 10 of which are nDNA encoded. The catalytic core of the
complex is comprised of the three mtDNA encoded subunits (COXIII). There are no known
mutations that cause disease in the 10 nuclear encoded genes, however defects in COXIII can
cause phenotypes such as Leigh Syndrome, fatal infantile COX deficiency, hypertrophic car-
diomyopathy and myopathy[203]. Complex V comprises 16 subunits of which 14 are nuclear
encoded and do not have known pathogenic mutations to date. Complex V defects (in the
mtDNA encoded subunit) are, however, associated with Leighs syndrome and a syndrome of
neuropathy, ataxia and retinitis pigmentosa (NARP) [208]. Although respiratory chain enzyme
activities were found to be normal in skeletal muscle from sibling II.4, complex V activity was
not measured as the reaction conditions (which include phosphate buffers) were not explicitly
designed to test this activity and would artifically provide free phosphate. It is interesting to
note that that the COXIII variant observed in this family is present on a background of the mito-
chodrial haplogroup U, previously shown to increase the severity of cardiomyopathies [209, 210].
Mitochondrial disorders have been extensively discussed in the literature, but there are no
previous reports on PPA2 associated with human disease. A study in yeast [199] has shown
that the pyrophosphatase encoded by PPA2 is essential for mitochondrial DNA maintenance.
When PPA2 function was disrupted the strain was viable, but could no longer grow using res-
piratory carbon sources such as glycerol, acetate, or ethanol. Fluorescent microscopy showed
that these cells appeared to be a p0 strain, completely lacking mitochondrial DNA. However,
a study of PPA2 in a cohort of patients with mtDNA depletion syndromes failed to show any
pathogenic mutations, and provided no evidence for PPA2 involvement in mitochondrial deple-
tion in humans [197].
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All three variants identified in this family affect proteins that are located in the OXPHOS path-
way within the mitochondria, specifically one mtDNA variant within complex IV (COXIII), and
two compounding variants within PPA2, which functions to hydrolyse pyrophosphatase (Pi-Pi)
to individual phosphate molecules (Pi) for use in various catalytic processes including ATP
generation at complex V, the ATP synthesis unit. Further clarification of the role of PPA2
within the mitochondria is required to understand the possible disease mechanism(s) involved
in this pedigree. Identifying other families with PPA2 mutations and OXPHOS dysfunction was
considered a priority to fully establish a causative role of PPA2 in this cardiac disorder.
s
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Chapter 6
Wider investigations of PPA2
6.1 Intro
The previous chapter discussed the discovery of two variants in the gene PPA2 which were
considered putative causal mutations resulting in a cardiac phenotype seen in our index family.
Following this discovery, we approached collaborators who had access to a database of exome
data from patients with mitochondrial disease. After re-examining their data, and approach-
ing other laboratories with similar cases, a further three families with PPA2 mutations were
identified based on genotype (not clinical features). These families represent an additional six
patients, bringing the total of affected patients including our index family to ten. This chapter
will discuss these additional cases, and our efforts to demonstrate pathogenicity. We also aimed
to link the varying phenotypes seen between the four affected families to PPA2 mutations of
varying pathogenicity, and more theoretically propose a potential disease mechanism for PPA2
dysfunction.
6.2 Case details
The affected individuals in each family are shown in Figure 6.1, including the index cases which
will be herein referred to as Family Christchurch. Individuals P5-P7 (Family Basel) were born
to consanguinous parents of Sri Lankan origin and affected children were homozygous for the
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Figure 6.1 PPA2 pedigrees
A Pedigrees of four families identified with mutations in PPA2 (GenBank NM 176869.2) encoding the mito-
chondrial inorganic pyrophosphatase.B Location of mutations within the gene, and phylogenetic conservation
of the predicted missense mutations. C Space fill model showing position of p.Pro228 at boundary of dimers
and p.Glu172 in the active site. D Left: Structural model of one molecule of PPA2 showing the position of 4
mutations in folded structure (red). Residues that are known to be critical to PPA2 function in S. cerevisiae
are highlighted in yellow. Right: Space fill of the PPA2 active site showing three mutations are located at
the surface of the active site.
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PPA2 mutation c.500C>T (p.Pro167Leu). Individual P5, a boy, was born spontaneously after
an uneventful pregnancy. Birth weight was 2,820g, length 49 cm, head circumference 33.5 cm,
and Apgar scores 9/10/10. The first days of life were uneventful and mother and child left the
hospital on day six. On the 11th day of life the child was readmitted to hospital with signs
of tonic clonic seizures and vomiting. The patient was hypotonic, somnolent and pale, though
heart and lung function seemed normal. Lactate was elevated at 10.5 mmol/l (normal 0.4-2.8
mmol/l). In the following days he again had tonic-clonic seizures, which could be suspended
temporarily by treatment with Diazepam and Phenobarbital. Oxygen saturation was persis-
tently low necessitating intubation. Respiration did not improve requiring artificial ventilation.
Generalised tonic clonic seizures persisted. A subsequent ECG investigation showed a convex
ST segment elevation and the child died hours later with severe bradycardia. Investigation of
plasma amino acids showed elevated alanine. Investigation of organic acids was normal. Inves-
tigation of heart autopsy revealed fresh myocardium necrosis, mainly of the right heart, and
interstitial lymphocyte infiltration. Electron microscopy of the heart showed mitochondria with
degeneration of cristae but no evidence of viral infection.
Individual P6, a girl, was born after a normal pregnancy and spontaneous delivery with good
postnatal adaptation. At the age of 14 days, two hours after an unremarkable routine check
by a paediatrician, the child suddenly deteriorated and was admitted with marked tachypnea.
The child had vomited once and showed generalized seizures. Muscle tone was slightly hypo-
tonic. In the intensive care unit a marked metabolic acidosis with a blood pH of 6.9 (normal
7.35-7.45), HCO3 at 4 mmol/l (21-26 mmol/l), lactate 22 mmol/l, and pyruvate 253 mmol/l
(normal 84-784) was recorded. In the following hours there was a cardio-respiratory decom-
pensation and the girl died 6 hours after the onset of symptoms. Autopsy revealed acute and
sub-acute necrosis of the myocardium in both the left and right heart, though more prominent
in the right heart. Electron microscopy of the heart showed mitochondria with degeneration of
cristae as observed in her brother (P5). Furthermore, multiple sub-acute necroses were found
in both cerebral hemispheres. Investigation of the respiratory chain enzymes and pyruvate de-
hydrogenase were normal in skeletal muscle and fibroblasts.
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Individual P7, a boy, was born at term after a normal pregnancy. He was hospitalized in
intensive care unit from the first minute of life and carefully observed due to the family his-
tory. He was perfectly healthy in his first days of life, similar to his siblings. Assuming that
the siblings might have suffered from a defect in the respiratory chain isolated to the cardiac
muscle this patient was supplemented with a cocktail of vitamins usually given in defects of the
respiratory chain (coenzyme Q10, riboflavin, vitamins C, E, carnitine, biotin, beta-carotene).
In the following days he exhausted during feeding and developed signs of slight cardiac failure.
Selective screening of inborn errors did not reveal any pathological findings. Plasma lactate
remained in the normal range. On day nine, the clinical symptoms reminded a clinician of
a nutritional thyamine deficit, and the patient was given intravenous thiamine hydrochloride
20 mg/d, which markedly improved his condition. Carnitine, vitamin K, biotin and coenzyme
Q10 as well as thiamine were discontinued on day 11 since the patient seemed to be perfectly
well. However, his condition worsened again and heart failure became evident with occasional
arrhythmia. Levels of troponin and transaminases increased. Echocardiography showed im-
paired function of the enlarged right ventricle. On day 15 it was decided to supplement him
with thiamine 3 x 100mg/day orally. Carnitine, vitamin K, biotin and Q10 were reintroduced.
Heart function improved, and the troponin and transaminase level normalized. However, on
day 17 recurring tachycardia occurred, which responded temporarily to adenosine and then to
electroconversion, but it recurred in the following days. With 5-20 mg i.v. thiamine, a regular
sinus rhythm could be obtained and the patient improved dramatically. However, in spite of
thiamine 30-80 mg i.v. daily and propafenone, severe arrhythmia (Hf approx. 140 bpm) which
turned out to be ventricular became a serious problem. Cardiac function remained stable and
troponin and transaminase level normal as well. On day 30 ventricular arrhythmia persisted
and did not respond to lidocaine and electroconversion. The patient was neurologically normal
for his age, alert and fine. He died in the early morning of the 32 day of life from untreatable
arrhythmia. A final echocardiography showed a hypodynamic right ventricle, while the left
ventricle was still in a sufficient status (SF about 28-30%). Autopsy revealed a myocardium
without necrosis and inflammatory infiltrations. Myocytes with reduced amount of myofibrils
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were found. In the myocardium of the right heart there was fibrosis. Investigation of the res-
piratory chain in autopsy samples of the heart showed a moderate decrease of complex I 4.1
mU/mg protein (normal 5.5-51.5 mU/mg protein) and complex IV 64 mU/mg protein (normal
73.2-516.6) in the left ventricle. In the right ventricle the activity of complex I was not de-
tectable and complex IV was reduced to 42 mU/mg protein. Normal activities were found in
skeletal muscle and fibroblasts.
Individuals P8-P9 (Family Leeds) were born to consanguinous parents of Pakastani origin and
affected children were homozygous for the PPA2 mutation c.500C>T (p.Pro167Leu), as also
seen in Family Basal. Individual P8, a girl, was seemingly well with normal growth and de-
velopment until the age of 5.5 months. She was then admitted to Bradford Royal Infirmary
following a 24 hour history of vomiting and diarrhoea and had suffered a seizure at home. She
had further seizures on arrival, and a poor response to treatment so was intubated and ven-
tilated. A CT head scan was normal. Echocardiogram showed poor contractility and a small
amount of tricuspid regurgitation. She was transferred to Sheffield Childrens Hospital and had
a cardiac arrest on route. She then suffered further multiple cardiac arrests and despite maxi-
mal attempts at resuscitation she eventually died during the course of these. On post mortem
examination there were no specific macroscopic abnormalities. Infection screen identified ro-
tavirus in the stool. The brain showed hypoxic injury. The liver showed mild fatty change.
Skeletal survey, metabolic and toxicology screens were normal. Fatty acid oxidation levels were
carried out on skin fibroblasts and were normal. The heart appeared normal in size, shape and
structure. Histology of the heart showed areas of recent necrosis, thought to be related to the
recent cardiac arrests. There was also evidence of long-standing myocyte loss with increased
interstitial collagen and focal myocyte fibre disarray in the left ventricle and interventricular
septum. The disarray was considered insufficient for a diagnosis of Hypertrophic Cardiomyopa-
thy. Tests for myocarditis were normal. CSF glucose was low, but this was performed on a post
mortem sample.
Individual P9, a girl, suffered a viral illness at the age of 8 months and then suffered a weeks
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history of increasing hypotonia and weakness. CK was 15,000 at this time and plasma lactate
was raised at 5. Free carnitine was normal at 43.6, but propionylcarnitine raised at 2.38. Urine
organic acids were normal. There was no involvement of respiratory muscles. Renal function
was normal. Over a period of two weeks her weakness and hypotonia improved and her CK
reduced. Echocardiogram at this time was normal. She presented again at the age of 11 months
to the Leeds General Infirmary with diarrhoea and vomiting, her oral intake was poor and she
was not passing urine. She became increasingly drowsy and capillary refill was prolonged at 3
seconds. An initial blood gas showed pH 6.9, bicarbonate 13.8, base excess -13.1, lactate 8.7
and glucose 6.18. She then suffered a focal seizure with lateral gaze to the left and left sided
upper limb jerks. This became a generalized seizure which lasted 12 minutes. She was given
IV Lorazepam, a fluid bolus, IV antibiotics and acyclovir. Further seizures followed which
were treated with IV Lorazepam, Phenytoin and PR Paraldehyde. At three hours following
admission seizures had settled but she was still drowsy. CT head scan at this time was normal.
Not long after this she suffered a further focal seizure involving the left upper limb. She then
suffered a cardiac arrest and was intubated and ventilated. Maximal CPR was continued for 20
minutes but was not successful. Post mortem examination showed very extensive fibrosis of the
heart muscle and normal appearance of the skeletal muscle. The brain looked normal at post
mortem. Norovirus infection was confirmed on stool samples from admission. Respiratory chain
analysis on peripheral muscle tissue was normal, and histological and histochemical assessment
of muscle biopsy did not reveal any major mitochondrial abnormalities.
6.2.1 Family N Ireland
Family N Ireland consists of one affected and one healthy sibling born to unrelated healthy
parents from Northern Ireland. Individual P10 died at 11 months following diarrhoea, vomiting,
focal then generalised seizure and cardiac arrest. Investigation of the respiratory chain in the
autopsy sample of the cardiac muscle revealed a decreased activity of complex I (0.026 units/unit
citrate synthase, normal 0.125 0.048). In the skeletal muscle tissue, activities were within the
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normal range. Extensive fibrosis of the heart muscle was observed.
6.3 PPA2 activity
In silico modelling of PPA2 variants (as reported in the previous chapter), although useful, did
not provide direct evidence that the mutations described here in family Christchurch affect PPA2
function causing the condition seen in all four siblings of our index family. Direct biochemical
testing of affected tissue can provide valuable information on pathogenicity, however suitable
tissue is difficult to obtain, or is of limited quantity and/or stability. Use of model organisms that
show conservation with the gene/protein of interest can provide excellent biological evidence of
mutation pathogenicity, but are also an investment in terms of both time and money. There are
several approaches to using a model organism to examine the effect of a potentially pathogenic
mutation. Often creation of a knock-out (KO) strain is appropriate where the gene of interest is
interrupted or made non-functional by the introduction of mutations in key regulatory regions.
This can provide an insight into the normal gene function, as the developing organism will likely
show defects related to the loss of the gene expression. Both of these methodologies have been
employed to investigate PPA2 mutations and the results of these presented below.
6.3.1 Western blotting of PPA2 protein in human tissue
Western blotting was used to determine levels of PPA2 protein in various tissue types from af-
fected patients and was performed by collaborators from Paracelsus Medical University Salzburg.
Normal levels of PPA2 protein were observed in fibroblasts obtained from individuals P5-P7.
Autopsy muscle tissue of individual P9, however, showed decreased levels of protein, though
this was inconsistent with the elevated levels seen in muscle tissue from P6 and P7 who carry
the same PPA2 mutation. In heart autopsy material from P10, we noted decreased PPA2 levels
and also of a complex I structural protein (subunit NDUFS4), correlating with the observed
decrease in complex I activity in this tissue. In the cardiac autopsy sample of P7, PPA2 and
complex I subunit levels were decreased, as well as expression of the mitochondrial marker pro-
tein porin. This is suggestive of a more general reduction of mitochondrial number possibly due
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Figure 6.2 Human PPA2 and Yeast PPA2 protein alignment
Alignment of homologous proteins showing conserved residues particularly at Glu172 and Pro228.
to changes in tissue composition (Figure 6.3).
6.3.2 ppa2 knockout growth phenotype on aerobic media
The S. cerevisiase pyrophosphatase (ppa2 ) shows significant homology to human PPA2, par-
ticularly at key residues of interest (Figure 6.2). Previously ppa2 knockout yeast strains have
been shown to have a growth defect phenotype when plated on an aerobic media where the
yeast are required to utilise the mitochondrial respiratory chain [199]. This growth phenotype-
was confirmed in the BY4742 S. cerevisiae strain by comparing growth of wild type (WT) and
ppa2 knockout yeast on yeast peptone (YP) glucose media which allows fermentative growth,
to growth on YP galactose media which requires oxidative growth. As previously established,
growth on galactose was abolished in the ppa2 knockout yeast strain, indicating that mitochon-
drial respiration was not available (Figure 6.3).
6.3.3 Oxidative stress sensitivity
Diamide is a substance that oxidises intracellular thiols and mimics oxidative stress in yeast
grown on diamide-containing media. Sensitivity of ppa2 knockout yeast vs WT yeast was
assessed at a range of diamide concentrations (0mM, 1mM, 1.25mM, 1.5mM). At 1mM and
1.25mM concentrations the clearest sensitivity is observed in PPA2 knockout BY4742 S. cere-
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visiae cells characterised by a reduced growth phenotype, approimately estimated to be in the
range of 20-fold more sensitive than WT to oxidative stress (Figure 6.3).
Figure 6.3 Western blot analysis and yeast PPA2 knockout strains
A Western blot analysis in heart, skeletal muscle and fibroblast mitochondria in individuals with PPA2 mu-
tations. NDUFS4; a subunit of complex I, porin; a mitochondrial outer membrane protein, GPI; a glucose-
6-phosphate isomerase, which is a cytosolic housekeeping protein. LV, left ventricle; RV, right ventricle. B
Growth defect of a PPA2 knockout (KO) S. cerevisiae strain on aerobic medium showing that PPA2 is critical
for mitochondrial respiration. C Oxidative stress sensitivity of PPA2 -KO S. cerevisiae as measured by growth
defect of diamide, which oxidises intracellular thiols and mimics oxidative stress in yeast.
6.3.4 Pyrophosphatase activity of recombinant PPA2
Pyrophosphatase activity was compared in isolated mitochondria from fibroblasts of controls
and affected individuals by measuring the hydrolysis of PPi and quantifying the orthophosphate
(Pi). The activity of PPA2 was significantly decreased in isolated fibroblast mitochondria from
affected individuals P5 and P7 at all PPi and MgCl2 concentrations investigated (0.001 - 0.1
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mol/l and 0.5 or 3.0 mmol/l respectively). Inactivation by CaCl2 was similar in affected in-
dividuals compared to controls. Equal amounts of either wild type or mutant recombinant
PPA2 proteins were used for the pyrophosphatase activity assay. Compared to wild type the
p.Pro167Leu and p.Glu172Lys mutations showed 5-10% residual activity at PPi substrate con-
centrations 18-500 mol/l. The p.Pro228Leu mutation had a residual activity of 24-28% in this
concentration range compared to wild type (Figure 6.4). The activities of wild type and mu-
tants were similarly sensitive to inhibition by Ca2+ (data not shown). This work was performed
in Austria, by Hans Mayhr’s laboratory.
6.4 Discussion
6.4.1 PPA2 in a mitochondrial context
Production of ATP is a coordinated system of two processes. Electrons (in the form of hydro-
gen ions derived from NADH and FADH2) are transported through the chain in the following
manner. Complex I, complex II, coenzyme Q, complex III, cytochrome c, complex IV, before
interacting with molecular oxygen to form water. Simultaneously, protons are pumped across
the inner membrane from the matrix to the intermembrane space by complexes I, III and IV.
ATP is produced by the movement of these protons back into the matrix via complex V [208].
On the face of it, it would appear that dysfunction of a mitochondrial pyrophosphatase would
inhibit ATP production due to reducing the pool of free Pi ions available for uptake into com-
plex V during ATP synthesis. However, the presence of cytosolic Pi molecules that can be
imported across the inner membrane complicates this theory. Movement of many substrates
across the largely impermeable inner mitochondrial membrane is facilitated by mitochondrial
carriers (MCs), part of a super-family of nuclear encoded secondary transport proteins. These
carriers have roles in a range of metabolic pathways and cell functions, and mutations in the
genes encoding them lead to a number of identified diseases [211]. In humans, over 48 MCs
have been identified, with approximately 39 distinct functions. Several classes of transporters
are required to facilitate the transport of varying substrates, including nucleotides, carboxylic
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Figure 6.4 PPA2 enzyme activity in fibroblast mitochondria
A - B Activity of inorganic pyrophosphatase in fibroblast mitochondria from affected individuals (P) P5 and
P7 compared to 12 controls C at different PPi concentrations and either A 0.5 mmol/l MgCl2 or B 3.0 mmol/l
MgCl2. C - D Inhibition of inorganic pyrophosphatase in fibroblast mitochondria from affected individual
P5 (red squares) and 3 controls (black circles) at different CaCl2 concentrations and either (C 0.01 mmol/l
PPi or D 0.1 mmol/l PPi. E Pyrophosphatase activity of equal amounts of recombinant proteins at different
PPi concentrations. F Amount of residual activity in different mutants. *P<0.02, **P<0.0002 in Students
unpaired t-test.
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acids, co-factors, inorganic anions and amino acids [212]. The MCs can be divided into two
general functional groups. The first group are involved in metabolic energy generation within
the cell, and are associated with the transport of products and substrates required for OX-
PHOS reactions. This includes the AAC (ADP/ATP carrier), the PiC (phosphate carrier)
and the UCP (uncoupling protein) that functions as a proton carrier. The secondary group
involves those transporters needed for intermediary metabolism, including, but not limited to,
amino acid metabolism and mtDNA replication. Transport of metabolites across the inner mi-
tochondrial membrane is performed in a highly regulated manner, so as to not disrupt the H+
electrochemical potential gradient across the membrane generated by the OXPHOS chain [213].
Mitochondrial carrier reactions utilise either the electrical or chemical nature (or both) of the
H+ electrochemical potential gradient and/or the solute concentration gradient across the inner
mitochondrial membrane. The transport of ADP/ATP by the ACC (encoded by the nuclear
gene SLC25A4) is via an antiporter mechanism, where one ATP4− is exchanged for one ADP3+
molecule simultaneously. ATP preferentially travels along the membrane potential across the
inner mitochondrial membrane to the cytosol. The high electrical component of the proton mo-
tive force provides the power to eject ATP4− against the concentration gradient. In contrast,
the phosphate carrier (PiC) mechanism of Pi movement is electroneutral co-transportation.
Here, Pi− is translocated with an equivalent amount of H+ so there is no transfer of charge.
This reaction is dependant on the pH gradient across the inner mitochondrial membrane which
regulates the distribution of anionic and cationic solutes. The PiC is encoded by SLC25A3,
which is alternately transcribed to produce two isoforms PiC-A which is muscle/heart specific,
and PiC-B which is ubiquitous and has a higher substrate affinity. The differing affinity of these
isoforms is used to control import of Pi and therefore rate of ATP production during muscle
contraction [212, 211, 214, 212, 215]. Considering this highly regulated membrane transport
of molecules, particularly the PiC which imports Pi for complex V, the simplistic hypothesis
that PPA2 dysfunction reduced the Pi available for complex V was disregarded. A defect in
PiC-A-mediated uptake has been previously seen in the instance of a homozygous mutation
within exon 3A (alternately spliced in PiC-A and PiC-B). The defect led to inhibition of ATP
synthesis by OXPHOS, the carrier proteins function appeared severely compromised, and Pi
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was not being supplied to complex IV. This causes a terminal shortage of energy supply within
the heart/muscle cells, but not within all other tissues as they are supplied with Pi by PiC-B.
Patients with a PiC deficiency suffer from progressive hypertrophic cardiomyopathy, muscular
hypotonia, elevated plasma lactate levels and lactic acidosis which usually leads to heart failure
within the first 4 to 9 months of life [212]. This suggests that the levels of Pi provided by
hydrolysis of PPi within the mitochondria are likely negligible in terms of supply to complex V
and other mechanisms of pathology need to be considered.
6.4.2 Theoretical proposal of PPA2 disease mechanism
A proposed alternate mechanism for PPA2 -related mitochondrial dysfunction based on our lim-
ited knowledge of PPA2 function is shown in Figure 6.5. If PPA2 activity is reduced due to
pathogenic mutations, there are two immediate effects. Firstly, the thermodynamic pull pro-
vided by hydrolysis of PPi in many cellular synthesis reactions is likely to be reduced, and may
result in a decrease of critical products involved in the mitochondria and wider cell. Secondly,
it is expected that PPi will accumulate in the mitochondrial matrix rather than be hydrol-
ysed to Pi. Increased matrix Pi may lead to increased membrane permeability, mitochondrial
swelling, and in extreme cases, initiation of the mitochondrial matrix permeability transition
(MMPT) which can cause mitochondrial and cell death. The current knowledge of these cellular
mechanisms is explored below in the context of PPA2 dysfunction.
Thermodynamic pull for synthesis
The hydrolysis of inorganic pyrophosphate to inorganic phosphate is a strongly exergonic reac-
tion with a G of -33.7kJ/mol, comparable to that of ATP hydrolysis at -35.7 kJ/mol [197]. It is
the rapid hydrolysis of PPi which is vital for providing the thermodynamic pull for over thirty
cellular reactions (including all individual aminoacyl-tRNA synthetases), detailed in Table 6.1.
In the instance of reduced PPA2 function, it is reasonable to assume that the equilibrium of
these reactions will be lost with the balance pushed away from synthesis. Pi-producing reactions
can be generally divided into functions related to RNA/DNA maintenance, the TCA cycle, and
the Electron Transport Chain, all of which are potentially critical in maintaining cell function.
132 Chapter 6 – PPA2 and mitochondrial disease
Several synthesis reactions dependant on PPA2 to provide thermodynamic pull are of particular
interest in the context of mitochondrial and cardiac disease seen in the pedigrees investigated
in this thesis. Bifunctional coenzyme A synthase (CoA synthase) is an enzyme which catalyses
the last two steps in CoA synthesis from pantothenic acid (vitamin B5). CoA is an essential
requirement for acetyl-CoA synthetases, which are then required for oxidation of pyruvate in the
TCA cycle as well as having a role in synthesis and oxidation of fatty acids. PPA2 hydrolysis
drives the production of both CoA and Acyl-CoA. The double hit of reduced CoA as well as
Acyl-CoA from limited substrate (CoA) and PPA2 dysfunction may result in limited Acyl-CoA
entry to the TCA cycle from both glycolysis and fatty acid metabolism. PPA2 dysfunction
may also negatively effect reactions directly involved in the ETC such as CoQ synthesis and
FAD synthesis. CoQ (ubiquinone) serves as a redox carrier in the ETC and is a lipid-soluble
antioxidant. One of the final reactions in the biosynthesis of CoQ is the prenylation of parahy-
droxybenzoate with an all-trans polyprenyl group. This step is catalysed by CoQ2 which is a
product of a PPA2 driven reaction. In addition, formation of decaprenyl-diphosphate synthase
subunits 1 and 2 are driven by PPA2 hydrolysis. This interferes with the formation of side chains
of ubiquinone-10, which is a known cause of Q10 deficiency. FAD-dependent proteins function
in a large variety of metabolic pathways including electron transport, DNA repair, nucleotide
biosynthesis, beta-oxidation of fatty acids, amino acid catabolism, as well as synthesis of other
cofactors such as CoA, CoQ and heme groups. During the TCA cycle, succinate dehydrogenase
(complex II in the electron transport chain) requires covalently bound FAD to catalyze the
oxidation of succinate to fumarate by coupling it with the reduction of ubiquinone to ubiquinol.
At least 20 tRNA synthetases are products of a PPA2 driven synthesis reaction, as is tRNA
dimethylallytransferase involving charging of amino acids to their cognate tRNA, providing the
substrates for global protein synthesis, as well as stabilisation of tRNA structure. In particular,
Alanyl-tRNA synthetase (mtAlaRS), encoded by AARS2 has been previously associated with
fatal infantile hypertrophic mitochondrial cardiomyopathy, with near-total deficiency of respira-
tory complexes I, III, and IV in heart tissue [216]. Additionally tRNA dimethylallytransferase
(encoded by TRIT1) has been associated with severe combined mitochondrial respiratory chain
defects and corresponding perturbation in mitochondrial protein synthesis [217]. The other
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products affected by PPA2 dysfunction include DNA-directed RNA polymerase, Poly(A) RNA
polymerase, Polyribonucleotide nucleotidytransferase (all involved in RNA synthesis, expres-
sion, and RNA metabolism), as well as Deoxyuridine 5’-triphosphate nucleotidohydrolase and
mitochondrial DNA polymerase catalytic subunit (involved in pyrimidine metabolism and gen-
eral mitochondrial synthesis). Key effects that may arise due to PPA2 dysfunction may include
a reduction of CoA and Acyl CoA which limits the Acyl CoA entry to the TCA cycle from both
glycolysis and fatty acid metabolism, in turn providing less electrons to the ETC. A reduction in
CoQ may impair the antioxidant effect of CoQ and possible lead to a CoQ deficiency. Reduced
tRNA synthesis and impaired mRNA maintenance due to less poly(A) affects the stability of the
structure, while inclusion of more dUTP in DNA instead of dTTP (due to dUTP being present
in the deoxynucleotide pool in higher concentrations) can also lead to a hyperactive futile cycle
of DNA repair. It would be interesting to investigate the possiblity of CoQ suplementation in
patients with PPA2 dysfunction.
PPi accumulation in mitochondrial matrix
Although there is not a specific transporter for the movement of PPi, it appears that this
substrate can exit the mitochondria via the AAC in exchange for cytosolic ADP. The transport
affinity of PPi is extremely low, and the activity of PPi exchange is about 1/10th of that of
ADP/ATP exchange [213]. Therefore PPi is inefficiently exported from the matrix. It is also
suggested that the AAC can transport small univalent cations when PPi is bound, and that
the conformation of the AAC when PPi is bound has an effect on the permeability of the
inner mitochondrial membrane to K+. Swelling of the mitochondria occurs when an anion
such as phosphate is taken up to compensate for K+ uptake and as osmotic imbalance is
created. The mitochondria will swell until the K+/H+ antiporter is sufficiently stimulated to
balance K+ entry. When the mitochondrial inner membrane permeability increases, the gradient
potential maintained by OXPHOS is lost and ATP synthesis is severely is impaired. A further
consequence of PPi binding to the AAC will be seen in the exchange of adenine nucleotides into
the mitochondria as PPi is effluxed, although the consequences of this are unclear [218]. These
two processes, thermodynamics and PPi accumulation, may be considered separately here but
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Table 6.1 Cellular reactions requiring PPA2 involvement
Cellular processes and synthesis products which rely on PPA2 function.
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in the context of the cell, overlap and interact. We suggest that PPA2 mutations are implicated
in reduced progression of of several enzyzmatic reactions, the subsequent build-up of PPi in the
matrix, and the decrease of ATP produced within the mitochondria due to this, rather than a
lack of Pi supplied to complex V as previously considered.
6.4.3 Alcohol sensitivity and PPA2
A striking feature in the index family with segregating PPA2 mutations is an exquisite alcohol
sensitivity, which may act as a ”trigger” effect on arythmia and heart function. A proposed
mechanism for a compounding influence of ethanol ingestion on PPA2 dysfunction is outlined
in Figure 6.6. Ethanol metabolism predominantly occurs in the liver, although the effects of
impaired metabolism can be wide-ranging as evidenced in the common ’flushing’ reaction seen in
individuals who accumulate toxic acetaldehyde (a by-product of ethanol metabolism). Ethanol
is oxidised to acetaldehyde by alcohol dehydrogenase (ADH) in the cell cytosol, which is then
metabolised to acetate by aldehyde dehydrogenase (ALDH2) within the matrix. The resulting
acetate has to be activated to acetyl-coenzyme A, which is accompanied by the formation
of equimolar amounts of PPi. This esterification reaction is catalyzed by short-chain acyl-
CoA synthetases encoded, for example, by ACSS1, an enzyme with high expression in heart
mitochondria [219]. Both of these enzymatic reactions involve reducing NAD+ (nicotinamide:
an intermediate carrier of electrons) to NADH. The reducing equivalent of the NADH produced
in the cytosol is transported into the mitochondria by molecules known as the malate-aspartate
shuttle [220]. An increase in NADH within the cell during ethanol metabolism results in a
reduced cytosolic and mitochondrial environment, and cells are then particularly vulnerable to to
damage by by-products such as acetaldehyde. The ratio of NADH to NAD+ determines the rate
at which the reactions can occur, therefore rapid ethanol metabolism relies on efficient oxidation
of NADH within the mitochondrial electron transport chain. An undesirable outcome of NADH
oxidation is the production of reactive oxygen species (ROS). These act by removing hydrogen
atoms from other molecules, and converting these molecules into highly reactive free radicals.
We have demonstrated that ppa2 knockout yeast show increased sensitivity to oxidative stress,
and also suggested a mechanism for increased sensitivity due to a reduced CoQ antioxidant effect
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Figure 6.6 Proposed influence of ethanol ingestion on PPA2 dysfunction
A proposed mechanism for a compounding influence of ethanol ingestion. Ethanol metabolism predominantly
occurs in the liver, although the effects of impaired metabolism can be wide-ranging as evidenced in the
common ’flushing’ reaction seen in individuals who accumulate toxic acetaldehyde (a by-product of ethanol
metabolism). Ethanol is oxidised to acetaldehyde by alcohol dehydrogenase (ADH), which is then metabolised
to acetate by aldehyde dehydrogenase (ALDH2). Both of these enzymatic reactions involve reducing NAD+
(nicotinamide: an intermediate carrier of electrons) to NADH. An increase in NADH within the cell during
ethanol metabolism results in a reduced cytosolic and mitochondrial environment, and cells are then particu-
larly vulnerable to to damage by by-products such as acetaldehyde. The ratio of NADH to NAD+ determines
the rate at which the reactions can occur, therefore rapid ethanol metabolism relies on efficient oxidation of
NADH within the mitochondrial electron transport chain. An undesirable outcome of NADH oxidation is the
production of reactive oxygen species (ROS). These act by removing hydrogen atoms from other molecules,
and converting these molecules into highly reactive free radicals. An excess of ROS results in a state of
oxidative stress, and can lead to lipid peroxidation, in particular, peroxidation of the inner mitochondrial
membrane. Peroxidation of the membrane has several detrimental effects. Peroxidation of the membrane has
several detrimental effects, namely increased membrane permeability, and a reduced electrical charge gradient.
These two changes will contribute to a flux of molecules exiting the mitochondria which can induce apoptosis,
and reduced ATP production causing necrosis respectively.
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(Figure 6.3). An excess of ROS creates a cellular state of oxidative stress, and can lead to lipid
peroxidation, in particular, peroxidation of the inner mitochondrial membrane. Peroxidation of
the membrane has several detrimental effects, including increased membrane permeability, and a
reduced electrical charge gradient. These two consequences will contribute to a flux of molecules
leaving the mitochondria which can induce apoptosis, and reduce ATP production leading to
necrosis. Affected individuals in our index family reported experiencing generalised myopathy
and discomfort after ethanol ingestion. The surviving male (P2) also reported a sensitivity to
cooked shellfish (mussels) in vinegar when questioned about a possible effect of acetate. As
acetate is formed during ethanol metabolism and it’s conversion to acetyl-CoA requires PPA2
hydrolysis, it was of interest to know that some acetate sensitivity was present without prior
ethanol intake. The other surviving female (P4) did not recall any sensitivity to vinegar or
other foods containing acetate so the response of P2 is likely to be less acute than the exquisite
alcohol sensitivity described in this family. Consumption of acetate in these individuals rather
than ethanol would result in a build up of acetate due to inefficient conversion to acetyl-CoA,
but not acetaldehyde or ethanol which would occur with ethanol ingestion. This reaction does
not involve reducing NAD+ and therefore would not be expected to cause the same effect of
increased NADH as ethanol metabolism, perhaps explaining a milder phenotypic effect. In this
family, the fibrosis in the heart (likely caused by chronic low-level ATP depletion) may have
primed the affected individuals to a secondary trigger event of arrhythmia. A trigger of sudden
death is not a new concept, particularly in the case of Long QT syndrome which is known to be
associated with genotype-specific triggers of life-threatening arrhythmias. Immersion of the face
in cold water in cases of swimming or diving is a common trigger of arrhythmia in patients with
Long QT syndrome 1 [221, 222]. In Long QT syndrome 2, auditory stimulus (usually during
sleep) such as an alarm or bell has been described to cause syncope and subsequent death
[223, 222]. Although no other family had a recorded sensitivity such as this alcohol intolerance,
presumably from lack of exposure due to their neonatal stage of life, it is worth noting that both
affected individuals in Family Leeds had a history of vomiting, diarrhoea and seizures prior to
admission to hospital. Viral infection (rotavirus (first) and norovirus (second)) was confirmed
in stool samples taken at time of admission. A norovirus infection was also detected in P10
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from the United Kingdom. Although no viral illness was recorded in other individuals, similar
symptoms also preceded hospital admission in two siblings of Family Basel. This may indicate
that a viral stressor was responsible for adversely affecting mitochondrial metabolism in these
cases, in the same way that alcohol was a trigger for arrhythmia in Family Christchurch.
6.4.4 Proposed Mechanism for SCD due to PPA2 mutations
In addition to considering a mechanism for disease in the index family, we also propose several
interactions which may lead to the multiple symptoms which presented in all four families cur-
rently identified with PPA2 mutations. Figure 6.7 illustrates some of the possible links discussed
in this thesis into one general scheme, including features such as lactic acidosis and arrhythmia
observed in the affected infants with PPA2 mutations in our other pedigrees. Generally we pro-
pose that PPA2 dysfunction due to compounding or homozygous mutations directly impacts
the mitochondrial ATP output and increases mitochondrial sensitivity to stress. This occurs
through the loss of thermodynamic pull in critical enzymatic reactions, as well as accumula-
tion of PPi in the matrix, as discussed in section 6.4.3. The immediate effects of severe ATP
depletion are likely to be lactic acidosis and arrhythmia as glycolysis is employed to provide
immediately available energy to the cell. More chronic effects of PPi build-up in the matrix may
include mitochondrial swelling and a reduction in membrane potential, as well as a more mild
reduction of ATP leading to cardiac fibrosis. The effects of impairing synthesis reactions de-
pendant on PPA2 are largely to do with sensitisation of the mitochondria. Inhibiting CoA and
acyl-CoA synthesis can lead to impaired metabolism of alcohol, while reducing Co-Q synthesis
impacts the antioxidant protection. These pathways all lead to reduced ATP production, an
increased sensitivity to oxidative stress, and reduced Ca2+ regulation. In the three additional
families identified it is expected that severe ATP depletion had an acute effect causing death
from lactic acidosis and cardiomyopathy prior to any chronic damage developing. A feature of
partial PPA2 function provided by the assumed less severe Pro228Leu mutation in the index
family may be that more chronic effects such as accumulation of cardiac fibrosis occur instead
of the acute symptoms expected from near total PPA2 dysfunction. In Family Christchurch
ethanol ingestion has been proposed as the trigger underlying sudden death. We propose that
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the metabolism of alcohol (in mitochondria with limited CoA and acyl-Coa synthesis) signifi-
cantly increases NADH concentration, and the oxidation of this results in ROS production. In
mitochondria already predisposed to oxidative stress (due to reduced CoQ antioxidant effect)
this ROS production may precipitate a cascade of reactions that involves peroxidation of the
mitochondrial membrane, swelling, Ca2+ overload, and opening of the mitochondrial perme-
ability transition pore (MPTP). The MPTP is described as the reversible opening of a pore
in the inner mitochondrial membrane that allowed the passage of any molecule of <1500 Da
which is observed in response to certain pathological conditions such a reperfusion injury. The
result of opening the MPTP will be a loss of proton-motive force, rendering the mitochondria
incapable of ATP production and initiating cell death mechanisms. This process can quickly
become non-reversible, as once a single MPTP has opened, the mitochondrion is sensitised to
Ca2+ concentrations which induces multiple pore openings in the same organelle. The Ca2+
released upon swelling of this mitochondrion, is subsequently taken up by surrounding mito-
chondria, which induces further MPTP opening, creating a cascade of organelle failure. MPTP
opening is promoted by Ca2+, oxidative stress, high phosphate concentrations and depletion
of matrix adenine nucleotides. Opening is, however, inhibited by low pH, which occurs as a
result of glycolosis. In the case of reperfusion injury, ischemia causes the respiratory chain to
stop producing ATP. When oxygen is reperfused and the respiratory chain restarts, the mito-
chondria can take up the Ca2+ which has accumulated during ischaemia, but also produces a
surge of ROS. The combination of oxidative stress and Ca2+ concentration, prime the MPTP
opening, however, it is only when the intracellular pH returns to normal that MPTP opening
can occur. We propose that a similar stress occurs upon consumption of alcohol in the index
family. Non-fatal events which led to pain and discomfort may have been a product of lactic
acid build up (lactic burn), while the sudden cardiac death events were a result of secondary
energy failure of the heart, subsequent to the alcohol-induced effects leading to MPTP opening
[224].
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6.4.5 Conclusion
In our index family, we suggest that PPA2 mutations lead to chronic ATP depletion and sen-
sitisation of the mitochondria (particularly in high energy tissues such as the heart), which
leads to the accumulation cardiac fibrosis observed in affected individuals. The symptoms of
pain and sudden cardiac death after alcohol ingestion may be attributed to the cumulative
effect of this chronic ATP depletion/mitochondrial sensitisation, and then the additional stess
to already damaged cardiac tissue as a result of ethanol metabolism. This theory is supported
by the observation that symptoms of alcohol-related pain did not occur immediately, but 30-60
minutes after ingestion, and both deaths occurred in the hours following alcohol consumption
despite cardiac fibrosis being present prior to death. Our proposed mechanism is based on
published biochemistry, but has not been explored experimentally and should be considered
only as a starting point for further investigations into the role of PPA2 in mitochondrial dis-
ease. PPA2 mutations were also identified in three additional families, harbouring mutations
which were associated with a more severe phenotype. Analysis of pyrophosphatase activity as-
sociated with the various mutations confirmed that less activity associated with a more severe
phenotype and earlier death, although variation was observed between identical genotypes. In
conclusion, we have identified biallelic missense mutations in PPA2 as a new cause of mito-
chondrial cardiomyopathy and sudden cardiac death. This finding highlights a critical role of
PPA2 in mitochondrial function, and warrants further functional investigation. Importantly,
mild mutations in PPA2 may not have an immediate life threatening effect until triggered by
a stressor such as viral illness, alcohol metabolism or possibly exercise, predisposing otherwise
healthy individuals to sudden cardiac death. Considering the relatively high frequency of PPA2
mutations present in the ExAC database, it is important that mutations in PPA2 are screened
in clinically relevant populations where cardiac MRI might reveal fibrosis. Moreover, applica-
tion of an implantable cardioverter defibrillator may prevent sudden cardiac death in at-risk
individuals who harbour biallelic PPA2 mutations.
Chapter 7




Although modelling of ppa2 dysfunction in yeast provided some evidence of pathogenicity, there
are limits to what can be extrapolated to a human disorder. For example, when investigating
a disorder involving the heart, yeast becomes a far less useful model organism. During ver-
tebrate embryogenesis the heart is the first organ to form and function. In zebrafish (Danio
rerio), which are transparent and rapidly develop, the heart starts beating as early as 24 hours
post fertilisation (hpf), and strong circulation can be seen by 1.5 days post fertilisation (dpf).
Despite significant anatomical differences, zebrafish and human hearts are surprisingly similar
in terms of beating rates and eletrophysiology. The fish heart is initially formed from migra-
tion of myocardial and endothelial cells into a linear tube with a distinct outer myocardial and
inner endocardial layer. The heart tube then folds into a looped organ with four distinct cham-
bers; sinus venosus, atrium, ventricle and bulbus artreiosus (outflow tract). Due to their size,
zebrafish embryos can obtain enough oxygen through passive diffusion to allow for relatively
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normal development for several days even in the absence of blood circulation and a functional
cardiovascular system. This makes them an good model for the study of cardiac phenotypes,
particularly as their transparency allows rapid and reliable in vivo visualisation and characteri-
sation of embryos by light microscopy. This makes it possible to study genetic defects that may
lead to early lethality in other animals [225].
A useful technique to transiently knock-down a gene of interest in zebrafish (and other mod-
els) without needing to produce a stable gene knock-out strain is to use morpholino antisense
oligomers (MO). A morpholino is a synthetic oligo which when injected into a developing ze-
brafish embryo, will target a complementary sequence in a gene of interest and prevent produc-
tion of protein. Although expression of the gene will not be entirely suppressed, the morpholino
enables researchers to view the effect of partial knockdown, particularly useful in cases where a
knockout organism would not be viable. Co-injection of morpholino and mRNA is often used
in RNA rescue experiments to show that a phenotype in a morpholino injected fish can be ’res-
cued’ by co injection of the WT mRNA which enables near-to normal levels of protein expression.
Zebrafish were successfully used to demonstrate that the ciliopathies Meckel-Gruber syndrome
(MKS) and Bardet-Biedl syndrome (BBS), are allelic forms of the same molecular spectrum de-
spite being clinically distinct, and that particular MKS1 mutations were functionally pathogenic.
Leitch et al [226] used a combination of morpholino based suppression of mks1, and co-injection
with wildtype human MKS1 mRNA to rescue the morphant phenotype, showing variable func-
tionality of previously in silico predicted pathogenic variants.
This chapter introduces ongoing research using zebrafish to model PPA2 dysfunction, aim-
ing to produce a stable ppa2 knockout strain in which to observe the effects of specific ppa2
mutations seen in the family presented in Chapter 5. This work was performed in collaboration
with the Otago Zebrafish Facility, led by Assoc. Prof Julia Horsfield.
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Figure 7.1 Human PPA2 and Zebrafish PPA2 protein alignment
Alignment of homologous zebrafish and human pytophosphatase proteins showing conserved residues, partic-
ularly at residue 172 and 228 (human), representing the mutated residues seen in Family Christchurch.
7.2 Zebrafish ppa2
Sequence information on the zebrafish ppa2 gene, on chromosome 1, was obtained from NCBI
(Gene ID: 402961). The zebrafish ppa2 transcript is 1468 base pairs long and encodes 250
amino acids. Comparison to known sequences identified ppa2 as part of the Pyrophosphatase
Superfamily, with 57% identity to the human protein (NCBI BLAST; Human PPA2 accession
number AAH57219.1). The alignment of human and zebrafish PPA2 is shown in Figure 7.1.
7.3 Morpholino knockdown - preliminary experiments
Morpholinos were designed to target two complementary zebrafish ppa2 sequences: one at the
5’UTR and the other at an internal splice site (Figure 7.2). In addition, a random sequence oligo
(MIS-5) was used to act as an injection control, and ensure that phenotypic effects observed
were due to ppa2 expression knockdown and not off target effects of the morpholino.
Titrations of injection volume for the 5UTR MO, SPLX MO, and MIS-5 MO were per-
formed to identify an optimal injection concentration for phenotype characterisation. Too high
a concentration results in lethality, while a low concentration may not induce any mutant char-
acteristics in the fish. Optimal concentration was measured by survival and characterisation of
phenotype in 1dpf and 2dpf zebrafish embryos. The survival rates of embryos with a 5’UTR or
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Figure 7.2 Zebrafish ppa2 sequence, showing binding sites of Morpholinos.
A Full zebrafish ppa2 cDNA sequence showing binding of the 5’UTR MO and Splice site (SPX) MO. B
Specific sequence details of the binding site for the 5’UTR MO. C Specific sequence details of the binding
site for the SPX MO.
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SPX MO injection concentration of 0.125pmol, 0.25pmol and 0.5pmol at 1dpf was variable, but
didn’t correlate with a dose dependant effect, which would have suggested any concentration-
dependant lethality. Unfortunately the MIS-5 MO appeared to have a significantly detrimental
effect and survival rates were too low for use as an suitable control. Injection of sterile wa-
ter into embryos was used as an injection control in the following experiments. At 2dpf, the
concentrations 0.25pmol and 0.5pmol of MO, produced consistent yolk edema phenotypes in
the SPLX MO embryos, and a tail malformation of varying severity in both SPLX MO and
5’ UTR MO embryos (Figure 7.3). Additionally, some SPLX MO embryos were missing pec-
toral fins at this stage. A dose-dependant hypopigmentation effect was observed in the UTR
MO embryos, but count data was not undertaken for pectoral fins and hypopigmentation effects.
At 5dpf, additional consistent phenotype abnormalities were noted. At a gross level these
consisted of protruding jaws and a curved tail tip (Figure 7.4). Based on these initial obser-
vations, it was decided that an intermediate titration of MO (0.35pmol) would be suitable for
future phenotype experiments to ensure acceptable survival rates and a measurable phenotype
was observed.
7.4 RNA Rescue with wildtype ppa2
Preliminary results for RNA rescue of the observed ppa2 knockdown phenotype were achieved
by co-injecting embryos with MO and wildtype zebrafish ppa2 mRNA. MO concentration was
0.35pmol, while WT mRNA was injected at either 50pg or 100pg. One general and one specific
feature observed in earlier MO titration experiments were used to quantify the success of the
rescue.
A gross severity score (No phenotype/Mild/Medium/Severe) was assigned to individual fish in
each treatment group based on several key characteristics observed in preliminary experiments.
No phenotype was defined as fish with no obvious defects, and grossly normal development. A
mild score designated fish that had a slightly curved or small tail OR yolk adema or cardiac
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Figure 7.3 Preliminary data from 1dpf and 2dpf zebrafish embryos injected with differing concentra-
tions of both 5’UTR and SPX morpholino preparations (248 embryos counted across 4 experiments)
A Survival of zebrafish embryos at 2dpf. B Observation of tail malformation phenotype. C Observation yolk
adema phenotype. D Examples of 2dpf zebrafish embryo phenotypes in each treatment condition.
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Figure 7.4 Preliminary data from 5dpf treated and untreated zebrafish embryos (92 embryos
counted across 2 experiments)
A Observation of tail tip phenotype. B Observation of protruding jaw phenotype. C Examples of 5dpf
zebrafish embryo phenotypes in each treatment condition.
adema/blood backflow or pooling. A medium score required fish to have a slightly curved or
small tail, AND yolk adema or cardiac adema or blood backflow or pooling. Severe fish displayed
a very curved tail AND yolk adema/cardiac adema/blood backflow or pooling (Figure 7.5). In
the ’No treatment’ control group, 100% of fish were phenotypically normal. When morpholino
was introduced, greater than 68% of fish developed defects scored as either mild, medium or
severe. The percentage of fish counted as severe was 25.49%. When mRNA was co-injected
with the morpholino treatment, the percentage of fish classed as severe dropped significantly to
7.36% (Note that the p-value displayed relates to the reduction in severe phenotype only, it is
based on the Fisher’s exact test and only appropriate for comparing one class). The reduction
of fish classed as severe (and consequent increase in mild phenotype fish) is consistent with a
partial RNA rescue
The second measure used was of abnormal fin development of fish in each treatment group.
It was observed in preliminary experiments that PPA2 knockdown fish displayed very stunted
dorsal fin growth compared to wildtype fish (Figure 7.6). At 3dpf there was a clear difference in
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Figure 7.5 RNA rescue of ppa2 knockdown embryos with RNA (50pg) (302 embryos counted
across 4 experiments)
A Percentage of embryos displaying a phentoype in four severity groups by treatment type. No phenotype =
no obvious defects, and gross normal development; Mild = slightly curved/small tail OR yolk adema/caridac
adema/blood backflow or pooling; Medium = slightly curved/small tail AND yolk adema/cardiac adema/blood
backflow or pooling; Severe = very curved tail AND yolk adema/cardiac adema/blood backflow or pooling.
Fisher’s exact test p-value only relates to severe embryos B Example phenotypes at 2 dpf indicitive of each
grouping in A.
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Figure 7.6 RNA rescue of ppa2 knockdown (758 embryos counted across 5 experiments)
APercentage of abnormal fins per treatment type. p-value calculated using Fisher’s exact test. B Example
normal fin embryo phenotype at 2 dpf. C Example abnormal fin embryo phenotype at 3 dpf (enlarged right)
fin size between knockdown and rescue fish, although dissection to directly measure fin area was
not possible. Instead a count of the percentage of fish in each treatment type with abnormal
fins was used to demonstrate a significant effect of the RNA rescue group over morpholino only.
This was consistent for both a medium dose (50pg) and high dose (100pg) of mRNA with a
standard concentration of MO (at 0.35pmol).
7.5 Additional phenotype characterisation methods
Several other phenotypic features were observed as zebrafish embryos developed, and although
not enough replicated experiments have yet been performed to accurately quantify these features
in treatment groups, various methods of visualising and measuring these features have been
trialled.
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Figure 7.7 Zebrafish ventrical shortening fraction can be used as a measure of heart function
The shortening fraction is measured by using the formula: (max VS/max VD)*100 = Shortening faction.
Maximum VS and VD are measured in still captures from a movie of a beating zebrafish heart.
7.5.1 Heart related features
Measurement of shortening fraction
The normal function of the heart requires the ventricals to contract and relax in coordinated
motion to pump blood through the organ. The ventricular shortening fraction measures the
diastolic dimension that is lost during systole and is a measure of heart function. Still images
were captured from video clips of 2dfp zebrafish hearts at maximum ventricular systole (VS)
and maximum ventricular diastole (VD). An example of maximum VS and VD is shown in
Figure 7.7. No significant difference in shortening fraction was observed in preliminary data
available. MO injected zebrafish embryos had an average shortening fraction of 83.7% compared
to 80.9% in control fish (data not shown).
Measurement of heartrate
Preliminary data of a small number (n=20) of zebrafish either injected with MO or a control
(water) indicated that MO zebrafish may show a decreased heatrate. The average heartrate of
MO injected zebrafish was 75 beats per minute (bpm), as opposed to 86bpm in controls (Figure
7.8).
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Figure 7.8 Zebrafish heartrates
Preliminary data on zebrafish embryo heartrates between MO treatment and untreated controls, indicating a
decreased heartrate in MO fish. Average heartrate for each group is indicated by dashed line.
7.6 CRISPR/cas9 targeted genome editing
Based on the promising results from these preliminary morpholino data, it was decided that
a stable ppa2 knockout zebrafish line would be useful to confirm the morpholino phenotype,
and further investigate the possible heart dysfunction and other relevant features. Addition-
ally, ppa2 sequences containing specific mutations of interest could then be introduced into the
model, producing strains of fish that mimic the genotype seen in the human patients. In order
to efficiently produce a ppa2 knockout zebrafish line the CRISPR/cas9 system was utilised.
The CRISPR/cas 9 system is a prokaryotic immune system that recognises and cuts exoge-
nous genetic elements providing a form of acquired immunity. By synthesising a guide RNA
that specifies a DNA target, and introducing this guide with cas9 the system can effectively
be reprogrammed for targeted genome editing. Three guide RNA sequences were designed and
introduced to zebrafish embryos with cas9 protein (100pm mRNA + 200pg cas9). At the time
of writing these fish were being raised as fry.
Although it will take further breeding and genotyping to ascertain if a stable ppa2 knock-
out line has been produced, many of these early fry will be mosaic ppa2 knock-outs and some
early anecdotal observations are promising. At 2dpf, tail and fin defects are observed, mimick-
ing the defects characterised in the morpholino experiments. At 4dpf, elongated ’beaky’ jaws
are observed, again mimicking a feature in the morpholino experiments (Figure 7.9). At the
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Figure 7.9 CRISPR/cas9 fry
Early mosaic fish phenotypes presenting with protruding jaws and absent or stunted pectoral fins.
time of writing, this work was still in preliminary stages, but further characterisation and geno-
typing of the next generation of zebrafish will be performed, alongside replicate experiments of
morpholino injections in order to increase the data cohort to a statistically meaningful size.
7.7 Discussion
Although the experimentation in this chapter are ongoing and no final data is presented, this
is largely only pending replication of experiments to increase zebrafish sample size.
Based on these preliminary results, it appears that injection of ppa2 -targeted morpholinos
results in stable phenotype that involves both cardiac and developmental features.
The severity of this phenotype is significantly reduced by co-injection of wildtype ppa2 mRNA
which acts to rescue normal ppa2 expression in developing embryos. Two measures to quan-
tify phenotype severity were used; a gross developmental score (based on set criteria), and a
specific presence or absence of stunted pectoral fins. An expansion of these experiments aims
to increase the sample size of these rescue experiments, and compare rescue success-rates when
mutant ppa2 mRNA is coinjected in place of wildtype mRNA.
Due to the potential for off target effects in morpholino knockdown experiments, the gold
standard approach is still to produce a complete ppa2 knockout model. The considerable time
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and cost involved in producing a knockout model made morpholino work a practical alterna-
tive to initially explore the effect of ppa2 in zebrafish. There was also a concern that a ppa2
knockout zebrafish model would be lethal in the homozygous state.
Given the promising preliminary results from the morpholino experiments, it was consid-
ered necessary to attempt to produce a knockout strain to validate the phenotype observed.
CRISPR/cas9 was used for targeted genome edited in zebrafish embryos to produce mosaic
ppa2 knockout fry. The offspring of these fish will be genotyped to determine if germline incor-
poration occurred in some fish, and heterozyous ppa2 knockout fish will become the breeding
stock for a heterozygous ppa2 knockout line.
The long term aim of producing a ppa2 knockout line, is to eventually knock in wildtype
and mutant human PPA2 to observe the specific effects of mutations seen in human patients.
In the short term, the knock out zebrafish will be used to repeat the phenotype characterisa-
tion and RNA rescue experiments previously performed in the morpholino fish. Wildtype and
human PPA2 mRNA will also be introduced to both morpholino and CRISPR/cas9 knockout
fish in the RNA rescue experiments to ascertain if complementation will occur between the two
gene homologs.
As with any experimental model, features seen in zebrafish with altered ppa2 (or even PPA2 )
expression cannot be extrapolated to the human counterpart. Zebrafish ppa2 may perform a
subtly different function, and zebrafish are fundamentally different in development of structure
such as gills, fins and tails. Bearing in mind these differences, it may still be possible to learn
more about the function of PPA2 in humans by observing the phenotype of morpholino KO
and CRISPR/cas9 zebrafish models.
It should be noted that in the course of these studies, which were primarily directed at prov-
ing the phenotypic consequences of the compound heterozygous mutations within PPA2, other
human families with PPA2 mutations emerged in a group of European laboratories. The func-
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tional analysis of PPA2 in yeast and zebrafish, although still very pertinent and biologically
important, become less critical to the discovery of PPA2 as causative of cardiac disease, and
the functional studies of the variants were undertaken in patient fibroblasts and by enzymatic
kinetic studies published by the European laboratories which we collaborated with and shared
data. In actuality, Family Christchurch presented in the thesis, enabled the exome data stored
in Europe, to be meaningful, as otherwise the variants may have remained VUS for a further
period of time [1].
Chapter 8
Conclusions and future directions
8.1 Analysis of an intellectual disability pedigree
Despite exome analysis of three affected siblings in this pedigree, no genetic cause of their
ID was identified. Due to the repetitive nature of the sex chromosomes, we were unable to
exclude a causative feature on the Y-chromosome, and also encountered issues with mapping
and alignment of reads on the sex chromosomes leading to some false variant calls. This case
study proved invaluable in identifying some of the potential pitfalls associated with embarking on
a new technology. Several recommendations (such as assessing X and Y chromosome coverage,
and establishing a clear inheritance pattern where possible in a pedigree) for the implementation
of exome sequencing in the clinical laboratory setting arose as a direct consequence of our
experience during the analysis of this index case and subsequently their siblings. In this family,
and future cases where an inheritance pattern is not certain, linkage association studies would
be useful prior to launching into analysis exome data.
8.2 Trio analysis - a sporadic case of premature aging
A mutation was identified in BCOR which is putatively causative of some or all of the symptoms
seen in this proband. This missense mutation is de novo in the proband, and occurs on the
X chromosome. Two defined genetic disorders have been associated with mutations in BCOR,
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these are LM in males, and OFCD in females. The proband is not affected by OFCD, but shows
symptoms that could be related to the function of BCOR. A common feature of pathogenic X-
linked gene mutations in female carriers is skewed X-inactivation, preferentially expressing the
X chromosome with a wildtype allele in tissues where this may confer a proliferation or survival
benefit. Analysis of this individual showed moderately skewed inactivation (88:12) in peripheral
blood, supporting the presence of a pathogenic X-linked mutation. Buccal and skin fibroblast
DNA displayed normal X-inactivation.
An early avenue of investigation in this individual during childhood was to exlude a diag-
nosis of FA. Mitomycin c sensitivity of chromosomes from peripheral blood was measured, and
returned a normal result. Given the recent identification of skewed X-inactivation in this pa-
tient, the mitomycin c assay for FA was repeated on cultured fibroblasts. This also returned
a normal result, however there have been questions raised over possible confounding issues
around the mitomycin c assay in the presence of BCOR mutations. A previous case of siblings
with a familial nonsense mutation causing OFCD were also analysed for FA by mitomycin c
sensitivity. Despite the same BCOR genotype and a defined phenotype, one sibling returned a
positive result for FA. The phenotype was later identified as OFCD not FA but there may be
potential for some overlap between these phenotypes in individuals with mutations in BCOR.
As such, BCOR is considered a strong candidate for pathogenicity in this patient although the
work needed to establish a causal link is beyond the scope of this PhD. More generally it would
be interesting to follow up on the possible link between BCOR mutations and mitomycin C
sensitivity.
8.3 Analysis of a pedigree with sudden cardiac death
Exome sequencing of affected siblings and their unaffected parents led to identification of com-
pounding heterozygous mutations in PPA2. These mutations were predicted to be pathogenic
by in silico algorithms and were in a mitochondrial-related gene, although PPA2 had not been
previously described in human disease. This work led to a collaboration with several European
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laboratories, resulting in the identification of a further three families with compounding or ho-
mozygous mutations in PPA2 and a mitochondrial phenotype resulting in death during infancy
[1]. The consistency of the phenotype in the three European families implies that mitochon-
drial symptoms and infantile death is likely to be the standard presentation of PPA2-associated
disease. Functional experiments in yeast and zebrafish supported that normal PPA2 function
is crucial to mitochondrial respiration, whereas decreased expression of PPA2 led to increased
sensitivity to oxidative stress (yeast), developmental and growth issues of the heart and other
’high energy requirement’ tissues (zebrafish). Continued work by collaborators supported this
data, and provided evidence that the severity of p.Pro228Leu is less than the other PPA2 mu-
tations identified. This explains the relatively mild phenotype seen in the original family, but
raises concerns that other mild PPA2 mutations may put seemingly healthy individuals at risk
of SCD. A mechanism of pathology for PPA2-associated disease has been hypothesised, based
on what is known about the biochemistry of the mitochondria and the OXPHOS chain. Part
of this mechanism is the exquisite alcohol sensitivity experienced in the original family. We
hypothesise that alcohol is acting as a trigger of SCD, by significantly increasing the stress on
mitochondria which are functinally sub optimallly.
Indentification of multiple unrelated families harbouring PPA2 mutations, supported by func-
tional data in yeast, zebrafish, recombinant E coli and patient fibroblasts have newly established
this gene as pathogenic in the field of mitochondrial disorders. PPA2 dysfunction should now
be considered in cases of neonatal or infantile death with symptoms of mitchondrial disease,
and additionally may be relevant in SCD of apparently healthy individuals in the absence of
more prevalent causes.
A mammalian model would provide another model which is a closer representation of human
PPA2 function, and a Ppa2 knock-in mouse would be the logical next step. Several large scale
commercial projects are currently underway to sequentially knockout mouse genes. During the
course of this PhD, at least one company has made a Ppa2 constitutional knockout mouse
model available for purchase (Taconic; http://www.taconic.com/). Further elucidation of the
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mechanism of PPA2 function, and in this case, alcohol metabolism and stress would be best
provided with a mammalian model such as mice. Modelling would be crucial for increasing
our understanding of this relatively unexplored enzyme and to give a system in which to test
possible therapies.
8.4 Recommendations from thesis
Based on our experience with the MPS performed in this thesis, several learnings have emerged
specific to our laboratory situation. Although exome sequencing has been utilised as a proof of
concept in case studies presented here, exome sequencing will not be the focus of implementing
MPS in our laboratory. Initially the priority would be to transfer and extend the Sanger se-
quencing currently performed to an MPS platform. A focused gene panel approach would be a
more realistic introduction, to streamline the analysis burden in the first instance. Decisions on
which genes, or groupings of disorders would be included on a panel will take into consideration
the individual laboratory requirements such as turn-around time, read coverage, and sample
volumes.
It may be beneficial to design multiple MPS panels which cover a group of genes associated
with a general phenotype (such as hereditary deafness). In this scenario patient samples are
only analysed for genes relevant to their condition. However, it may work out more economical
and efficient to run all laboratory samples through a much larger panel incorporating genes
associated with multiple phenotypes, then refine the analysis to only relevant genes. In this
way, the laboratory will reduce the variants of uncertain significance that are identified, which
currently don’t contribute to a meaningful result for the clinician requesting testing. Work on
defining which genes of interest will be included a panel, as well as looking at commercially
available panels, is currently in process, and will like evolve beyond the course of this thesis. It
is likely that exome or genome sequencing will be offered in the future, but this is dependant
on a robust clinical pipeline for generating and analysing MPS which will be initially validated
on MPS panels. More general learnings from the work produced in thesis are listed below.
1. Inheritance patterns (especially in striking families) are not always obvious. The assump-
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tion that inheritance was X-linked or dominant in the cases of ID and SCD presented in this
thesis was based on the high prevalence of affected individuals (5/5 males) and (4/4 offspring)
respectively in these two families. Had we continued searching for dominant variants, and not
considered all modes of inheritance in the family with SCD we would never have identified
PPA2 as the causative gene in this disorder.
2. Many exome analyses will not yield a diagnosis, even when you have a clear phenotype
and obvious inheritance. Exhaustive analysis of the case of ID presented in Chapter 3 did not
reveal any promising candidate variants, and this experience proved the futility of continued
analysis in the same dataset. ID cases have one of the highest proportion of no-diagnosis follow-
ing exome sequencing, and this is only slightly increased by whole genome sequencing. While
we are continuing to look for non-synonymous variants in coding regions of the genome, we will
continue to miss diagnoses that have more subtle pathology.
3. Even missense mutations in functionally relevant genes (to the disorder of interest) can
require extensive validation. Our work on PPA2 has taken 3.5 years and we have still not
elucidated the mechanism of pathogenicity.
4. Our historical references of ’normal’ sequences will always contain pathogenic variants, and
therefore blanket exclusion of variants in a filtering process because they are included in dbSNP
(for example) is going to result in false negative results. Although newer sources of population
genetic data such as ExAC are more carefully curated, there will always be pathogenic variants
documented.
5. You need to select the right approach for the diagnostic scenario. A disease targeted panel
for cardiomyopathies would never have identified PPA2 variants in the family with SCD. In
contrast, specific gene sequencing was entirely appropriate in two other clinical cases published
during this thesis, which are not presented in the body of this work ([227, 228]).
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6. It is important to have good clinical assessment data and phenotyping. Assessing relevance
of candidate genes can be based entirely on the clinical description of the disorder involved, and
if this is sparse you risk disregarding the relevant gene.
7. Always keep in mind the potential for mosaicism and sample mix up, results may not
always be clear cut.
8.5 Summary
The process of working through the case studies of undiagnosed and complex genetic disease
presented here has proved invaluable in gaining a understanding of how a technology such as
massively parallel sequencing could be implemented in a clinical laboratory setting. The value
of this analysis in cases of a defined phenotype with affected and unaffected family members is
clear. Less certain is the approach we woudl take with singleton cases, as the variant filtering
and analysis in this situation of dramatically less power, would require a much greater time
investment than that of a highly powered family analysis with more than one affected individual.
Although exome analysis has been used in all case studies in this thesis, the knowledge gained
pertains to whole genome sequencing as well as targeted sequencing of gene panels. What was
abundantly clear was that MPS was a very effective method of identifying disease candidates,
not limited only to known causative genes. This presents the new dilemma of how far does the
responsibility of the diagnostic lab stretch to prove pathogenicity of genetic variants detected
which have not been previously catalogued. This thesis demonstrates how some characterisation
of variants can be performed within the clinical setting, as well as via collaboration with research
groups and suggests that characterisation, not identification, of genetic variants is the greatest
challenge that diagnostic laboratories currently face.
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8.6 Future directions
An unexpected outcome of this thesis was the discovery of an associated between PPA2 and
SCD, cardiomyopathy and other mitochondrial symptoms. As such, the key work expected
to continue beyond the course of this PhD is to further characterise specific PPA2 mutations,
elucidate a mechanism(s) of pathogenicity, and explain the heterogeneity seen between affected
families, including the alcohol sensitivity seen in Family Christchurch.
Future areas of investigation are detailed here:
1. Create a stable heterozygous zebrafish CRISPR/cas9 knockout line (currently breeding,
in conjunction with the Horsefield group, Otago Univesity).
2. Use CRISPR/cas9 technology to create a knock in of specific PPA2 variants in this line.
3. Continue mitochondrial function analysis of several cell types (monocytes, lymphocytes
and fibroblasts) on the Seahorse XF instument (in conjunction with Andree Peason and Mark
Hampton of the Free Radical group, University of Otago-Christchurch).
4.Use currently frozen fibroblasts and EBV transformed lymphocytes from affected and un-
affected individuals (of Family Christchurch and age matched controls) to assess mitochondrial
depletion, morphology of the mitochondria, levels of PPi in the mitochondrial matrix, mito-
chondrial activity when faced with ethanol stress, and other relevant experiments that may
help to elucidate a mechanism of pathogenicity.
5. As mentioned in the above section, a mouse model is the final goal in order to be able
to explore possible therapies for PPA2 dysfunction. Grant funding will be required for this
project, and it will likely be a project taken on by a future student or post-doctoral researcher
at the University of Otago.
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Table A.1 Primers used in general methods
Gene Variant Direction Sequence Comment
Universal Forward GTAAAACGACGGCCAGT For sequencing M13 tagged PCR products
Universal Reverse CAGGAAACAGCTATGACC For sequencing M13 tagged PCR products
Table A.2 Primers used in Chapter 3
Gene Variant Direction Sequence Comment
DACH2 p.Glu425Asp Forward GTAAAACGACGGCCAGTTGTGGCTTAGTGAGACTTTTGA M13 Tagged
DACH2 p.Glu425Asp Reverse CAGGAAACAGCTATGACGGGAATCCAGCGGGCAATG M13 Tagged
KMT2C p.Gly838Ser Forward GTAAAACGACGGCCAGTAGACTTGCCTTCGCATGACA M13 Tagged
KMT2C p.Gly838Ser Reverse CAGGAAACAGCTATGACCCTACCTGTTTGGACCGAGG M13 Tagged
KMT2C p.Leu291Phe Forward GTAAAACGACGGCCAGTTACCCCTTTCAGCGATGTGC M13 Tagged
KMT2C p.Leu291Phe Reverse CAGGAAACAGCTATGACCAATGTGTTCTGGACAAAGC M13 Tagged
KMT2C p.Gly838Ser Forward GTAAAACGACGGCCAGTCTTCAGACTTGCCTTCGCATGACATGCTGGA Specific for KMT2C
KMT2C p.Gly838Ser Reverse CAGGAAACAGCTATGACCCAACTGAGTTGAAATTCCAAATAAGATGA Specific for KMT2C
KMT2C p.Leu291Phe Forward GTAAAACGACGGCCAGTTTGCAGGTTCAATTTGTTTTACTTGTGATA Specific for KMT2C
KMT2C p.Leu291Phe Reverse CAGGAAACAGCTATGACAAATACATTGGTTGAAGTTTAAAAGTCTATC Specific for KMT2C
Table A.3 Primers used in Chapter 4
Gene Variant Direction Sequence Comment
BCOR p.Gly1303Ser Forward GTAAAACGACGGCCAGTCTGGCTACAACTGTGTAACG
BCOR p.Gly1303Ser Reverse CAGGAAACAGCTATGACCACAGCACATCTGTCTTCTGG
BCOR p.Gly1303Ser Forward TCCCTGCACTGGTGGATGAAAGACTCTTC Mutation specific nest primer
BCOR p.Gly1303Gly Forward CCCCTGCACTGGTGGATGAAAGACTCTTC WT specific nest primer
AR n/a Forward /56-FAM/TCCAGAATCTGTTCCAGAGCGTGC
AR n/a Reverse GCTGTGAAGGTTGCTGTTCCTCAT
Table A.4 Primers used in Chapters 5-6
Gene Variant Direction Sequence Comment
PPA2 p.Glu172Leu Forward TGGCATGAATAAACCAAAACTCACG PCR/Seq
PPA2 p.Glu172Leu Reverse GACTTGGGAAGATCCCCATGAAA PCR/Seq
PPA2 p.Pro228Leu Forward AGATTCTCATCTTCACCTTG PCR/Seq
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Figure B.1 pExpress-1
Vector map of pExpress-1 showing cloning sites.
Table B.1 Morpholino sequences
Used for transient knockdown of ppa2 expression.
Construct Construct Name MO Sequence
1 PPA2 5’UTR CTGAACACATTATTTACATCCACTC
2 PPA2 SPX GCAAAAACAGAACATCACCTGTGGA
3 PPA2 MIS-5 GAAAAAAAAGAAAATCACCTATGAA
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Figure B.2 pCS2+ Plasmid
Vector map of pCS2 showing cloning sites.
Figure B.3 pCS2+ cloning plan
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Appendix C
Gene lists used in exome analysis
Table C.1 Intellectual disability (ID) associated genes
Gene list examined against variants identified during exome analysis of the pedigree in Chapter 3.
ABCC6 ATRX CLN3 FGD1 HCFC1 LYST NHEJ1 PRSS12 SLX4 TSHR
ABCD1 AUH CNTNAP2 FGF14 HDAC4 LZTFL1 NHP2 PTCHD1 SMARCA4 TSPAN7
ABCG5 AVP COG5 FGFR1 HDAC8 MAGT1 NHS PTEN SMARCB1 TTC8
ACAT1 AVPR1A COG7 FGFR2 HEPACAM MAN1B1 NIPBL PTPN11 SMARCE1 TTC37
ACOX1 AVPR2 COL1A2 FGFR3 HEXB MAN2B1 NLGN3 PYCR1 SMC1A TTR
ACSL4 BBIP1 CP FKRP HOXA1 MANBA NLGN4X PYGL SMC3 TUBA1A
ACY1 BBS2 CPA6 FKTN HOXD10 MAOA NPC1 RAB39B SMS TUBA8
ADAR BBS4 CPS1 FLNA HPD MAP2K1 NPC2 RAB40AL SNIP1 TUBB2B
ADSL BBS5 CRADD FMR1 HPRT1 MAP2K2 NPHP3 RAD21 SOBP TUBB3
AFF2 BBS7 CREBBP FOLR1 HRAS MAPT NRAS RAF1 SOS1 TUSC3
AFP BBS9 CRBN FOXG1 HSD17B10 MAT1A NRXN1 RAI1 SOX10 TWIST1
AGL BBS10 CTC1 FOXP1 HSPD1 MBD5 NSD1 RAPSN SOX2 UBE2A
AGT BBS12 CTCF FOXP2 HUWE1 MBTPS2 NSDHL RBBP8 SOX3 UBE3A
AGTR2 BBS14 CTNNB1 FRMPD4 IDH2 MCCC1 NSUN2 RBM10 SPR UPB1
AHI1 BBS18 CTSA FTO IDS MCCC2 OCRL RELM SPRED1 UPF3B
AIFM1 BCOR CUL4B FTSJ1 IGBP1 MCOLN1 OFD1 RFX6 SPTAN1 UROC1
ALDH18A1 BCS1L CYB5R3 G6PC3 IGF1 MCPH1 OPHN1 RPGRIP1L SPTLC1 USP9X
ALDH4A1 BDNF CYP27A1 GABRG2 IGF1R MECP2 ORC1 RPL10 SRD5A3 VLDLR
ALG11 BIN1 D2HGDH GALE IL1RAPL1 MED12 PACS1 RPS6KA3 SRPX2 VPS13B
ALG12 BRAF DARS2 GAMT INSR MED17 PAFAH1B1 SACS ST3GAL3 WDPCP
ALG6 BRCA2 DBT GAN IQSEC2 MED23 PAH SAMHD1 STAT5B WDR62
ALX4 BRIP1 DCX GATAD2B IRX5 MEF2C PAK3 SATB2 STRA6 WDR81
AMER1 BRWD3 DDHD2 GBA ITGA7 MET PAX6 SCN1A STX11 WRN
ANK3 BUB1B DHCR24 GBE1 KCNJ10 MFSD8 PCDH19 SCN2A STXBP1 XIST
AP1S1 C12orf57 DHCR7 GCK KCNJ11 MGAT2 PCNT SCN8A SUCLG1 XPNPEP3
AP1S2 CA8 DIP2B GDI1 KCNK9 MID1 PDE4D SDCCAG8 SYN1 ZBTB16
AP3B1 CACNA1C DLG3 GFAP KCNQ2 MKKS PDHA1 SGCA SYNGAP1 ZBTB24
AP4B1 CACNG2 DMD GFM1 KCTD7 MKS1 PDHX SGSH SYP ZC3H14
AP4E1 CAMTA1 DPYD GHR KDM5C MLL2 PDSS1 SHANK2 SYT14 ZDHHC9
AP4M1 CANT1 DYNC1H1 GLI3 KIAA2022 MMADHC PEX7 SHANK3 TBC1D24 ZDHHC15
AP4S1 CASK DYRK1A GLRA1 KMT2D MOCS2 PGK1 SHOC2 TBCE ZEB2
APOB CBL EBP GLUL KIF11 MPI PHF6 SHROOM4 TBX1 ZFP57
AQP7 CBS EFNB1 GLYCTK KIF1A MPZ PHF8 SIL1 TCF4 ZFYVE26
AR CC2D1A EHMT1 GM2A KIF21A MRAP PHKA2 SLC16A2 TECR ZIC2
ARFGEF2 CC2D2A EIF2S3 GNAS KIF5A MTFMT PHKG2 SLC20A2 TGIF1 ZNF41
ARG1 CCDC22 ELOVL4 GNPAT KIF7 MTHFR PIGL SLC25A1 TH ZNF81
ARHGEF6 CCDC88C EPB41L1 GNPTAB KIRREL3 MTR PIGO SLC25A12 THRB ZNF526
ARHGEF9 CDH7 ERCC2 GNPTG KLF8 MYCN PIGV SLC25A13 TINF2 ZNF674
ARID1A CDH8 ERCC3 GPC3 KRAS MYO5A PLA2G6 SLC25A15 TMCO1 ZNF711
ARID1B CDH15 ERCC5 GRIA3 L1CAM MYO7A PLP1 SLC2A1 TMEM165
ARL6 CDKL5 ERCC6 GRIK2 L2HGDH NAA10 PNKP SLC2A2 TMEM216
ARX CDKN1C ERCC8 GRIN1 LAMA2 NAGA POMGNT1 SLC35C1 TMEM67
ASPM CEP290 ERLIN2 GRIN2A LAMP2 NBN POMT1 SLC46A1 TMEM70
ASS1 CEP41 EZH2 GRIN2B LARGE NDP POMT2 SLC4A4 TPH2
ATL1 CEP57 F5 GRM1 LBR NDUFA1 POU1F1 SLC5A2 TPK1
ATM CHD7 FAM126A GSS LHX3 NDUFAF5 PPOX SLC5A5 TRAPPC9
ATP13A2 CDH15 FANCG GUSB LIG4 NDUFS1 PQBP1 SLC6A4 TRHR
ATP1A2 CDKL5 FBLN5 GYS2 LINS NF1 PRICKLE1 SLC6A8 TRIM32
ATP6AP2 CHRNA4 FBN1 HAX1 LMBRD1 NFIX PRKAR1A SLC7A7 TSC1
ATP7A CLIC2 FBN2 HCCS LRP5 NGF PRPS1 SLC9A6 TSC2
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Table C.2 Autism spectrum disorder (ASD) associated genes
Gene list examined against variants identified during exome analysis of the pedigree in Chapter 3.
ABAT CACNA1H DEAF1 FABP7 HOMER1 MAGED1 NXPH1 PSMD10 SLC38A10 TRPC6
ABCA7 CACNA1I DEPDC5 FAM135B HOXB1 MAGEL2 ODF3L2 PTGER3 SLC39A11 TRPM1
ACTN4 CACNA2D3 DGKZ FAN1 HS3ST5 MAL OGT PTGS2 SLC4A10 TSN
ADA CACNB2 DIAPH3 FAT1 HSD11B1 MAOB OPRM1 PTPRB SLC6A3 TTI2
ADAMTS18 CADM1 DIP2A FBXO15 HTR1B MAP2 OR1C1 PTPRC SLC9A9 TTN
ADARB1 CADM2 DISC1 FBXO33 HTR2A MAPK1 OTX1 PTPRT SLCO1B3 TUBGCP5
ADCY5 CADPS2 DLG1 FBXO40 HTR3A MAPK12 OXTR PXDN SLIT3 TYR
ADK CAMK4 DLG4 FER HTR3C MAPK3 P2RX4 RAB11FIP5 SLITRK5 UBA6
ADNP CAMSAP2 DLGAP1 FEZF2 HTR7 MAPK8IP2 PARD3B RAB19 SMG6 UBE2H
ADORA2A CAPRIN1 DLGAP2 FGA HYDIN MARK1 PARK2 RAPGEF4 SNAP25 UBE3C
ADORA3 CASC4 DLGAP3 FGFBP3 ICA1 MBD1 PAX5 RASD1 SND1 UBL7
ADRB2 CCDC64 DLX1 FHIT IL16 MBD3 PCDH10 RASSF5 SNRPN UBR5
AFF4 CD38 DLX2 FLT1 IL1R2 MBD4 PCDH15 RB1CC1 SNTG2 UBR7
AGAP1 CD44 DLX6 FOLH1 IL1RAPL2 MBD6 PCDH8 RBFOX1 SNX19 UPF2
AGBL4 CD99L2 DMPK FRK IMMP2L MC4R PCDH9 RBM8A SOD1 UPF2
AGMO CDC42BPB DNAH10 GABRA1 INADL MCC PCDHA1 RBMS3 SOX5 USP9Y
ALDH1A3 CDH10 DNAJC19 GABRA3 INPP1 MDGA2 PCDHA10 REEP3 SPAST UTRN
ALDH5A1 CDH11 DNER GABRA4 ITGA4 MED13L PCDHA11 RELN SRD5A2 VASH1
ALOX5AP CDH22 DNM1L GABRB1 ITGB3 MIB1 PCDHA12 RERE SRRM4 VIL1
AMPD1 CDH9 DOCK10 GABRB3 ITGB7 MKL2 PCDHA13 RFWD2 ST7 VIP
AMT CDKN1B DOCK4 GABRQ JARID2 MPP6 PCDHA2 RGS7 ST8SIA2 WAC
ANK2 CECR2 DOLK GAD1 JMJD1C MSN PCDHA3 RHOXF1 STK39 WDFY3
ANKRD11 CELF4 DPP6 GALNT13 KANK1 MSNP1AS PCDHA4 RIMS1 STX1A WDR93
ANKS1B CELF6 DRD1 GALNT14 KATNAL2 MSR1 PCDHA5 RIMS3 STXBP5 WNK3
ANXA1 CHD2 DRD2 GAP43 KCND2 MTF1 PCDHA6 RNPS1 SUCLG2 WNT1
APBA2 CHD7 DRD3 GAS2 KCNJ12 MTX2 PCDHA7 ROBO1 SUV420H1 WNT2
APC CHRM3 DSCAM GATM KCNJ15 MYH4 PCDHA8 ROBO2 SYAP1 XIRP1
APH1A CHRNA7 DST GDA KCNJ2 MYO1A PCDHA9 RORA SYN2 XPC
APP CHRNB3 DUSP22 GIGYF1 KCNMA1 MYO9B PCDHAC1 RPP25 SYN3 XPO1
ARHGAP11B CHST5 DYDC1 GLO1 KCNQ3 MYOZ1 PCDHAC2 RPS6KA2 SYNE1 YEATS2
ARHGAP15 CIB2 DYDC2 GLRA2 KCNT1 MYT1L PCDHGA11 SAE1 SYT17 YTHDC2
ARHGAP24 CLSTN3 EEF1A2 GNA14 KCTD13 NAA15 PDE1C SBF1 SYT3 YWHAE
ARNT2 CLTCL1 EFR3A GNB1L KDM5B NBEA PDE4A SCFD2 TAF1C ZBTB20
ASH1L CMIP EGR2 GPC6 KDM6B NCKAP1 PDE4B SCN5A TAF1L ZMYND11
ASMT CNR1 EIF4E GPD2 KHDRBS2 NCKAP5 PDZD4 SCN7A TBC1D5 ZNF18
ASTN2 CNR2 EIF4EBP2 GPHN KIAA1586 NCKAP5L PECR SDC2 TBC1D7 ZNF385B
ASXL3 CNTN3 EML1 GPR139 KIF13B NDNL2 PER1 SDK1 TBL1X ZNF407
ATG7 CNTN4 EN2 GPR37 KIF5C NDUFA5 PHF2 SEMA5A TBL1XR1 ZNF517
ATP10A CNTN5 EP300 GPX1 KIT NEFL PIK3CG SERPINE1 TBR1 ZNF713
ATP2B2 CNTN6 EP400 GRID1 KLC2 NELL1 PIK3R2 SETBP1 TCF20 ZNF774
ATRNL1 CNTNAP3 EPC2 GRID2 KMO NFIA PINX1 SETD2 TCF7L2 ZNF8
ATXN7 CNTNAP5 EPHA6 GRID2IP KMT2A NIPA1 PITX1 SETD5 TDO2 ZNF804A
AUTS2 CSMD1 EPHB2 GRIK3 KMT2C NIPA2 PLAUR SETDB1 TGM3 ZNF827
BAIAP2 CSNK1D EPHB6 GRIP1 KMT2E NLGN1 PLCB1 SETDB2 THAP8 ZSWIM5
BCAS1 CTNNA3 EPS8 GRM4 KPTN NLGN2 PLCD1 SEZ6L2 THBS1
BCKDK CTTNBP2 ERBB2IP GRM5 LAMA1 NLGN4Y PLN SGSM3 THRA
BCL11A CUL3 ERBB4 GRM8 LAMB1 NOS1 PLXNA4 SH3KBP1 TLK2
BCL2 CX3CR1 ERG GRPR LAMC3 NOS1AP POGZ SHANK1 TM4SF20
BIRC6 CXCR3 ESR1 GSK3B LEP NOS2A PON1 SLC16A3 TMEM231
BTAF1 CYFIP1 ESR2 GSN LIN7B NPAS2 POT1 SLC16A7 TMLHE
BZRAP1 CYP11B1 ESRRB GSTM1 LMX1B NR3C2 PPFIA1 SLC1A1 TNIP2
C11orf30 DAB1 ETFB GTF2I LPL NRCAM PPP1R1B SLC1A2 TNN
C15orf43 DAGLA EXOC3 GUCY1A2 LRFN5 NRG1 PPP1R3F SLC22A15 TNRC6B
C3orf58 DAPK1 EXOC5 HCN1 LRP2 NRP2 PRICKLE2 SLC24A2 TOMM20
C4B DAPP1 EXOC6 HDAC6 LRP2BP NRXN2 PRKCB SLC25A14 TOP1
CA6 DCTN5 EXOC6B HERC2 LRPPRC NRXN3 PRKD1 SLC25A24 TOP3B
CACNA1B DCUN1D1 EXT1 HLA-A LRRC1 NTNG1 PRODH SLC25A27 TPO
CACNA1D DDC F13A1 HLA-DRB1 LRRC7 NTRK1 PRSS38 SLC29A4 TRIM33
CACNA1F DDX11 FABP3 HMGN1 LZTS2 NTRK3 PRUNE2 SLC30A5 TRIO
CACNA1G DDX53 FABP5 HNRNPH2 MACROD2 NXF5 PSD3 SLC35A3 TRIP12
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